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CHAPTER 1
Chemical evolution of autotaxin inhibitors: An introduction
Harald M.H.G. Albers and Huib Ovaa, Accepted for publication in Chemical Reviews.
Abstract. Autotaxin (ATX) is a potential drug target implicated in various diseases, including 
cancer. ATX was originally isolated as a tumor cell motility factor from melanoma cells in 1992. 
It then took a decade to find that ATX has lysophospholipase D activity and is responsible 
for the production of the bioactive lipid lysophosphatidic acid (LPA). The link between ATX-
LPA axis and disease has triggered the development of ATX inhibitors. This chapter focuses 
on the development of ATX inhibitors described in academic and patent literature covering 
both lipid-based and small molecule inhibitors, including the ATX inhibitors described in the 
following chapters of this thesis to place them in context of the current literature.
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1.1 Introduction
In 1992, autotaxin (ATX or ENPP2) was isolated as an autocrine motility factor from melanoma 
cells.1 The ~120 kDa glycoprotein ATX belongs to a small family named ecto-nucleotide 
pyrophosphatase and phosphodiesterase (ENPP) which consists of 7 family members.2 
ATX is the only ENPP family member with lysophospholipase D (lysoPLD) activity and is 
responsible for the hydrolysis of lysophosphatidylcholine (LPC) to produce the bioactive lipid 
lysophosphatidic acid (LPA) (Scheme 1).3,4 LPA 
acts on specific G protein-coupled receptors 
and thereby stimulates the migration, 
proliferation and survival of many cell types.5,6 
ATX is produced in various tissues and is the 
major LPA-producing enzyme in the circulation. 
After biosynthesis by ATX, LPA is subject 
to degradation by membrane-bound lipid 
phosphate phosphatases (LPPs).7,8
ATX is essential for vascular 
development9,10 and is found overexpressed in 
various human cancers.11 Forced overexpression 
of ATX or individual LPA receptors promotes 
tumor progression in mouse models,12-
15 while LPA receptor deficiency protects 
from colon carcinogenesis.16 In addition, 
to its role in cancer, ATX-LPA signaling has 
been implicated in lymphocyte homing and 
(chronic) inflammation,17 fibrotic diseases,18,19 
thrombosis20 and cholestatic pruritus.21 Given 
its role in human disease, the ATX-LPA axis is 
an interesting target for therapy that deserves 
significant attention. The fact that ATX is an 
extracellular enzyme makes it even more 
attractive as a drug target.
1.2 ATX protein 
Alternative splicing of the ATX gene (enpp2) 
results in three distinct isoforms (α, β and γ) 
which are differentially expressed.22,23 ATX 
β (863 aa) is the best studied isoform and is 
identical to plasma lysoPLD. ATX β is mainly 
expressed in peripheral tissues, whereas lower 
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Scheme 1: ATX is responsible for hydrolyzing 
LPC into LPA in an extracellular environment. 
This reaction is catalyzed by a threonine 
residue and two zinc ions present in the ATX 
active site. LPA activates specific G protein-
coupled receptors stimulating migration, 
proliferation and survival of cells. ATX is 
displayed as a cartoon representation of the 
crystal structure (PD ID 2XR9) with the SMB 
domains in purple, the PDE domain in green 
and the nuclease-like domain in blue.
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expression levels are observed in the central nervous system. In contrast, the ATX γ (889 aa) 
isoform is predominately expressed in the central nervous system. ATX α (915 aa), the original 
melanoma-derived isoform, exhibits the lowest expression levels in both the central nervous 
system and peripheral tissues. The ATX α isoform contains a non-specific protease cleavage 
site which is not present in the other isoforms.22 All the three ATX isoforms exhibit similar 
catalytic activities in vitro.22
ATX is produced initially as a pre-pro-enzyme that has an N-terminal signal peptide 
required for secretion.24 This signal peptide is removed by a signal peptidase and ATX 
is subsequently cleaved by proprotein convertases (PCs) like furin.24 The removal of an 
N-terminal octapeptide in ATX by PCs is associated with an enhancement of ATX activity.24 
The proteolytically processed ATX is secreted and it consists of several domains. Starting 
from its N-terminus ATX has two somatomedin B (SMB)-like domains, a central catalytic 
phosphodiesterase (PDE) domain and an inactive nuclease-like domain as displayed in 
Scheme 1. The hydrolytic activity of ATX predominately originates from a threonine residue 
and two zinc ions in the ATX active site located in the PDE domain.25 Extending from the ATX 
active site there is a hydrophobic pocket where the alkyl chain of its lipid substrates binds.26
1.3 Natural substrates of ATX
Next to LPC hydrolysis, ATX is also capable of hydrolyzing sphingosylphosphorylcholine 
(SPC, Figure 1) into sphingosine 
1-phosphate (S1P).27 S1P has 
signaling properties comparable to 
those of LPA while acting on S1P 
receptors.28-30 It is however, doubtful 
how relevant the contribution of 
ATX is to S1P production in vivo. S1P 
is thought to originate mainly from 
the phosphorylation of sphingosine 
by sphingosine kinases, rather than 
through SPC hydrolysis by ATX.31
Next to recognizing the lipids 
LPC and SPC as substrates, ATX can 
also hydrolyze nucleotides, like its 
family members ENPP1 and ENPP3. 
In vitro established nucleotide and 
nucleotide-derived substrates of ATX 
consist of adenosine-5'-triphosphate 
(ATP), diadenosine polyphosphates 
(ApnA), uridine diphosphate glucose 
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Figure 1: Identified natural substrates of ATX.
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(UDP-glucose), nicotinamide adenine dinucleotide (NAD+) and 3’-phosphoadenosine-5’-
phosphosulfate (Figure 1).2 The physiological relevance of ATX-mediated hydrolysis of these 
nucleotide substrates is still unclear.
1.4 Assays to study ATX activity
In the search for inhibitors, appropriate in vitro assays are required to monitor the activity 
of the enzyme of interest. Over the last ten years various assays have been developed and 
used to study the activity of ATX. ATX assays can roughly be divided in two classes depending 
on the kind of ATX substrate used for the activity measurement. The first class uses the 
physiological ATX substrate LPC and the second class uses unnatural ATX substrates.
1.4.1 LPC-based assays
As depicted in Table 1, ATX hydrolyzes LPC into LPA and choline. Both products can be used 
to measure ATX activity. When a 14C label is introduced in the lipid tail of LPC, ATX activity can 
be measured by radiometry.32,33 When radiolabeled LPC is hydrolyzed by ATX the produced 
LPA contains this radiolabel. After lipid extraction of the ATX-LPC incubation mixture and 
separation of LPC and LPA using thin layer chromatography (TLC),4  activity of ATX can be 
quantified from the 14C-LPA product. Although this classical method is robust and very 
sensitive it is not very suitable for high-throughput screening (HTS).
Another way to measure the formation of LPA is by using liquid chromatography–
tandem mass spectrometry (LC-MS/MS).34,35 From an ATX incubation mixture, LPC and LPA are 
separated by LC and detected by tandem MS. This method is very sensitive and suitable to 
detect naturally occurring LPA in biological fluids (i.e. plasma).34-36
ATX activity can also be measured by the detection of choline.4,37 When choline is 
released from the ATX-mediated LPC hydrolysis it can be converted by choline oxidase into 
betaine (trimethylglycine) and hydrogen peroxide. Subsequently, hydrogen peroxide is used 
by horseradish peroxidase (HRP) to convert a coloring substrate into its oxidized chromophoric 
state. Different HRP coloring substrates can be used like 2,2'-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid) (ABTS), homo-vanillic acid (HVA) or Amplex red. ABTS can be detected using 
absorbance while HVA and Amplex red are detected by fluorescence.36,38,39 The throughput of 
this assay is high and suitable for HTS screening.
A danger of the latter assay is that small molecules that don’t inhibit ATX may 
interfere with the readout by inhibiting the enzymes (HRP or choline oxidase) used in the 
coloring reaction, which will result in false positives. Another possibility what could result 
in false positives is that reactive compounds tested in this assay can react with the coloring 
agent or hydrogen peroxide that is generated during that coloring reaction. Incubating 
the molecules that are active in this assay with only choline and subsequently adding the 
coloring reagents should reveal if identified actives are interfering with the assay readout.38
15
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1.4.2 Unnatural ATX substrate-based assays
As a member of the ecto-nucleotide pyrophosphatase and phosphodiesterase (ENPP) family, 
ATX also hydrolyzes nucleotides. Therefore, the nucleotide thymidine 5’-monophosphate 
para-nitrophenyl ester (pNP-TMP) can be used as an ATX substrate (Table 1).3,25 Upon 
hydrolysis of pNP-TMP by ATX, 4-nitrophenol is released which has an absorbance at 405 
nm and is detectable by colorimetry. The same product is formed when bis-para-nitrophenyl 
phosphate (bis-pNPP) is hydrolyzed by ATX (Table 1).33,38  Bis-pNPP is a cheap ATX substrate 
that provides a direct readout. 
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Table 1: Substrates for ATX-activity assays.
a LPA can be detected by radiometry or mass spectrometry. Choline can be detected in a two-step enzymatic 
colorimetric reaction.
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Another artificial ATX-
substrate is CPF4, which has 
a similar core structure as 
bis-pNPP. In CPF4 the two 
nitro groups of bis-pNPP 
are replaced by coumarin 
and fluorescein (Table 
1).33,40 When the coumarin 
donor group in CPF4 is 
excited Förster fluorescence 
resonance energy transfer 
(FRET) between coumarin 
and the fluorescein acceptor 
occurs. After hydrolysis the 
FRET pair is separated and 
FRET is lost, providing a very sensitive assay reagent. Although this reagent was originally 
developed for phosphodiesterase I40 it provides a very sensitive ATX activity sensor as well.33
FS3 is another synthetic ATX substrate, which is based on LPC (Table 1).41 In this 
substrate a dabcyl moiety, a quencher of fluorescein, is connected via a lipid backbone to 
fluorescein. The fluorescein moiety in FS3 is quenched by the dabcyl moiety and becomes 
fluorescent when FS3 is hydrolyzed by ATX. A common advantage of the above mentioned 
assays is that they provide a realtime readout allowing direct kinetic studies of ATX activity.
In addition, a first generation ATX activity-based probe (ATX-ABP) has been reported 
(Table 1).42 This probe makes use of the activity of ATX to label ATX covalently. Upon the 
hydrolysis of the phosphodiester bond in ATX-ABP, the released intermediate undergoes an 
1,6-elimination of a fluoride atom (Scheme 2). This generates a reactive quinone methide 
species that traps nearby nucleophiles in the ATX active site resulting in covalent labeling 
of ATX with a fluorescent Cy5 dye in an activity-dependent manner. This ATX-ABP is able to 
label all the three known ATX isoforms.42 In addition, ATX-ABP can label ATX in human plasma, 
however, an additional affinity-purifying step with an anti-ATX monoclonal antibody is required 
to make Cy5 labeled ATX detectable. Further development of this type of probes could turn 
them into diagnostic reagents to monitor ATX activity in complex samples such as body fluids.
1.5 Inhibitory effect of metal chelators on ATX activity
L-histidine has been reported as the first in vitro ‘ATX inhibitor’ with millimolar IC
50
 values for 
ATX using LPC or pNP-TMP as assay substrate.43 It acts by scavenging metal ions in solution, 
such as zinc, which are essential for ATX activity. In addition, other metal chelating agents 
such as ethylenediaminetetraacetic acid (EDTA) and 1,10-phenanthroline also have an 
inhibitory effect on ATX activity.43
ATX active site
Nu Nu
NuNu
Cy5Cy5
Cy5Cy5
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Scheme 2: Labeling mechanism of ATX with ATX-ABP. Only one 
of the potential labeled products resulting from the labeling is 
shown.
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1.6 Natural lipids and lipid-based inhibitors of ATX
A distinct class of ATX inhibitors are based on lipids. The discovery of product inhibition of ATX 
by its lipid products LPA and S1P33 triggered the development of lipid-based ATX inhibitors 
(Table 2). One class of lipid-based inhibitors includes thiophosphates.44-46 An example of 
this class is thiophosphate 3 (IC
50
 = 0.6 μM, bis-pNPP) depicted in Table 2. The reported 
thiophosphates also act as agonists or antagonists for LPA
1-3 
 receptors.44-46 This is a general 
danger of lipid-based ATX inhibitors, that they may act on downstream LPA/S1P receptors due 
to their structural similarity with LPA and S1P. 
There is also a class of ATX inhibitors based on cyclic phosphatidic acid (cPA) which is 
a naturally occurring analog of LPA where the sn-2 hydroxy group forms a 5-membered 
ring with the sn-3 phosphate.47,48 cPA analog 4 (Table 2, IC
50
 = 0.14  μM, bis-pNPP) has no 
significant agonist activity at LPA receptors. Recently, a sulfur analog of cPA, 3-O-thia-cPA (5) 
has been reported as ATX inhibitor (Table 2).49
Another class of lipid-based ATX inhibitors is based on α-bromomethylene 
phosphonates like BrP-LPA (6, Table 2).50,51 In addition, phosphonate 6 acts as a pan LPA
1-4
 
receptor antagonist. α-Bromobenzyl phosphonates are well known protein tyrosine 
phosphatase inhibitors that target the active site covalently.52 Whether phosphonate 
6 inhibits ATX in a covalent manner is unknown. An inhibitor that is expected to bind ATX 
covalently is flouromethylphenyl phosphate 7 (Table 2).53 The binding mechanism of 7 with 
ATX is postulated to be the same as for the ATX-ABP as depicted in Scheme 2.
Interestingly, phosphorylated FTY720 (FTY720-P, 8, Table 2) inhibits ATX with a Ki of 0.2 
μM using pNP-TMP as an ATX assay substrate.54,55 FTY720-P is a synthetic analog of S1P and 
acts as an S1P
1
 receptor antagonist (EC
50
 = 5 nM)55 that activates this receptor, causing its 
internalization and subsequent polyubiquitination leading to proteasomal degradation of the 
S1P
1
 receptor. This results in unresponsiveness of lymphocytes to S1P.56
Potencies of the previously described lipid-based inhibitors all have been determined 
in assays using unnatural and different ATX substrates (bis-pNPP, pNP-TMP, CPF4 and FS3) as 
reporter molecules. Therefore it is difficult to compare potencies of distinct inhibitors measured 
in different assays. In addition, inhibitors in these assays that use unnatural substrates of 
ATX might have no effect on LPC hydrolysis by ATX due to alternate binding of the substrate. 
Using assays based on LPC hydrolysis gives a direct answer if ATX inhibitors could inhibit LPA 
production by ATX. The most potent (IC
50
 = 5.6 nM, LPC) lipid-based inhibitor measured in 
an LPC hydrolysis assay is S32826 (9, Table 2).39,57,58 This phosphonate inhibitor is a result of 
screening 13,000 small molecules for their ability to inhibit ATX. Unfortunately, the poor in 
vivo stability and/or bioavailability of the compound did not permit further use in animal 
models. A last lipid-like inhibitor class is based on a tyrosine building block and an example 
of this class is inhibitor 10, which has a micromolar potency (Ki = 1.0 μM, LPC, Table 2).
59-61
A frequently observed phenomenon for ATX inhibitors is their incapability to fully inhibit ATX. 
Examples are inhibitors 3, 4 and 9 depicted in Table 2 that have residual ATX activity (RA) for ATX.
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Entry Inhibitor Substrate Activity References a 
1 
LPA 
CPF4 Ki = 0.11 μM
 [33] 
2 
S1P 
CPF4 Ki = 0.05 μM [33] 
3 
Thiophosphate 
Bis-pNPP 
IC50 = 0.60  μM 
RA = 27% b 
[44] [45] [46] 
4 
 
cPA-based 
Bis-pNPP 
IC50 = 0.14  μM 
RA = 9% 
[47] [48] 
5 
3-O-thia-cPA 
FS3 PI = 55% [49] 
6 
BrP-LPA 
FS3 PI = 94%  [50] [51] 
7 
Fluoromethylphenyl
FS3 PI = 95% [53] 
8 
 
FTY720-P 
pNP-TMP Ki = 0.2 μM [54] [55] 
9 
S32826 
LPC 
IC50 = 5.6 nM 
RA ≈ 10% 
[39] [57] [58] 
10 
 
Tyrosine-based 
LPC Ki = 1.0 μM [59] [60] [61] 
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Table 2: Lipid and lipid-based inhibitors of ATX.
a First reference corresponds with displayed structure the following references refer to similar inhibitor 
structures. b RA; residual ATX activity. c PI; percentage inhibition.
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1.7 Small molecule inhibitors of ATX
Since 2008 many small molecule inhibitors have been reported in both academic and 
patent literature (Table 3). The most potent inhibitor (IC
50
 = 1.7 nM, LPC) reported to date 
is PF-8380 (11).62,63 Interestingly, this compound reported by employees of Pfizer62 is based 
on an inhibitor described in a Merck KGaA patent application.63 Due to the high potency 
and favorable pharmacokinetic properties, PF-8380 is a suitable tool compound for in vivo 
evaluation of ATX inhibition.
Another very potent ATX inhibitor is the boronic acid HA155 (12, IC
50
 = 5.7 nM, LPC, 
Table 3), which is described in more detail in Chapter 3 of this thesis.36,38 This molecule 
resulted from screening ~40,000 small molecules followed by medicinal chemistry efforts 
on the resulting screening hit. In the original screening hit a carboxylic acid moiety was 
replaced by a boronic acid moiety, designed to target the threonine oxygen nucleophile in 
the ATX active site. HA130,36,38 a positional boronic acid isomer of HA155 that is described in 
Chapter 2 and 3, together with PF-8380 are the only two inhibitors to date that have been 
demonstrated to lower LPA levels in vivo (rat or mice).
Recently, other boronic acid-based inhibitors have been reported64 as a result of a 
structure-based study resulting in E-28 (13, Table 3), a potent inhibitor of ATX (IC
50
 = 5.3 nM, 
LPC). This study is described in Chapter 4 of this thesis.
A common feature of the three most potent inhibitors reported so far (11-13, Table 3) is 
that they share a long linear and flexible structure, which is also reflected in the structure of 
LPC and LPA. Probably this structural feature helps the inhibitors to accommodate to the lipid 
binding site since they bind to the ATX active site. Most of the other reported small molecules 
inhibitors lack this structural feature. 
Several Merck KGaA patent applications claim ATX inhibitors (15-18) with in vitro 
potencies between 0.1 and 10 µM (LPC).65-71 Structural diversity of these inhibitors is large as 
can be judged from Table 3.
Screening a phosphodiesterase targeted inhibitor library revealed that Vinpocetin 
(19, Table 3), a PDE type 1 inhibitor (IC
50
 = 8-50 µM), inhibits ATX with an IC
50
 value of 122 
µM using LPC as a substrate.72 In addition, screening a second library consisting of  kinase 
inhibitors known to target the ATP binding site in kinases resulted in the discovery of 
Damnacanthal (20, Table 3), a p56lck tyrosine kinase inhibitor (IC
50
 = 17-620 nM), as ATX 
inhibitor (IC
50
 = 139 µM, LPC).72
Several ATX screening programs used libraries from the National Cancer Institute (NCI). 
This led for example to the discovery of arsenic acid NSC-48300 (21, Table 3) as ATX inhibitor, 
reported by two independent groups.38,73,74 It is a competitive inhibitor which could suggest 
that the arsenic acid moiety in 21 acts as a non-hydrolyzable phosphate mimic. In addition, 
NSC-9616 (22, Table 3) has been identified as ATX inhibitor from screening an NCI library.75
The first virtual screen for ATX inhibitors led to the discovery of H2L-7905958 (23, 
Table 3).76 This inhibitor has a Ki value of 1.9 µM (FS3) for ATX.
77 At the time of this virtual 
20
CHAPTER 1
11 
PF-8380 
LPC IC50 = 1.7 nM [62] [63] 
12 
HA155 
LPC IC50 = 5.7 nM
 [36] [38]  
13 
E-28 
LPC IC50 = 5.3 nM [64] 
14 LPC IC50 > 0.1 μM [65] [66] 
15 LPC IC50 = 0.1-1 μM  [67] [68] 
16 LPC IC50 > 1 μM [69] 
17 LPC IC50 > 5 μM [70] 
18 LPC IC50 = 1-10 μM [71] 
19 
Vinpocetin 
LPC IC50 = 122 μM [72] 
20 
Damnacanthal 
LPC IC50 = 139 μM [72] 
21 
NSC-48300 
FS3 Ki =  0.240 μM [ 73] [38 ] [74] 
22 
NSC-9616 
FS3 Ki =  0.271 μM [75] 
23 
 
H2L-7905958 
FS3 Ki = 1.9 μM [76] [77] 
24 FS3 Ki = 66 μM [73] [74] 
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Table 3: Activities of small molecule inhibitors of ATX.
a First reference corresponds with displayed structure the following references refer to similar inhibitor 
structures.
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screen the ATX structure was not resolved. Therefore, the authors generated a homology 
model of ATX based on a X. axonopodis pV. citri (Xac) ENPP structure and used this homology 
model for virtual screening. Recently, a follow-up study has been reported describing new 
analogs of 23.77
Another ATX inhibitor is bithionol (24, Table 3),73,74 a known metal ion chelating 
molecule like L-histidine and EDTA.78 The latter two inhibit ATX by scavenging metal ions in 
solution, which are required for ATX activity. However, inhibitor 24 appears to act directly on 
ATX and not via metal chelation since the Ki value of 24 for ATX is two orders of magnitude 
lower than the used metal ion concentration.
1.8 ATX structure and inhibitor design
In 2011, the crystal structure of ATX has been resolved independently by two groups.26,79 Next 
to the unliganded ATX structure, structures of ATX with different species of LPA26 and the 
inhibitor HA155 liganded ATX structure79 have been reported. Binding of HA155 to the ATX 
active site is predominately driven by hydrophobic interactions and by a boronic acid moiety 
binding to the threonine oxygen nucleophile in the ATX active site (Figure 2A and B).79 The 
latter binding was predicted because the boronic acid moiety in HA155 was designed and 
introduced to target the threonine oxygen nucleophile in the ATX active site. In addition, the 
ATX-HA155 structure showed that one of the boronic acid hydroxyl moieties is simultaneously 
tethered by the two zinc ions in the ATX active site (Figure 2B). Therefore, the boronic acid 
moiety not only targets the threonine oxygen nucleophile but also the two zinc ions that are 
essential for catalytic activity of ATX. Another feature of HA155 binding to the ATX active site 
is that its 4-fluorobenzyl moiety binds to the hydrophobic lipid binding pocket of ATX (Figure 
2A), preventing that the alkyl chain of the lipid binds to this pocket.26,79
Thr
C
A HA155-ATX structure B HA155 targetting the ATX active site
Zinc (II)
Figure 2: The inhibitor HA155 liganded ATX structure (PD ID 2XRG). (A) Binding of HA155 with 
ATX. (B) Boronic acid in HA155 targeting the threonine (Thr) oxygen nucleophile and two zinc ions 
in the ATX active site.
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The ATX structure liganded with HA155 triggered an ATX structure-based inhibitor 
design, which is described in Chapter 4 of this thesis.64 This study led to E-28 (IC
50
 = 5.3 nM, 
LPC, Table 3) a hydantoin analog of HA155 (IC
50
 = 5.7 nM, LPC, Table 3). Remarkably, E-28 is an 
E-isomer while HA155 is a Z-isomer. To understand how E-28 binds to ATX, molecular docking 
experiments were performed, which suggested a binding pose for E-28 different from that of 
the original binding pose of HA155 or from the Z-isomer of 28 for ATX. This study predicted 
that the 4-fluorobenzyl moiety in HA155 and E-28 binds differently to the hydrophobic 
pocket in ATX. This finding may be used to design new inhibitors that fully exploit the ATX 
hydrophobic pocket opening further options for inhibitor design.
 
1.9 Concluding remarks
ATX is an attractive therapeutic target for LPA-related diseases. In the past decade, several 
ATX inhibitors have been discovered and developed ranging from metal chelators, lipid and 
lipid-based inhibitors to small molecule inhibitors. Over the last three years many patents on 
ATX inhibitors have appeared from pharmaceutical industry and academia emphasizing the 
interest on ATX as drug target. Finally, the recently reported crystal structure of ATX will aid 
medicinal chemistry efforts to further develop ATX inhibitors into therapeutic agents.
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Biological validation of a boronic acid-based inhibitor of au-
totaxin reveals rapid turnover of LPA in the circulation
Harald M.H.G. Albers, Anping Dong, Laurens A. van Meeteren, David A. Egan, Manjula Sunk-
ara, Erica W. van Tilburg, Karianne Schuurman, Olaf van Tellingen, Andrew J. Morris, Susan S. 
Smyth, Wouter H. Moolenaar and Huib Ovaa, Proceedings of the National Academy of Sciences 
of the United States of America 2010, 107, 7257-7262.
Abstract. Autotaxin (ATX or ENPP2) is a secreted ecto-nucleotide pyrophosphatase/ 
phosphodiesterase (ENPP) that functions as a lysophospholipase D to produce the lipid 
mediator lysophosphatidic acid (LPA), a mitogen, chemoattractant and survival factor for 
many cell types. The ATX-LPA axis has been implicated in angiogenesis, chronic inflammation 
and tumor progression, making this system an attractive target for therapy. However, potent 
and selective non-lipid inhibitors of ATX were not available at the beginning of this study. 
By screening a chemical library, thiazolidine-2,4-diones have been identified that selectively 
inhibit ATX-mediated LPA production both in vitro and in vivo. Inhibitor potency was a 100-
fold increased (IC
50
 ~30 nM, HA130) after the incorporation of a boronic acid moiety, designed 
to target the active site threonine (T210) in ATX. Intravenous injection of this inhibitor into 
mice resulted in a rapid decrease in plasma LPA levels, indicating that turnover of LPA in the 
circulation is much more dynamic than previously appreciated. Thus, boronic acid-based small 
molecules hold promise as candidate drugs to target ATX.
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2.1 Introduction 
Autotaxin (ATX or ENPP2) is a secreted ecto-nucleotide pyrophosphatase/ phosphodiesterase 
(ENPP) originally isolated as an autocrine motility factor from melanoma cells.1 ATX, a ~120 
kDa glycoprotein, is unique amongst the ENPPs in that it functions as a lysophospholipase 
D (lysoPLD) that converts extracellular lysophosphatidylcholine (LPC) into the lipid mediator 
lysophosphatidic acid (LPA).2-5 LPA acts on specific G protein-coupled receptors and thereby 
stimulates the migration, proliferation and survival of many cell types (Figure 1).6,7 ATX is 
produced by various tissues and is the major LPA-producing enzyme in the circulation. Newly 
produced LPA is subject to degradation by membrane-bound lipid phosphate phosphatases 
(LPPs).8,9 However, little is known about the dynamic regulation of steady-state LPA levels in 
vivo.  
ATX is essential for vascular development10,11 and is found overexpressed in various 
human cancers.12 Forced overexpression of ATX or individual LPA receptors promotes 
tumor progression in mouse models,13-16 while LPA receptor deficiency protects from colon 
carcinogenesis.17 In addition, to its role in cancer, ATX-LPA signaling has been implicated in 
lymphocyte homing and (chronic) inflammation,18 fibrotic diseases19,20 and thrombosis.21 
Therefore, the ATX-LPA axis qualifies as an attractive target for therapies. 
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Figure 1: The ATX-LPA receptor signaling axis. Secreted ATX hydrolyzes extracellular LPC into LPA, 
a reaction catalyzed by active site residue T210. LPA signals through multiple G protein-coupled 
receptors to stimulate the proliferation, migration and survival of many cell types. LPA is degraded 
to monoacylglycerol (MAG) by lipid phosphate phosphatases (LPPs), which are membrane-bound 
ecto-enzymes.
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Potent and selective ATX inhibitors are now needed as a starting point for the 
development of targeted anti-ATX/LPA therapy. Direct targeting of LPA receptors seems 
to be a less attractive strategy, since LPA acts on multiple receptors that show overlapping 
activities.5,7 Since the initial finding that ATX is subject to product inhibition by LPA and 
sphingosine 1-phosphate (S1P),22 various synthetic phosphate and phosphonate lipids have 
been explored as ATX inhibitors.23-26 However, such lipid inhibitors have the inherent danger of 
inadvertently activating downstream LPA/S1P receptors, thereby inducing the opposite of the 
intended effect. Furthermore, lipids offer relatively few avenues for chemical diversification 
and usually have poor pharmacokinetic properties. Non-lipid inhibitors of ATX have recently 
been identified, but their potencies are low.27 
In this study we screened small molecule libraries to search for novel ATX inhibitors. 
We identified thiazolidine-2,4-dione compounds that selectively inhibit ATX activity and are 
readily amenable to further chemical diversification. We have optimized these molecules 
by adopting an active site-targeted strategy that has proved successful for the development 
of the boronic acid-based proteasome inhibitor bortezomib,28 which is in clinical use.29 We 
show that a boronic acid-based inhibitor potently inhibits ATX both in vitro and in vivo.  When 
administered to mice, our inhibitor (HA130) induces a remarkably rapid fall in plasma LPA 
levels, indicating that the turnover of circulating LPA is much more dynamic than previously 
appreciated. We conclude that boronic acid-based inhibitors hold promise as candidate drugs 
to target the ATX-LPA axis in vivo.
2.2 Discovery of small molecule inhibitors of ATX 
The hydrolytic activity of ATX originates from a single catalytic site at threonine 210 (T210) in 
the central phosphodiester domain (Figure 1).2 To discover novel ATX inhibitors, we screened 
a collection of ~40,000 drug-like small molecules using the hydrolysis of bis-para-nitrophenyl 
phosphate (bis-pNPP) by ATX as a readout. Among the most potent hits, we selected a 
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Figure 2: ATX inhibitors discovered by high-throughput screening and validation of compound A. 
(A) IC
50
 values based on bis-pNPP (1 mM) hydrolysis. (B) TLC analysis of 14C-LPC to 14C-LPA 
conversion at different concentrations of A (range: 0-30 µM).
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thiazolidine-2,4-dione series for optimization since the thiazolidine-2,4-dione core is readily 
amenable to chemical diversification (Figure 2A). Inhibitor A showed an IC
50
 value of 56 nM 
using 1 mM bis-pNPP as substrate. For validation of A, we measured the inhibition of the ATX-
catalyzed release of choline from LPC. We established that recombinant ATX has a K
m
 value 
for LPC of 94 µM (Supporting Figure S1). Compound A inhibited ATX with an IC
50
 value of 2.5 
µM using 40 μM LPC as a substrate (Figure 3A). However, it should be noted that A has a 35% 
residual ATX activity (Figure 3B). Inhibition of ATX-mediated LPA production was confirmed by 
measuring the conversion of 14C-LPC to 14C-LPA using thin-layer chromatography (Figure 2B). 
2.3 Boronic acid-based optimization
Having identified compound A as a novel ATX inhibitor, we set out to improve its potency. We 
engineered a synthetic route (see Chapter 3), which allowed the synthesis and isolation of 
more than 100 derivatives of A in a short time frame.  
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Figure 3: Analysis of ATX inhibition by compounds A, HA51 and boronic acid HA130, as measured 
by choline release from LPC (40 μM). (A) IC
50
 values and residual ATX activity (RA) for the 
three inhibitors tested. (B) Dose-inhibition curves for the inhibitors shown in (A). (C) Washout 
experiments showing that ATX inhibition is reversible. (D) Lineweaver-Burk plot analysis of ATX 
inhibition, showing competitive inhibition by A and HA51 and mixed-type inhibition by HA130.
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All derivatives were tested in the ATX-mediated choline release assay. Figure 3A shows 
the IC
50
 values of the three most important molecules in the optimization process. Omitting 
the methoxy group and replacing the carboxylic acid to the meta position (HA51) resulted 
in a 2.5-fold increase in potency, concomitant with a significant drop in residual ATX activity, 
from 35 to 7% (Figure 3A and B). Lineweaver-Burk analysis revealed that A and HA51 act 
as competitive inhibitors (Figure 3D), suggesting that they bind at or close to the catalytic 
threonine residue (T210). 
We next sought to target active site residue T210. We reasoned that the acid moiety of 
A and HA51 may bind to the phosphate ester acceptor site in ATX and that the T210 oxygen 
nucleophile could be targeted by a boronic acid moiety. Boronic acid is known for its high 
affinity for hard oxygen nucleophiles over soft nucleophiles, such as sulfur, which is found in 
many phosphate ester hydrolytic enzymes. This approach has an important precedent in the 
proteasome inhibitor and anti-cancer drug bortezomib (Velcade), which is a peptidyl boronic 
acid that targets the threonine oxygen nucleophile in the proteasome active site through its 
boronic acid moiety.28,30 We adopted a similar approach to target the T210 oxygen nucleophile 
in ATX. This improves selectivity over phosphate ester hydrolyzing enzymes that depend on a 
sulfur (cysteine) nucleophile. 
Replacing the carboxylic acid in HA51 by a boronic acid yielded compound HA130. 
This resulted in a ~100-fold increase in potency compared to screening hit A (IC50 = 28 nM) 
(Figure 3A). Furthermore, HA130 abolished the residual ATX activity observed with inhibitors 
A and HA51. Kinetic analysis revealed that HA130 is a mixed-type inhibitor, producing a 
reduction in V
max
 and an increase in K
m 
(Figure 3D). Thus, inhibition of ATX by HA130 results 
from a combination of a decreased turnover number and decreased affinity for its substrate. 
Washout of HA130 and the other inhibitors fully restored ATX activity, indicative of reversible 
inhibition (Figure 3C).
2.4 Selective inhibition of ATX
Since boronic acids can target the proteasome active site, we examined whether HA130 
may affect proteasome activity. HA130 did not affect the chymotryptic, caspase and tryptic 
activities of the proteasome (Supporting Figure S2B). Conversely, bortezomib did not affect 
ATX activity. We next tested our inhibitors for selectivity against recombinant ENPP1, 
which is the closest relative of ATX, alkaline phosphatase (AP) and a broad-spectrum 
phosphodiesterase (PDE). None of these enzymes were affected by the ATX inhibitors at 
doses up to 10 µM (Supporting Figure S2A). Furthermore, cell viability was not compromised 
by HA130 (Supporting Figure S2C).
2.5 Inhibition of ATX-driven melanoma cell migration  
ATX was originally identified as an autocrine motility factor for human A2058 melanoma 
cells.1 We examined the ATX-mediated chemotactic migration of A2058 cells using a Boyden 
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chamber assay. ATX hydrolyzes exogenously added LPC into LPA, a potent chemoattractant 
for A2058 cells. As shown in Figure 4A, ATX inhibitors A, HA51 and HA130 inhibited ATX-
mediated cell migration with increasing potencies. None of the inhibitors affected LPA-induced 
cell migration, indicating that they do not act on LPA receptor signaling pathways.
2.6 Inhibition of plasma ATX activity 
ATX is identical to plasma lysoPLD3,4 and responsible for virtually all LPA-producing activity in 
plasma and serum.31 Inhibitors were tested for their ability to inhibit ATX/lysoPLD activity in 
human plasma ex vivo. As shown in Figure 4B, all three inhibitors were found to inhibit plasma 
ATX activity with the expected ranking order of potency. Inhibition of plasma ATX activity was 
long-lasting (24 h), indicating that HA130 is stable in plasma (Supporting Table S1). 
2.7 HA130 decreases circulating LPA levels in mice
To investigate how ATX inhibition affects circulating plasma LPA levels, we administered HA130 
(1 nmol g-1) or vehicle as a single bolus injection into the jugular vein of anaesthetized mice. As a 
non-vehicle control we used compound HA51. Levels of HA130 or LPA in plasma samples rapidly 
isolated from venous blood were monitored before and after dosing.  As shown in Figure 5A, 
intravenous administration of vehicle or HA51 (Supporting Figure S3) had little or no effect on 
plasma LPA levels. Following administration of HA130 (t = 10 min), plasma levels of the inhibitor 
rose rapidly to a concentration approaching 0.35 μM. This was accompanied by a parallel 
decrease in plasma LPA levels (3.8-fold) which returned slowly towards baseline as plasma levels 
of HA130 declined. Figure 5B shows summarized data from replicate experiments in which mice 
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Figure 4: Effect of inhibitors on ATX-induced cell migration and on plasma ATX/lysoPLD 
activity. (A) ATX (1.2 nM), LPC (1 µM) and BSA (1 mg mL-1) were added to the lower chambers 
of 48-wells Boyden chambers and the trans-well migration of A2058 melanoma cells was 
assayed after 4 h in the presence or absence of ATX inhibitors. None of the compounds 
inhibited LPA-induced cell migration (inhibitor and LPA added at 0.3 μM). (B) Inhibition 
of endogenous ATX/lysoPLD activity in human plasma ex vivo, as measured by choline 
release from LPC. Inhibition was maintained for at least 24 h (see Supporting Table S1). 
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were dosed with vehicle or HA130 while plasma LPA levels were measured before, 2 and 10 
min post dosing (see also Supporting Figure S3). Administration of HA130 produced statistically 
significant decreases in plasma LPA levels compared to baseline, vehicle and HA51. The mean 
decrease in plasma LPA levels was 48% of the baseline control at 2 min post administration 
of HA130. Plasma HA130 levels correlated well (R2 = 0.751) with plasma LPA levels (Figure 
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Figure 5: Effects of HA130 on circulating LPA levels in mice. (A) Vehicle or HA130 was administered 
intravenously into an anaesthetized mouse and plasma levels of the inhibitor or total LPA were 
determined at the indicated time points. Compound HA51 was used as a non-vehicle control 
(see Supporting Figure S3). (B) Plasma levels of LPA were determined at baseline and at 2 and 
10 min post dosing of vehicle or HA130. The data shown are means +/- SD (6 mice treated 
with HA130; 5 mice treated with vehicle alone). The difference between baseline LPA levels 
and LPA levels at 2 min in HA130-treated mice are statistically significant (p < 0.01, **) by 
paired t-test. (C) Plasma levels of LPA and HA130 at 2 min post administration closely correlate 
(R2 = 0.751). (D)  C17-LPA (10 μL of a 10 mM solution in saline containing 0.1% fatty acid-free 
BSA) was injected into the jugular vein of anaesthetized mice and plasma levels of C17-LPA 
were determined at different time points. The inset shows a semi-log plot used to calculate 
the half-life for clearance of C17-LPA from the circulation. Data points are means +/- SD (n = 3).
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5C). Taken together, these findings suggest that continual production of LPA by ATX-catalyzed 
hydrolysis of circulating LPC is required to sustain plasma levels of LPA at their observed steady-
state level. To confirm this, we injected C17-LPA and found that the levels of this unnatural LPA 
analog were elevated at the earliest measurable time point, but then decayed rapidly following 
pseudo first-order kinetics with a half-life of approximately 3 min (Figure 5D).
2.8 Discussion and conclusions
In this study we have identified and optimized a class of thiazolidine-2,4-dione compounds as 
potent and selective inhibitors of ATX that can reduce LPA plasma levels in mice. Our chemical 
optimization strategy was based on targeting the catalytic T210 residue in ATX by introducing 
a boronic acid moiety. Boronic acid has previously been shown to be instrumental in the anti-
cancer drug bortezomib, which targets the threonine oxygen nucleophile in the active site of 
the proteasome.30 Strikingly, replacing the carboxylic acid in HA51 by a boronic acid increased 
the potency for ATX inhibition by two orders of magnitude compared to the screening hit A. 
This boronic acid inhibitor named HA130 did not affect either ENPP1 or proteasome activity, 
which have both a catalytic threonine residue. Injection of HA130 into mice resulted in a rapid 
fall in circulating LPA levels, which is in keeping with the rapid degradation of intravenous 
administered C17-LPA observed in these animals. This result indicates that maintenance of 
steady-state LPA levels in plasma involves a highly dynamic balance between its ATX-mediated 
synthesis and its degradation by LPPs. Consistent with this, LPP1-deficient mice show a 
significantly reduced rate of [32P]LPA degradation in the bloodstream.32 Thus, ATX and LPPs 
are key determinants of LPA turnover in vivo and their activity balance sets the steady-state 
level of LPA in the circulation and, most likely, in the interstitial space. 
Several questions concerning circulating ATX remain to be answered, including its 
tissue origin and metabolic fate, although recent evidence indicates that ATX is rapidly 
cleared from the circulation by liver sinusoidal endothelial cells.33 Circulating ATX and LPA 
do not, of course, reflect the levels in intercellular spaces, since ATX is produced locally by 
many different cell types while the LPC substrate level in interstitial fluids is much lower than 
that in plasma. Another key question concerns how ATX activity is regulated under (patho)
physiological conditions. Interestingly, ATX binds to activated lymphocytes and platelets in an 
integrin-dependent manner,18,21 which could lead to altered catalytic activity and serve as a 
mechanism for localized LPA production at sites of inflammation and injury. 
In conclusion, we have used a boronic acid-based inhibitor to demonstrate that ATX is a 
valid target for manipulating LPA levels in vivo. Further development of boronic acid inhibitors 
of ATX holds promise for therapeutic use in ATX/LPA-dependent pathologies, including chronic 
inflammation, tumor progression and fibrotic diseases. 
35
Biological validation of a boronic acid-based inhibitor of autotaxin
2.9 Experimental section
Chemicals and enzymes. Small molecule libraries were obtained from the NCI and purchased from 
SPECS (Delft, The Netherlands). The compounds AN-988/40680277, AN-989/41697944 and AN-
989/40746701 are all from the SPECS collection and are abbreviated by A, B and C, respectively. 
1-Oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC, 18:1) and 1-heptadecanoyl-sn-glycero-3-
phosphate (C17-LPA) were purchased from Avanti Polar Lipids. Horseradish peroxidase (HRP), 
choline oxidase and phosphodiesterase I from Crotalus atrox were obtained from Sigma-Aldrich. 
Alkaline phosphatase from calf intestine was from Roche. Radiolabeled LPC (1-[1-14C]palmitoyl) was 
from Amersham Biosciences UK (specific activity 925 kBq mL-1). 
Recombinant ATX. HEK293 cells were transfected with the pcDNA3 vector containing a 6xHis-
tagged human teratocarcinoma ATX sequence. After transfection, cells were washed and serum-free 
medium was added and cells were allowed to secrete His-tagged ATX into the culture medium for 48 
h. Medium was collected and ATX was purified using TALON-affinity beads (Clontech) as described. 
Imidazole was removed by dialysis against Tris-buffered saline (140 mM NaCl, 5 mM KCl, 1 mM CaCl
2
, 1 
mM MgCl
2
 and 50 mM Trizma, pH 8.0). Purity was verified by SDS-PAGE and Coomassie blue staining.
ATX/lysoPLD activity assay.34 ATX/lysoPLD activity was measured by choline release from LPC (18:1) 
(40 μM) in 96-well plates. Inhibitors in DMSO were added to recombinant ATX (20 nM) in Tris-HCl 
buffer (pH 7.4) at 310 K. After 3 h of incubation, 50 µL ABTS (2 mM) and horseradish peroxidase (10 
U mL-1) were added to 50 µL of the reaction mixture. Choline oxidase (50 µL, 10 U mL-1) was added 
for the colorimetric reaction. Absorbance was measured at 405 nm and data were analyzed using 
Graphpad Prism software. For a more detailed description of this assay see Experimental section 
Chapter 3.
Phosphodiesterase activity assays.22 ATX activity toward bis-pNPP hydrolysis was determined as 
follows. Inhibitors in 2 µL DMSO were added to a 384-wells plate containing 24 µL ATX (~40 nM) 
in buffer (140 mM NaCl, 5 mM KCl, 1 mM CaCl
2
, 1 mM MgCl
2
, 50 mM Tris, pH 7.8) containing fatty 
acid-free BSA (0.2 mg mL-1). Finally, 24 µL bis-pNPP (2 mM) was added to each well and the plate 
was incubated for 3 h at room temperature. Percentage inhibition (PI) was determined at a final 
concentration of 5 µM inhibitor. Absorbance was determined using a Perkin Elmer Envision plate 
reader (λ = 405 nm). ENPP1 activity was measured at an ENPP1 concentration of 180 nM. Reaction 
was carried out in 100 µL reaction buffer as described above and incubated at room temperature 
for 90 min. For PDE activity the same protocol was handed using 6 mU mL-1 of PDE incubating the 
reaction mixture at room temperature for 20 min. Graphpad Prism software was used for data 
analysis. 
14C-LPA formation. Incubations were carried out essentially as described in the choline release assay 
in the presence of 0.5 µM 1-[1-14C]palmitoyl-LPC. Reactions were terminated by adding 150 µL 
0.01 M acetic acid and 250 µL 1-butanol. After mixing and centrifugation, the 1-butanol phase was 
removed and the remaining water phase extracted with 1-butanol. The pooled butanol phases were 
washed and concentrated to dryness under vacuum. Reaction products were analyzed by thin layer 
chromatography (TLC). TLC plates were developed with CHCl
3
/MeOH/CH
3
COOH/H
2
O (50:30:8:4). 
Retardation factors for LPA and LPC were 0.5 and 0.13, respectively. Lipids were visualized by 
autoradiography.
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Selectivity and toxicity. Alkaline phosphatase activity was determined by hydrolysis of bis-para-
nitrophenyl phosphate (bis-pNPP). Inhibitors were added to 50 µl alkaline phosphate (0.4 U mL-1) 
in 50 mM Tris-HCl (pH 8.5) containing 0.1 mM EDTA. 50 µL bis-pNPP (0.6 mM) was added to each 
well and the plate was incubated at room temperature for 1.5 h. Absorbance was determined at a 
wavelength of 405 nm. 
Cell toxicity was determined using the CellTiter-Blue assay. Cells (1.5x105 mL-1) were incubated 
with or without inhibitors for 24 h. Phenylarsine oxide (PAO) was used as a control for cell death. 
After 19 h of incubation, 20 µL of resazurin (0.125 mg mL-1) was added for 5 h. Fluorescence was 
measured at λ
ex
/λ
em 
= 544/560 nm.
Proteasome activity. Purified bovine proteasome was preincubated with inhibitors for 30 min, 
followed by addition of AMC substrate.35 Fluorescence was measured every 10 min during 1 hr after 
substrate addition at 310 K. 1 µg of bovine proteasome was added to assay buffer (25 mM Tris pH 
7.4, 5 mM MgCl
2
, 1 mM DTT, 1 mM ATP). AMC substrates used: 100 µM LLVY-AMC (chymotryptic 
activity), 40 µM LLE-AMC (caspase-like activity) and 60 µM VGR-AMC (tryptic activity). Controls used 
for proteasome inhibition were MG132 (25 µM) and epoxomicin (1 µM).
Human plasma ATX activity. Plasma ATX activity was measured in 96-wells plates using LPC (18:1) 
as a substrate. Heparin-treated human plasma (2 µL) was added to 38 µL Tris-HCl buffer (100 mM 
Tris-HCl, pH 9, 500 mM NaCl, 5 mM MgCl
2
 and 0.05% Triton X-100). Subsequently, 0.8 µL inhibitor in 
DMSO was added. Finally, 40 µL of 2 mM LPC (18:1) in Tris-HCl buffer was added to each well and the 
plate was incubated at 310 K. The mixture with DMSO alone was used as a control. Plasma without 
added LPC was taken as control for endogenous LPA production. After 1.5 h of incubation, 150 µL 
homovanillic acid (2 mM) and horseradish peroxidase (1.6 U mL-1) in Tris-HCl (0.01% Triton X-100, 20 
mM CaCl
2
 and 50 mM Tris-HCl, pH = 7.4) was added to 20 µL of the reaction mixture. Choline oxidase 
was added (40 µL, 4 U ml-1) and fluorescence was determined at λ
ex
/λ
em
 = 320/450nm. 
ATX-mediated cell migration. A2058 melanoma cell chemotaxis was assayed using 48-well Boyden 
chambers. Fibronectin-coated polycarbonate membranes (8 µM pores, NeuroProbe Inc.) were used 
to separate the upper from the lower chamber. The lower chamber contained DMEM with BSA (1 
mg mL-1), ATX (1.2 nM) and LPC (1 µM). Cells (0.75 x 106 mL-1) were loaded in the upper wells and 
the chamber was incubated at 310 K for 4 h. Non-migrated cells were removed from the membrane 
and migrated cells were fixed and stained in Diff-Quick (Medion Diagnostics AG, Switzerland). The 
membrane was mounted on a glass slide and migrated cells were quantified.
Quantitation of HA130 by HPLC tandem mass spectrometry. HA130 was quantitated by HPLC 
tandem mass spectrometry using an ABI 4000 Q-Trap hybrid linear ion trap triple quadrupole mass 
spectrometer operating in triple quadrupole mode. The ion source settings were ion spray voltage 
+5500 V, declustering potential 126 V entrance potential 10 V ion spray voltage 5500 V, ion source 
temperature 823 K.  Material was separated by reverse phase HPLC on an Agilent Eclipse XDB 
C8 column (4.6 × 150 mm, 5 μM), flow rate 0.5 mL min-1 with a step gradient of solvent A 75/25 
methanol/water containing 0.5% formic acid and 0.1% ammonium formate, solvent B 99/1 methanol 
water containing 0.5% formic acid and 0.1% ammonium formate. HA130 was quantitated by selective 
reaction monitoring of precursor/product ion pairs with m/z 464/109, 464/135.1, 464/117.1 with 
optimized collision energies and colllision cell exit potentials for each ion pair. For analysis of HA130 
in mouse plasma, material was extracted/deproteinated using acidified organic solvents as detailed 
below. Recovery of HA130 was estimated to be ~70%; values were corrected for recovery of the C17-
LPA internal standard (see below).
37
Biological validation of a boronic acid-based inhibitor of autotaxin
Quantitation of LPA molecular species by HPLC tandem mass spectrometry. Whole blood was 
sampled and transferred directly into anticoagulant, centrifuged and plasma added directly to 
acidified organic solvents. After extraction, organic solvent soluble material was separated by reverse 
phase HPLC and 16 abundant LPA molecular species quantitated by tandem mass spectrometry 
using an ABI 4000 Q-Trap hybrid linear ion trap triple quadrupole mass spectrometer. Recovery was 
determined using C17-LPA as an internal standard and quantitation accomplished by reference to 
calibration curves determined using a series of synthetic LPAs that were independently quantitated 
by phosphorous analysis following wet digestion in perchloric acid.
Studies in mice. For intravenous administration, HA130 and HA51 in DMSO were diluted 10-fold into 
saline to give a drug concentration solution of 1 mM and a final DMSO concentration of 10%. This 
material was kept at 310 K and bath sonicated for 30 s immediately prior to intravenous administration. 
Male FVB mice were anaesthetized with isofluorane and dissected to expose the jugular vein. HA130 
(1 µL g-1, 1 mM) or vehicle were injected intravenously. HA51 served as a non-vehicle control. Whole 
blood was sampled from the jugular vein and collected directly into anticoagulant, mixed, centrifuged 
and plasma transferred to glass tubes containing acidified solvents for extraction of HA130 and LPA. 
All animal experiments conformed to the recommendations of the “Guide for the Care and Use of 
Laboratory Animals” (Department of Health, Education, and Welfare publication number NIH 78-23, 
1996) and were approved by the institutional Animal Care and Use Committee.
Chemical synthesis inhibitors. See Chapter 3.
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2.11 Supporting information
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Supporting Figure S1: Saturation kinetics of 
ATX. Rates of choline release from LPC are 
plotted against increasing concentration of LPC. 
ATX activity data points (absorbance; arbitrary 
units (AU)) were fitted to the Michaelis-Menten 
equation, yielding an apparent K
m
 value for LPC 
of 95 µM (n=5).
a Percentage inhibition (PI) by the three inhibitors (5 
µM) was measured at the indicated time points. ATX 
inhibition was constant over 24 h.
Supporting Table S1: Inhibition of ATX activity in 
human plasma over time. 
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Supporting Figure S2: Enzyme selectivity and toxicity of ATX inhibitors. (A) Lack of effect of ATX 
inhibitors on ENPP1, PDE and AP activity. (B) Lack of effect of HA130 (up to 10 µM) on the indicated 
proteasome activities. Proteasome inhibitors epoxomicin (epox) and MG132 were used as controls. 
(C) Toxic dose (TD
50
) of ATX inhibitors for human A2058, HEK293T and HepG2 cells. Phenylarsine 
oxide (PAO) was used as a control for cell death (nt: no toxicity below 100 µM).
Supporting Figure S3: Plasma levels of LPA 
were determined before and 2 min post 
dosing of mice treated with HA51 (n=4) 
and HA130 (n=6). The data shown are 
means +/- SEM.
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Discovery and optimization of boronic acid-based inhibitors 
of autotaxin: How did we exactly arrive at these inhibitors? 
Harald M.H.G. Albers, Laurens A. van Meeteren, David A. Egan, Erica W. van Tilburg, Wouter H. 
Moolenaar and Huib Ovaa, Journal of Medicinal Chemistry 2010, 53, 4958-4967.
Abstract. Autotaxin (ATX) is an extracellular enzyme that hydrolyzes lysophosphatidylcholine 
(LPC) to produce the lipid mediator lysophosphatidic acid (LPA). The ATX-LPA signaling axis 
has been implicated in diverse physiological and pathological processes, including vascular 
development, inflammation, fibrotic disease and tumor progression. Therefore, targeting 
ATX with small molecule inhibitors is an attractive therapeutic strategy. The previous 
chapter describes thiazolidine-2,4-diones that inhibit ATX activity in the micromolar range. 
Interestingly, inhibitory potency was dramatically increased by introduction of a boronic acid 
moiety, designed to target the active site threonine in ATX. Here the discovery and further 
optimization of boronic acid-based ATX inhibitors is described. The most potent of these 
compounds inhibits ATX-mediated LPC hydrolysis in the nanomolar range (IC
50
 = 6 nM). The 
finding that ATX can be targeted by boronic acids may aid the development of ATX inhibitors 
for therapeutic use.
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3.1 Introduction
Autotaxin (ATX or ENPP2), originally isolated as an autocrine motility factor from 
melanoma cells, belongs to the ecto-nucleotide pyrophosphatase and phosphodiesterase 
(ENPP) family.1-3 This extracellular enzyme acts as a lysophospholipase D, hydrolyzing 
lysophosphatidylcholine (LPC) into the lipid mediator lysophosphatidic acid (LPA), as depicted 
in Scheme 1.4,5  Hydrolytic activity of ATX originates from a threonine (T210) residue in the 
active site.1 LPA activates specific G protein-coupled receptors and thereby stimulates the 
migration, proliferation and survival of many cell types.6
The ATX-LPA axis has a vital role in vascular development.7,8 Furthermore, it has 
been implicated in various pathologies including tumor progression9 and metastasis,10 
inflammation11 and fibrotic disease.12 Given its role in human disease, the ATX-LPA axis is 
an obvious target for therapy. The fact that ATX is an extracellular enzyme makes it even 
more attractive as a drug target. Since there are at least six distinct LPA receptors, direct 
targeting of LPA receptors seems to be a less attractive strategy.13,14 On the basis of the initial 
discovery that ATX is inhibited by LPA and sphingosine 1-phosphate (S1P) under certain 
conditions,15 various synthetic phospholipid analogs have been explored as ATX inhibitors.16-
20 However, lipid-based inhibitors have the disadvantage that they could act as agonists or 
antagonists for any of the LPA/S1P receptors, thereby resulting in an effect opposite of the 
one intended. In addition, non-
lipid ATX inhibitors have been 
identified, but their inhibitory 
potential is low (IC
50
 ≥ 1 μM).21-23
The previous chapter 
describes a non-lipid ATX 
inhibitor (HA130)24 that rapidly 
lowers plasma LPA levels upon 
intravenous injection in mice. 
Using HA130 we found that 
the turnover of circulating LPA 
is much faster than expected, 
showing the usefulness of ATX 
inhibitors as tools to elucidate 
the role of ATX and LPA in vivo. 
Here we describe the 
discovery and optimization of 
boronic acid-based inhibitors 
of ATX. We screened ~40,000 
small molecules and identified 
thiazolidine-2,4-dione as ATX 
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Scheme 1. The hydrolysis of LPC by ATX into LPA and 
choline. The lysoPLD reaction is catalyzed by a threonine 
oxygen nucleophile (T210). Newly produced LPA triggers 
subsequent biological events via activation of specific G 
protein-coupled receptors.
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inhibitors, which proved to be suitable to further chemical optimization. In particular, we 
optimized these molecules by first introducing small systematic variations in the structure of 
a screening hit, followed by the introduction of more random variations. Finally, by targeting 
the T210 oxygen nucleophile in ATX through a boronic acid, the potency of the original 
thiazolidine-2,4-dione screening hit was increased over 400-fold (IC
50
 = 6 nM).
3.2 ATX inhibitor screen
To identify ATX inhibitors, a small molecule screen was carried out. We first used a collection of 
17,500 molecules from the National Cancer Institute (NCI) to optimize our screening protocol. 
This NCI library was initially screened using CPF4, an ATX activity reporter based on Förster 
resonance energy transfer (FRET) (Figure 1A).15,25 The phosphodiester bond which links the 
coumarin and fluorescein moieties in CPF4 is hydrolyzed by ATX, resulting in the loss of FRET. 
Since we have shown that LPA can inhibit ATX activity in this assay, it was used as a positive 
control for ATX inhibition.15 Approximately 250 active molecules were retested in a second 
assay using bis-para-nitrophenyl phosphate (bis-pNPP) as reporter substrate (Figure 1B).15 In 
Supporting Figure S1 the results of both assays are compared. Only a few compounds remained 
after retesting in the bis-pNPP assay. Since the CPF4 assay resulted in many false positives, 
we decided to reverse the assay order. The same NCI library was tested in the bis-pNPP assay 
using CPF4 as confirmation tool which led to reproducible hits corresponding to the findings of 
Saunders et al.26 Top three actives of the NCI screen can be found in Supporting Figure S2. 
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Figure 1. Three ATX assays used for screening and validation of ATX inhibitors. (A) CPF4 assay; This 
assay is based on Förster resonance energy transfer (FRET) between coumarin and fluorescein 
moieties of CPF4. (B) Bis-pNPP assay; In this assay bis-para-nitrophenyl phosphate (bis-pNPP) 
is hydrolyzed by ATX into the chromophore para-nitrophenol. (C) Choline release assay; The 
physiological substrate of ATX, LPC, is hydrolyzed by ATX to give LPA and choline. The release of 
choline can be detected in a two-step enzymatic coloring reaction.
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After setting up our screening protocol, we used a commercial library (SPECS) consisting 
of 23,000 small molecules with predicted drug-like properties. For active molecules in this 
screen the percentage inhibition (PI) at 5 µM and IC
50
 values (bis-pNPP assay) are shown in 
Figure 2. These actives were confirmed by the CPF4 assay (Figure 2). Among the confirmed 
active molecules were several thiazolidine-2,4-diones (1, 2, 4 and 5), a pyrano pyrazole (3) 
and a benzothiazole (6). Because the thiazolidine-2,4-diones are well represented among 
the positive hits and their amenability to fast chemical diversification, the most potent 
thiazolidine-2,4-dione 2 (IC
50
 = 56 nM) was selected for further optimization.
Structure Entry PI (%) IC50 (nM)
  
Bis-pNPP CPF4 Bis-pNPP 
1 92 89 161 
2 (A) 91 85 56 
3 87 77 46 
4 83 85 68 
5 75 55 111 
6 71 66 261 
LPA 80 67 442 
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Figure 2. ATX inhibitors discovered by high-throughput screening. Percentage inhibition (PI) at 5 
µM is based on the bis-pNPP or CPF4 assay. IC
50
 values are obtained using the bis-pNPP assay. LPA 
was used as a control for ATX inhibition.
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3.3 Chemistry
We next explored how to improve the potency of thiazolidine-2,4-dione 2 (compound A in 
Chapter 2) as an ATX inhibitor. We designed the convergent synthetic route toward inhibitor 
2 depicted in Scheme 2. The synthesis requires benzoic acid 7 which can be obtained via a 
one-pot-synthesis. First, vanillin was O-alkylated with methyl-4-(bromomethyl) benzoate.27 
The resulting benzoate was hydrolyzed to give benzoic acid 7. To afford the precursor 8, 
thiazolidine-2,4-dione was dissolved in DMF and N-alkylated with 4-fluorobenzyl chloride in 
the presence of sodium hydride. Finally, monosubstituted thiazolane-2,4-dione 8 was reacted 
via a Knoevenagel condensation with benzoic acid 7.28 Z-isomer 2 precipitated during reaction 
and washing the precipitate with ethanol resulted in homogeneous product (For 1H NMR 
and HPLC spectra see Supporting Figure S3). The synthetic route toward 2 appeared to be 
applicable for the fast parallel synthesis and purification of many analogs without the need 
for chromatography.
3.4 Systematic optimization
Inhibitor 2 contains two side chains attached to the thiazolidine-2,4-dione core, a benzyl and 
a benzylidene moiety (Scheme 2). To explore structure-activity relationships (SAR), we first 
generated a small library before embarking on a bigger effort. This resulted in the molecules 
listed in Table 1. LPA was used as a control that it inhibits the ATX-mediated hydrolysis of bis-
pNPP by ATX (IC
50
 = 0.4 µM).15
The best series of inhibitors are the benzoic acids (2 and 9-11), where the fluorinated 
compound 2 has the highest activity (IC
50
 = 56 nM) in the bis-pNPP assay (Table 1). 
Replacement of the 4-fluorine atom (2) for hydrogen (9), nitro- (10) or a tert-butyl group (11) 
reduced the potency of the inhibitor with increasing size of the functional group. With the 
replacement of the carboxylic acid in molecules 2 and 9-11 by a methyl ester (12-15), potency 
7
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Scheme 2. Convergent synthetic route towards thiazolidine-2,4-dione  2 (A). Reagents (i) KOH, 
DMSO, rt, 30 min. (ii) NaOH, DMSO/H2O (1:3, v/v), reflux, 4 h, 91%. (iii) NaH, DMF, rt, 22 h, 74%. 
(iv) Piperidine, EtOH, reflux, 20 h, 63%.
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is largely lost. Omitting the carboxylic acid 
(16-19) has the same effect. With removal 
of the methoxy group (R2) in molecules 
16-19, activity is regained (compare 16-19 
with 20-23). SAR analysis showed that the 
optimal combination of groups would be 
R1 = -OCH
2
-Ph-COOH, R2 = H and R3 = F. 
Encouraged by the SAR results sug-
gesting that the methoxy and carboxylic 
acid groups are important moieties, mol-
ecules 28-30 were synthesized (Figure 3A). 
Molecules 2, 9-11 and 28-30 were validat-
ed in the physiologically more relevant LPC 
hydrolysis (choline release) assay.17 The 
ATX-mediated release of choline from LPC 
is detected by a two-step enzymatic colori-
metric reaction (Figure 1C). In the first step 
choline is oxidized by choline oxidase into 
betaine (trimethylglycine) and hydrogen 
peroxide. Horseradish peroxidase (HRP) 
then consumes hydrogenperoxide to oxi-
dize 2,2’-azino-bis(3-ethylbenzothiazoline-
6-sulfonic acid) (ABTS) to a radical cation 
species which absorbs at 405 nm. 
The data obtained from the choline 
release assay are summarized in Figure 3A. 
The IC
50
 values obtained were some 10-fold 
higher than observed in with bis-pNPP as a substrate. It is noteworthy that compound 10 is 
incapable of fully inhibiting ATX at high concentrations (Figure 3B). This residual ATX activity 
for 10 is about 60%. However, 10 shows inhibition at a lower concentration than 11 which 
was also observed in the bis-pNPP assay. LPA did not inhibit ATX in the choline release assay 
as observed by Ferry et al.19
The established SAR was confirmed by the more active molecule 28 (IC
50
 = 1.63 μM) in 
which the methoxy group in 2 (IC
50
 = 2.50 μM) is omitted. Changing the carboxylic acid of 2 
from para to the meta position results in the more potent inhibitor 29 (IC
50
 = 2.05 μM) but 
less potent than 28. Changing the carboxylic acid in 28 from para to meta (30 (HA51), IC
50
 = 
1.07 μM) results in the most active molecule in this systematic optimization with a 2.5-fold 
reduction in IC
50
 value compared to 2 and also to a further reduction in residual ATX activity 
(from 35 to 7%) in the choline release assay.
R1 R2 R3 Entry 
(µM) 
RA
(%) 
 
OMe H 9 0.248 9 
OMe F 2 0.056 10 
OMe NO2 10 0.442 33 
OMe C(CH3)3 11 18.2 33 
     
     
OMe H 12 2.69 24 
OMe F 13 >100 - 
OMe NO2 14 60.9 31 
OMe C(CH3)3 15 >100 - 
     
     
OMe H 16 >100 - 
OMe F 17 5.87 12 
OMe NO2 18 >100 - 
OMe C(CH3)3 19 na - 
     
     
H H 20 2.69 32 
H F 21 0.700 37 
H NO2 22 >100 - 
H C(CH3)3 23 >100 - 
H H 24 >100 - 
H H F 25 >100 - 
H NO2 26 na - 
H C(CH3)3 27 na - 
     
     
- - - LPA 0.442 39 
IC50
N S
O
O
R1
R2
R3
HOOC
O
MeOOC
O
O
O
Table 1. Structure-activity data for molecules 
of the systematic optimization. IC
50
 values and 
residual ATX activity (RA) of the synthesized 
thiazolidine-2,4-dione  derivatives using the 
artificial ATX substrate bis-pNPP (na: not active 
at 5 µM).
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3.5 Variation in the benzyl moiety
Since our initial systematic optimization of 2 provided good structure-activity correlations we 
varied either the benzyl or the benzylidene moiety (Scheme 2). In this approach, either the 
benzyl or the benzylidene moiety corresponds to the screening hit 2 while the other part is 
alternated. First, the effect of changes in the benzyl part of the molecule was investigated by 
introducing halogens. The percentage inhibition (PI) values at 5 µM of compounds 31-40, as 
measured by the choline release assay, are listed in Table 2. The most potent inhibitor was 
bromo compound 39 (PI = 73%). However, its IC
50 
(2.80 µM) is similar to that of screening hit 
2 (IC
50 
= 2.50 µM). Other substituents (41-71) that were explored did not result in significant 
improvements.
3.6 Variation in the benzylidene moiety.
Next, variations were incorporated into the benzylidene moiety, resulting in molecules shown 
in Supporting Table S1. In contrast to the variation in the benzyl moiety, few molecules were 
active; only 30% of the compounds tested showed inhibition (PI
max
 = 12%). This indicates that 
variations in the benzylidene moiety of screening hit 2 are not well tolerated.
3.7 Boronic acid introduction and optimization
Because the benzyl and benzylidene moiety variations did not improve inhibition, we 
modified inhibitor 30 that resulted from the systematic optimization. Replacing the carboxylic 
acid in molecule 30 by a boronic acid resulted in molecule 72 (HA130, Table 3). We recently 
characterized 72 as a potent ATX inhibitor both in vitro and in vivo.24 We reasoned that the 
carboxylic acid moiety in molecule 30 could act as a phosphate mimic that binds near or at 
the active site threonine (T210). Replacing the carboxylic acid in molecule 30 by a boronic 
R1 R2 R3 Entry RA 
(%) 
  
 
OMe H 9 2.90 29 
OMe F 2 2.50 35 
OMe NO2 10 >5 56 
OMe C(CH3)3 11 13.6 27 
H F 28 1.63 40 
OMe F 29 2.05 42 
H F 30 
(HA51) 
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Figure 3. Validation of screening hit 2 and the benzoic acids of the systematic optimization in 
the choline release assay. (A) Structure-activity data of the systematic optimization. Residual ATX 
activity is abbreviated by RA (%). (B) Dose-response curves for the benzoic acids.
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acid could well be a good ATX targeting strategy. This strategy was inspired by the proteasome 
inhibitor bortezomib, which targets the N-terminal threonine oxygen nucleophile in the 
proteasome through a boronic acid.29 Furthermore, boronic acids have been reported to 
inhibit β-lactamases through targeting of the active site serine residue.30
The boronic acid modification resulted in a 100-fold more potent inhibitor (IC
50
 = 28 
nM) compared to screening hit 2 (IC
50
 = 2.50 μM). When the position of the boronic acid was 
changed from meta (72) to the para (73) position, potency increased by another 5-fold (IC
50
 
= 5.7 nM), while the potency of the ortho boronic acid 74 dropped (IC
50
 > 5.00 μM). Next, the 
  
2 / 55% 31 / 64% 32 / 41% 33 / 57% 34 / 29% 35 / 57% 
   
36 / 38% 37 / 23% 38 / 26% 39 / 72% 40 / 51% 41 / 21% 
42 / 44% 43 / 17% 44 / 48% 45 / 38% 46 / 13% 47 / 17% 
48 / 10% 49 / 32% 50 / 46% 51 / 28% 52 / 13% 53 / 12% 
54 / 10% 55 / 11% 56 / 20% 57 / 35% 58 / 23% 59 / 17% 
60 / 0% 61 / 4% 62 / 13% 63 / 11% 64 / 5% 65 / 19% 
 
66 / 15% 67 / 31% 68 / 49% 69 / 42% 70 / 31% 71 / 30% 
N
S
O
O
O
O COOH
R
F
F
F
Cl
Cl
Cl
Cl
Cl
Br
Br
Br Br
F NC
N
NNC
NC
O2N
O2N
N
F3C
F3C
F3C F3C
F OF3C
F
F
F F
F
O
O
O
Cl
O
Br
O
NO2
N
O
O
O2N
HOOC HOOC HOOC MeOOC COOMe
Table 2. Derivatives of screening hit 2 with a structural variation in the benzyl moiety (R). 
Percentage inhibition (PI, %) has been determined in the choline release assay at 5 μM. Molecules 
that show more than 50% inhibition are in bold (compound / PI).
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3-benzyloxy boronic acids analogs 75-77 were synthesized. The meta boronic acid (75) proved 
to be more potent than the para (76) and the ortho boronic acid (77) has a low potency.
3.8 Effect inhibitors on readout choline release assay
An inherent danger of the choline release assay is that small molecules can interfere with 
the readout by inhibiting the enzymes (horseradish peroxidase or choline oxidase) used in 
the coloring reaction, resulting in false positives. Another way to interfere with the choline 
release assay is that compounds can react with the ABTS or hydrogen peroxide generated 
during the coloring reaction. The latter could be an issue for the boronic acids reported here 
because aliphatic and aryl boronic acids have the ability to react with hydrogen peroxide.31-33 
We investigated the effect of the inhibitors 72, 73, 75 and 76 on the coloring reaction, and no 
effect was observed (Supporting Figure S4). Therefore, the choline release assay is a valid way 
to test the synthesized compounds here on ATX inhibition.
3.9 Mode of inhibition
For inhibitors 2, 30, 72 and 73, the mode of inhibition was determined from a Lineweaver-
Burk plot (Supporting Figure S5). Inhibitors 2 and 30 inhibit in a competitive manner using 
LPC as substrate. Kinetic analysis for boronic acids 72 and 73 revealed a mixed type inhibition.
Because these inhibitors contain a Michael acceptor, it could be that these inhibitors 
react irreversibly with ATX (or other enzymes), which is undesirable.  When ATX is incubated 
with 5 µM inhibitor 2, 30, 72 or 73 for 20 min at 310 K and these solutions are then washed 
with ethyl acetate, ATX activity is restored up to 97% of its original activity in the choline 
release assay (Supporting Figure S6). This indicates that these inhibitors reversible bind to ATX.
72 (HA130) 73 (HA155) 74 75 76 77 
      
99% / 28.3 nM 99% / 5.67 nM 36% / >5.00 µM 100% / 11.9 nM 100% / 29.6 nM 11% / >5.00 µM 
N
SO
O
F
R
O
B
OH
OH O
B
OH
HO
O
B
HO
OH
O
B
HO
HO
O
B
HO
OH
O
B
OH
HO
Table 3. Potent ATX inhibitors of the boronic acid optimization. For the boronic acids percentage 
inhibition (PI, %) at 5 μM and IC
50
 values have been determined in the choline release assay (PI / IC
50
). 
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3.10 Discussion and conclusions
This study shows that ATX can be targeted efficiently by boronic acid inhibitors. We discovered 
thiazolidine-2,4-diones as potent non-lipid ATX inhibitors. Replacing the carboxylic acid by 
a boronic acid in thiazolidine-2,4-dione screening hit 2 resulted in a 440-fold more active 
inhibitor (IC
50
 = 2.50 μM  6 nM).
We handed three different approaches for optimization of screening hit 2. The first is 
the systematic optimization of 2, which led to a 2.5-fold increase in potency in the choline 
release assay. The second is a randomized approach, changing separately the benzyl and the 
benzylidene parts of the molecule. This did not result in significantly more potent molecules. 
Finally, we replaced the carboxylic acid in screening hit 2 by a boronic acid. Our rationale was 
that the carboxylic acid could function as a phosphate mimic and thereby bind near or at the 
T210 oxygen nucleophile. In that case, the T210 oxygen nucleophile in ATX can be targeted 
via a boronic acid. A similar strategy has proven successful for the proteasome inhibitor 
bortezomib which binds to threonine oxygen nucleophile in the proteasome active site 
through the boronic acid moiety.29 Replacing the carboxylic acid moiety in screening hit 2 (IC
50
 
= 2.50 μM) by a boronic acid resulted in molecule 73 (IC
50
 = 6 nM), which is over 400-fold 
more potent than inhibitor 2. These results demonstrate that ATX activity can be targeted by 
boronic acids. Next, to their increased affinity for ATX, the boronic acids are also expected to 
improve selectivity over hydrolytic enzymes that depend on a sulfur (cysteine) nucleophile, as 
is commonly found in phosphate ester hydrolyzing enzymes. 
Kinetic analysis showed that inhibitors 2 and 30 inhibit in a competitive manner 
indicating that they bind at the active site of ATX. The acid moiety of these inhibitors 
likely mimics the phosphate group, facilitating inhibition.  Boronic acids 72 and 73 show a 
mixed-type inhibition. It is expected that the boronic acids have the same binding site as 
their carboxylic acid equivalents 2 and 30 based on their structural similarity. Binding of 
the boronic acid to the T210 oxygen nucleophile likely results in the Lineweaver-Burk plot 
ATX
T210
- H+
+ H+
R
R
B
HO OH
B
O
OH
OHOH
Figure 4. Our hypothesis on the binding of boronic acid-based ATX inhibitors with the T210 oxygen 
nucleophile in the ATX active site.
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observed. The washout experiment reveals that inhibitors 2, 30, 72 and 73 all bind to ATX 
in a reversible manner. Figure 4 shows how the boronic acid inhibitors may bind to the T210 
oxygen nucleophile of ATX.
In summary, we have identified thiazolidine-2,4-diones as ATX inhibitors and have found 
that targeting ATX with a boronic acid moiety resulted in a >400-fold increase in potency. 
This strategy to target ATX with a boronic acid should assist the development of future ATX 
inhibitors.
3.11 Experimental section
Chemicals and enzymes. Small molecule libraries were obtained from the National Cancer Institute 
(NCI) and purchased from SPECS, Delft, the Netherlands. NCI compounds NSC101794, NSC148368 
and NSC48300 are abbreviated in the text of the Supporting information by I, II and III respectively. 
SPECS compounds AN-989/40746701, AN-988/40680277, AJ-292/40674401, AN-989/41697652, AN-
989/41697944 and AQ-088/4201464 are abbreviated in the text by 1, 2, 3, 4, 5 and 6 respectively. 
1-Oleoyl-2-Hydroxy-sn-Glycero-3-Phosphocholine (LPC, 18:1) was purchased from Avanti Polar Lipids. 
Oleoyl-L-α-lysophosphatidic acid sodium salt (LPA, 18:1), horseradish peroxidase (HRP), choline 
oxidase, and all other chemicals were obtained from Sigma-Aldrich and used as received.
Recombinant ATX. See Experimental section Chapter 2.
Bis-pNPP assay.15 ATX activity toward bis-pNPP was determined as follows. In an opaque flat-bottom 
384-well plate an amount of 2 µL DMSO containing inhibitor was added to 24 µL recombinant ATX 
(~20 nM) in Tris-buffered saline (140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 50 mM 
Tris-HCl, pH 7.8) which contained albumin from bovine serum fatty acid free (BSA-FAF) (0.2 mg 
ml-1). Finally, 24 µL of bis-pNPP (2 mM) was added to each well and the plate was incubated for 3 
h at room temperature. This mixture with DMSO alone was used as a control. For each inhibitor 
ten concentrations were measured covering a range of   0.025 to 100 µM to determine IC
50
 values. 
Percentage inhibition was determined for a final concentration of 5 µM of inhibitor. Absorbance was 
measured in a Perkin-Elmer Envision plate reader (λ = 405 nm). The absorbance at 0 h was used to 
correct for molecules that absorb at 405 nm. Data were analyzed using Graphpad Prism software. 
IC
50
 values and percentage inhibition were determined in three independent experiments for each 
inhibitor. Percentage of residual activity (RA) is given as bottom value for curve fit.
CPF4 assay.15 This assay was carried out in the same manner as the bis-pNPP assay using a substrate 
concentration of 2 µM. Fluorescence was monitored in a BMG Fluorstar 96-well plate reader (λ
ex
 = 
355 nm, λ
em
 = 460 and 520 nm).
Choline release assay.17 Measuring ATX activity using LPC (18:1) as substrate was determined as 
follows. In an opaque flat-bottom 96-wells plate (Greiner) 1 µL of DMSO containing inhibitor was 
added to 49 µL of recombinant ATX (~20 nM) in Tris-HCl buffer (0.01% Triton X-100 and 50 mM Tris-
HCl, pH 7.4). Finally, 50 µL of 80 μM LPC (18:1) in Tris-HCl buffer (10 mM MgCl
2
, 10 mM CaCl
2
, 0.01% 
Triton X-100 and 50 mM Tris-HCl, pH 7.4) was added to each well and the plate was incubated at 310 
K. The above-described mixture with DMSO alone was used as a control. LPC without ATX was taken 
as control for autohydrolysis of LPC. For each inhibitor ten concentrations were measured covering 
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a range of   0.01 to 30 µM to determine IC
50
 values. Percentage inhibition (PI) was determined 
for a final concentration of 5 µM of inhibitor. After 3 h of incubation, 50 µL of ABTS (2 mM) and 
horseradish peroxidase (5 U mL-1) was added to 50 µL of the reaction mixture and absorbance was 
measured and used to correct for absorbance of the molecules. Finally, 50 µl choline oxidase (5 U 
mL-1) in Tris-HCl (0.01% Triton X-100 and 50 mM Tris-HCl, pH 7.4) was added for colorimetric reaction. 
Absorbance was measured in a Perkin-Elmer Envision plate reader (λ = 405 nm). Data were analyzed 
using Graphpad Prism software.
In addition, the effect of the inhibitors on the enzymatic coloring reaction was investigated using 
40 μM choline at 30 μM inhibitor using the above-described coloring reagents. No inhibition of the 
enzymatic reaction by inhibitors was observed.
Washout of inhibitors. ATX (~20 nM) in the same buffer used for the choline release assay was 
incubated with (5 µM) and without inhibitors at 310 K. After 20 min the incubation mixtures were 
washed out with ethyl acetate with 9 times the volume of the ATX solution. The ATX activity of these 
solutions was determined using the choline release assay.
Chemistry. All chemicals were obtained from Sigma-Aldrich and used without further purification. 
Dry N,N-dimethylformamide (DMF) from Biosolve was obtained by treatment with molecular 
molsieves (4 Å). Analytical thin layer chromatography was performed on aluminum sheets precoated 
with silica gel 60 F
254
. Column chromatography was carried out on silica gel (0.035-0.070, 90 Å, Acros).
For isolation by centrifugation a Heraeus Multifuge 3 
S-R 
centrifuge was used. Products were 
spun at 4400g at 277 K for 5 min. Nuclear magnetic resonance spectra (1H NMR and COSY) were 
determined in deuterated dimethyl sulfoxide (d
6
-DMSO) using a Bruker ARX 400 Spectrometer (1H: 
400 MHz) at 298 K, unless indicated otherwise. Peak shapes in the NMR spectra are indicated with 
the symbols ‘d’ (doublet), ‘dd’ (double doublet), ‘s’ (singlet), ‘bs’ (broad singlet) and ‘m’ (multiplet). 
Chemical shifts (δ) are given in ppm and coupling constants J in Hz. DMSO (δ = 2.50 ppm) was used 
as internal reference.
HPLC-MS measurements were performed on a system equipped with a Waters 2795 Seperation 
Module (Alliance HT), Waters 2996 Photodiode Array Detector (190-750 nm), Waters Alltima C18 
Column (2.1 mm x 100 mm) and an LCTTM Orthogonal Acceleration Time of Flight Mass Spectrometer. 
Samples were run at a flowrate of 0.40 mL min-1 using gradient elution (water/acetonitrile/formic 
acid) from 950/50/10 (v/v/v) to 50/950/10 (v/v/v). Purity of all compounds was verified by HPLC-MS.
The purity of all tested compounds was determined by HPLC-MS analyses and was greater than 95%.
4-[(4-formyl-2-methoxyphenoxy)methyl]benzoic acid (7).
To a solution of vanillin (1.41 g, 9.24 mmol) and KOH (0.640 g, 11.4 mmol) in DMSO (10 mL), methyl-
4-(bromomethyl)benzoate (2.00 g, 8.73 mmol) was added. The reaction mixture was stirred at room 
temperature and after 30 min, water (50 mL) was added and the solution was heated at 393 K for 2 
h. Subsequently, 1M NaOH (aq) (10 mL) was added under relfux till solution becomes clear. Finally, 
the reaction mixture was poured into water and was acidified with 1 M HCl to pH 2. The precipitate 
was isolated by centrifugation, washed with water, and lyophilized resulting in the title compound. 
Yield: 91%. 1H NMR: δ = 12.99 (bs, 1H, OH), 9.85 (s, 1H), 7.98 (d, J 8.3, 2H), 7.58 (d, J 8.3, 2H), 7.55 
(dd, J 1.9 and 8.3, 1H), 7.44 (d, J 1.8, 1H), 7.26 (d, J 8.3, 1H), 5.32 (s, 2H), 3.86 (s, 3H). MS: m/z [M+H]+ 
calc. 287.09, obs. 287.11.
Synthesis of 3-(4-fluorobenzyl)-1,3-thiazolane-2,4-dione (8).
To a cooled solution (273 K) of thiazolidine-2,4-dione (5.87 g, 50 mmol) in DMF (100 ml) sodium 
hydride (60% in oil, 1.8 g, 45 mmol) was added. A solution of 1-(chloromethyl)-4-fluorobenzene (4.3 
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ml, 36.8 mmol) in DMF (25 ml) was added to the reaction mixture. The mixture was allowed to warm 
up to room temperature and was stirred for 4 h. Then the mixture was poured in ice water (250 ml) 
and hexane (100 ml) was added. After a night at 277 K the precipitated crystals were filtrated and 
dried to give a white solid. Yield: 74%. 1H NMR: δ = 7.34-7.14 (m, 4H), 4.65 (s, 2H), 4.26 (s, 2H). MS: 
m/z [M+H]+ calc. 226.03, obs. 226.04.
Experimental details on compounds 9-30. This data is available free of charge via the Internet at 
http://pubs.acs.org.
General method for the synthesis of (2,4-dioxo-1,3-thiazolan-5-yliden) benzoic acids and benzene 
boronic acids.
To a solution of 1,3-thiazolane-2,4-dione 8 (0.293 mmol) in ethanol (2.5 mL), piperidine (12 µL, 0.207 
mmol) and the appropriate aldehyde (0.352 mmol) were added and the solution was refluxed for 22 
h. Upon cooling to room temperature the product precipitated out of solution. Centrifugation and 
washing with ethanol gave homogeneous compound.
4-[(4-{[3-(4-fluorobenzyl)-2,4-dioxo-1,3-thiazolan-5-yliden]methyl}-2-methoxy-phenoxy)-methyl]ben-
zoic acid (2). Yield: 63%. COSY was used to assign chemical shifts. 1H NMR: δ = 12.99 (bs, 1H, OH), 
7.97 (d, J 8.3, 2H), 7.92 (s, 1H), 7.56 (d, J 8.3, 2H), 7.38-7.16 (m, 7H), 5.27 (s, 2H), 4.82 (s, 2H), 3.84 (s, 
3H). MS: m/z [M-H]- calc. 492.10, obs. 492.10.
3-[(4-{[3-(4-fluorobenzyl)-2,4-dioxo-1,3-thiazolan-5-yliden]methyl}phenoxy)methyl] benzene boronic 
acid (72). Yield: 64%. 1H NMR: δ = 8.08 (s, 2H, OH), 7.92 (s, 1H), 7.87 (s, 1H), 7.76 (d, J 7.4, 1H), 7.60 
(d, J 7.1, 2H), 7.50-7.16 (m, 10H), 5.18 (s, 2H), 4.82 (s, 2H). MS: m/z [M +H]+ calc. 464.11, obs. 464.25.
4-[(4-{[3-(4-fluorobenzyl)-2,4-dioxo-1,3-thiazolan-5-yliden]methyl}phenoxy)methyl] benzene bo-
ronic acid (73). Yield: 81%. 1H NMR: δ = 8.05 (s, 2H, OH), 7.93 (s, 1H), 7.81(d, J 8.0, 2H), 7.61 (d, J 8.9, 
2H), 7.42 (d, J 8.3, 2H), 7.41-7.16 (m, 6H), 5.21 (s, 2H), 4.82 (s, 2H). MS: m/z [M+H]+ calc. 464.11, obs. 
464.21.
2-[(4-{[3-(4-fluorobenzyl)-2,4-dioxo-1,3-thiazolan-5-yliden]methyl}phenoxy)methyl] benzene boronic 
acid (74). Yield: 48%. 1H NMR: δ = 8.10 (s, 2H, OH), 7.93 (s, 1H), 7.62-7.13 (m, 12H), 5.32 (s, 2H), 4.82 
(s, 2H). MS: m/z [M+H]+ calc. 464.11, obs. 464.12.
3-[(3-{[3-(4-fluorobenzyl)-2,4-dioxo-1,3-thiazolan-5-yliden]methyl}phenoxy)methyl] benzene bo-
ronic acid (75). Yield: 40%. 1H NMR: δ = 8.10 (bs, 2H, OH), 7.94 (s, 1H), 7.87 (s, 1H), 7.76 (d, J 7.3, 
1H), 7.51-7.16 (m, 10H), 5.16 (s, 2H), 4.82 (s, 2H). MS: m/z [M +H]+ calc. 464.11, obs. 464.13.
4-[(3-{[3-(4-fluorobenzyl)-2,4-dioxo-1,3-thiazolan-5-yliden]methyl}phenoxy)methyl] benzene bo-
ronic acid (76). Yield: 26%. 1H NMR: δ = 8.07 (s, 2H, OH), 7.93 (s, 1H), 7.81(d, J 8.0, 2H), 7.49-7.16 (m, 
10H), 5.19 (s, 2H), 4.82 (s, 2H). MS: m/z [M+H]+ calc. 464.11, obs. 464.12
2-[(3-{[3-(4-fluorobenzyl)-2,4-dioxo-1,3-thiazolan-5-yliden]methyl}phenoxy)methyl] benzene bo-
ronic acid (77). Yield: 32%. 1H NMR: δ = 8.09 (s, 2H, OH), 7.94 (s, 1H), 7.57-7.12 (m, 12H), 5.29 (s, 
2H), 4.83 (s, 2H). MS: m/z [M+H]+ calc. 464.11, obs. 464.13.
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3.13 Supporting information
ATX inhibitor screen NCI library
Screening a small molecule library of the National Cancer Institute (NCI) we identified 
xanthine and arsonate derivatives as moderate ATX inhibitors as depicted in Figure S2 using 
the bis-pNPP assay. Interestingly, aryl xanthines are known as phosphodiesterase 5 inhibitors.1 
The structure of arsonate II is related to a phenyldiazenylphenyl ATX inhibitors reported by 
Parrill et al.2 Arsonate III, also known as NSC48300, was recently reported as ATX inhibitor 
and we also found it as screening hit.3 However, in our hands quality control of different 
independent batches of arsonate III by HPLC-MS revealed that it contains mainly impurities 
while the presence of arsonate III could not be confirmed.
Supporting references
 1.  Arnold, R. et al. 8-Aryl xanthines potent inhibitors of phosphodiesterase 5. Bioorg. Med. Chem. 
Lett. 12, 2587-2590 (2002).
 2.  Parrill, A. et al. Virtual screening approaches for the identification of non-lipid autotaxin 
inhibitors. Bioorg. Med. Chem. 16, 1784-1795 (2008).
 3.  Saunders, L. P. et al. Identification of small-molecule inhibitors of autotaxin that inhibit 
melanoma cell migration and invasion. Mol. Cancer Ther. 7, 3352-3362 (2008).
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Supporting Figure S1. Primary hits obtained after screening 17,500 molecules from 
the NCI library using the ATX activity reporter CPF4. Bis-pNPP was used as a secondary 
assay to confirm the obtained hits from the initial screen. Significantly more inhibitors 
were identified with the CPF4 probe compared to the bis-pNPP assay. Interference with 
the CPF4 probe by small molecules likely leads to the many false positives observed. For 
this reason the bis-pNPP assay was used for further screening and the CPF4 assay for 
confirmation of screening hits.
Supporting Figure S2. Structures of the identified inhibitor classes of the NCI library screen using 
the bis-pNPP assay. Xanthine and arsonate derivatives were identified as ATX inhibitors in the bis-
pNPP assay. For each structure the percentage of ATX inhibition (PI, %) is given at an inhibitor 
concentration of 5 µM. 
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Supporting Figure S3. (A) 1H NMR spectrum (d
6
-DMSO) of inhibitor 2. Inset shows the methylidene 
hydrogen (*) at 7.92 ppm which is indicative for the Z-isomer.28 (B) HPLC-chromatogram 
confirming the purity of inhibitor 2.
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Supporting Figure S4. Effect of the active 
boronic acids on the readout of the choline 
release assay. No effect was observed on the 
readout using 40 μM choline at a concentration 
of 30 μM inhibitor.
Supporting Figure S5. Lineweaver-Burk plots for the inhibitors of the optimization process. Kinetic 
analysis indicates competitive inhibition of ATX for 2 and 30. Boronic acids 72 and 73 seem to 
inhibit in a mixed manner. Lineweaver-Burk plots were obtained from the choline release assay.
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Supporting Figure S6. Washout experiment to study 
reversible binding the inhibitors with ATX. Incubating ATX 
with 5 µM of inhibitor 2, 30, 72 or 73 and washing out 
these solutions with ethyl acetate results in a recovery in 
ATX activity up to 97% in the choline release assay.
Supporting Table S1.  Derivatives of screening hit 2 with a structural variation in the benzylidene 
moiety (R). Percentage inhibition (PI, %) at 5 μM has been determined in the choline release 
assay (compound / PI).
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Structure-based design of novel boronic acid-based inhibi-
tors of autotaxin 
Harald M.H.G. Albers, Loes J.D. Hendrickx, Rob J.P. van Tol, Jens Hausmann, Anastassis Perrakis 
and Huib Ovaa, Journal of Medicinal Chemistry 2011, 54, 4619-4626.
Abstract. Autotaxin (ATX) is a secreted phosphodiesterase that hydrolyzes the abundant 
phospholipid lysophosphatidylcholine (LPC) to produce lysophosphatidic acid (LPA). The 
ATX-LPA signaling axis has been implicated in inflammation, fibrosis and tumor progression, 
rendering ATX to an attractive drug target. Chapter 3 describes the development of a boronic 
acid-based inhibitor of ATX, named HA155 (1). This chapter reports the design of new 
inhibitors based on the crystal structure of ATX in complex with inhibitor 1. Furthermore, 
the syntheses and activities of these new inhibitors are described and the potency of these 
inhibitors can be explained by structural data. To understand the difference in activity between 
two different isomers with nanomolar potencies, molecular docking experiments were 
performed using the crystal structure of ATX binding to inhibitor 1. Intriguingly, molecular 
docking suggested a remarkable binding pose for one of the isomers, which differs from 
the original binding pose of inhibitor 1 for ATX, opening further options for inhibitor design. 
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4.1 Introduction
The secreted glycoprotein autotaxin (ATX) is a phosphodiesterase responsible for the 
hydrolysis of lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA) and choline, 
as depicted in Scheme 1.1,2 The bioactive lipid LPA stimulates migration, proliferation and 
survival of cells by activating specific G protein-coupled receptors.3 The ATX-LPA signaling axis 
is involved in cancer, inflammation and fibrotic disease.4-6 Potent and selective ATX inhibitors 
are needed to elucidate the contribution of ATX action to signaling cascades that may result 
in disease in case of malfunction. 
ATX, also known as ENPP2, is a unique member of the ecto-nucleotide pyrophosphatase/
phosphodiesterase (ENPP) family of proteins. It is the only family member capable of 
producing LPA by hydrolysis of LPC.7 Recently reported crystal structures of mouse8 and 
rat9 ATX confirmed that a threonine residue and two zinc ions are necessary for activity of 
ATX.10 Furthermore, these structures showed that ATX specifically binds its lipid substrates in 
a hydrophobic pocket extending from the active site of ATX. This pocket accommodates the 
alkyl chain of the lipids in different poses as was also shown in various crystal structures.8 
In Chapter 2 we described the discovery of a boronic acid-based ATX inhibitors that 
helped to reveal the short half life (~5 min) of LPA in vivo.11,12 We introduced a boronic acid 
moiety in the inhibitor structure to rationally target the threonine oxygen nucleophile of ATX 
with a hard matching Lewis acid. The crystal structure of ATX in complex with HA155 (1),9 
confirmed our hypothesis described in Chapter 3 that this inhibitor targets the threonine 
oxygen nucleophile in the ATX active site via the boronic acid moiety, while the hydrophobic 
4-fluorobenzyl moiety of inhibitor 1 targets the hydrophobic pocket responsible for lipid 
binding (Figure 1).
Here, we report a number of synthetic routes, systematically substituting the ether linker 
and the thiazolidine-2,4-dione core in 1, while keeping the boronic acid moiety untouched. 
The observed structure-activity relations could well be explained from the ATX structure in 
complex with inhibitor 1. A remarkable binding pose of a novel inhibitor, as predicted from 
molecular docking experiments, suggests additional avenues for further inhibitor design.
CholineLPC LPA
ATX
+ NHOO
P
O
O
O
O
OH
O
n
N
O
P
O
O
O
O
OH
O
n
Scheme 1: Autotaxin (ATX) is responsible for hydrolyzing the lipid lysophosphatidylcholine (LPC) 
into lysophosphatidic acid (LPA) and choline.
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4.2 Results and discussion
4.2.1 Design of inhibitors
The crystal structure of inhibitor 1 bound to the ATX active site (Figure 1) showed that its 
4-fluorobenzyl moiety binds into the hydrophobic lipid binding pocket of ATX (Figure 1C, 
1D).9 This pocket also accommodates the lipid tail of LPA, the hydrolysis product of LPC.8 
The thiazolidine-2,4-dione core of 1 and the conjugated aromatic ring are located between 
the hydrophobic pocket  and the catalytic site (Figure 1D). The ether linker, bridging the two 
aromatic rings in 1, and especially a methylene and arylboronic acid moiety are well accessible 
to solvent (Figure 1C). Binding of inhibitor 1 to the ATX active site is predominately driven 
by hydrophobic interactions (the interaction interface is approximately 500 Å2) and by the 
boronic acid binding to the threonine oxygen nucleophile of ATX.9 The boron-oxygen distance 
observed is ~1.6 Å, which is consistent with a covalent bond. As expected, this binding is 
reversible evidenced by the fact that ATX activity can be fully restored upon washing out the 
Threonine
Zinc(II)
C
1 (HA155)
Ether linker Thiazolidine-2,4-dione core
A B
C D
Figure 1: ATX crystal structure liganded with inhibitor 1 (PDB ID: 2XRG). (A) Surface representation 
of ATX with inhibitor 1 (magenta). (B) Binding of inhibitor 1 to the threonine oxygen nucleophile 
and two zinc ions. (C) Visualizing the ether linker of inhibitor 1 bound to ATX. (D)  Visualizing the 
degree of freedom for the thiazolidine-2,4-dione core of inhibitor 1 in the ATX binding site. Images 
were made using the program PyMol.
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inhibitor (see Chapter 3).13 In addition, one of the boronic acid hydroxyl moieties is tethered 
by the two zinc ions in the ATX active site. Thus, the boronic acid moiety targets not only the 
threonine oxygen nucleophile, but also the two zinc ions that are essential for catalytic activity 
of ATX (Figure 1B). Remarkably, there are no hydrogen bonds or salt bridges that participate in 
binding of inhibitor 1 to ATX. Inhibitor 1 is locked in a pose with reduced molecular flexibility, 
forming an ideal starting point for a structure based approach to further modifications.
Previously, we determined that the 4-fluorobenzyl moiety is preferred from over 40 
benzylic substituents tested (Chapter 3).13 For this reason, we left the 4-fluorobenzyl moiety 
untouched in this study. We investigated new design options, starting by modifying the ether 
linker in inhibitor 1. We decided to replace the ether linkage (OCH
2
) with various amides, an 
amine and an E-configured double bond (CONH (17), CONCH
2 
(18), NHCO (19), NHCH
2
 (36) and 
(E)-CH=CH (20); see Table 1). The thiazolidine-2,4-dione core was investigated also. The sulfur 
atom in this core was replaced with (substituted) amino and methylene moieties (NH (26), 
NCH
3 
(28), or CH
2 
(32); see Table 2). The carbon double bond conjugated to the thiazolidine-
2,4-dione carbonyl moiety forms a possible Michael acceptor. Although this Michael acceptor 
is resistant to nucleophilic additions in vitro (Supporting Figure S1) it may be a biologically 
active Michael acceptor in vivo and therefore, we investigated its removal.
4.2.2 Chemical synthesis of modified inhibitors
We first explored synthetic routes to replace the ether linkage in 1. The synthesis of target 
molecules 17-20 (Scheme 2) starts with palladium catalyzed borylation of appropriate 
aldehydes via a Suzuki-Miyaura reaction13 as depicted in Scheme 2 (for syntheses of aldehydes 
2-6 see Supporting Information). This reaction provided intermediates 7-11. Next, the pinacol 
protecting group was hydrolyzed under acidic conditions and oxidatively destroyed by NaIO
4
 
giving boronic acid aldehydes 12-16. In the final step, 3-(4-fluorobenzyl)thiazolidine-2,4-dione 
is reacted with the boronic acid aldehyde by Knoevenagel condensation to selectively give the 
Z-isomer of the final products (1 and 17-20).
In order to remove the potential Michael acceptor present, we reduced the double 
bond in inhibitor 1 using hydrogen
 
and palladium on carbon (Scheme 3A), to give compound 
21. To reduce the carbonyl moiety also in the thiazolidine-2,4-dione core of 1, we used NaBH
4 
resulting in hemiaminal 22. After addition of sulfuric acid to the reaction mixture to eliminate 
the hydroxyl moiety in 22, unsaturated inhibitor 23 was obtained.
X-Y Br
O
X-Y B
O
OH
OH
X-Y B
OH
OH
SN
O
OF
SN
O
OF
X-Y
O
B
O
O
B
O
O
B
O
O
O CH2
C=O NH
C=O NHCH2
NH C=O
(E)-HC=CH -
Pd(dppf)Cl2
KOAc
NaIO4
Piperidine
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1   (HA155)
17
18
19
20
X Y
HCl
Scheme 2: Synthetic route toward linker modified inhibitors.
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For the syntheses of imidazolidine-2,4-dione-based inhibitors 26 and 28, imidazolidine-
2,4-dione (24) was mono N-alkylated with 4-fluorobenzyl bromide to give intermediate 25 
(Scheme 3B). Reaction of 25 by a Knoevenagel condensation with aldehyde 12 selectively 
resulted in the formation of the Z-isomer of 26. In parallel, intermediate 25 was methylated 
to give compound 27. Finally, 27 was condensed with aldehyde 12 resulting in target molecule 
28. Both the Z- and E-isomers were formed in a 1:4 (Z:E) ratio. To obtain and isolate solely the 
Z-isomer 28, we N-methylated compound 26.
Core-hopping from thiazolidine-2,4-dione to pyrrolidine-2,5-dione is depicted in Scheme 
3C. The route starts with the formation of a Wittig reagent starting from 2,5-pyrroledione 
(29), which is reacted with triphenylphosphine to form ylide 30.14 The Wittig reaction of the 
carbonyl stabilized ylide 30 with aldehyde 12 selectively leads to the E-isomer of intermediate 
31 as expected. Finally, compound 31 is N-alkylated with 4-fluorobenzyl bromide resulting in 
the pyrrolidine-2,5-dione product 32.
For the synthesis of a final tetrahydroisoquinoline-based core with a more rigid 
structure, the secondary amine in R- or S-tetrahydroisoquinoline 33 is reacted with 
4-fluorobenzyl isocyanate in the presence of sodium hydroxide to form a urea intermediate 
(Scheme 3D). The imidazolidine ring is then formed upon acidification with hydrochloric 
acid, resulting in compound R- or S-34. In the final step, intermediate 34 is O-alkylated with 
4-(bromomethyl)phenylboronic acid resulting in R- or S-35.
4.2.3 Structure-activity relations of inhibitors and autotaxin
Activity of the new molecules resulting from the linker and core modifications were 
determined in an LPC hydrolysis assay described previously,11,15 in which ATX-mediated release 
of choline from LPC is detected by a two-step enzymatic colorimetric reaction. The IC
50
 values 
observed for inhibitors with modified linkers and cores are listed in Tables 1 and 2.
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Scheme 3: Synthetic routes toward core modified inhibitors.
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When we replaced the ether 
moiety (OCH
2
, inhibitor 1, IC
50
 = 5.7 
nM) for an amide linker (CONH, 17), we 
observed a significant loss of activity (IC
50
 
= 147 nM). The dose-response curve of 
inhibitor 17 shows a biphasic curve16 that 
could suggest several binding sites of 
this inhibitor for ATX (Supporting Figure 
S2). Expanding the CONH linker (17) 
to a more flexible CONHCH
2
 linker (18) 
improved the IC
50
 value (71 nM) by two-
fold compared to inhibitor 17. Reversing 
the amide linker in 17 to yield compound 
19, results in high potency (IC
50
 = 10 
nM), similar to inhibitor 1. However, 
inhibitor 19 is not able to achieve full 
inhibition and 10% residual ATX activity 
is observed (Supporting Figure S3). 
Apparently, a more rigid amide linker 
results in suboptimal binding of the 
inhibitor. Therefore, we synthesized the 
more flexible amine analogue 36 (for the 
synthesis of inhibitor 36 see Supporting 
Information). This resulted indeed in a 
potent inhibitor (IC
50
 = 8.3 nM), similar 
to 1, and with no residual ATX activity 
(Supporting Figure S3). Introduction 
of an (E)-CH=CH linker resulted in 
compound 20, which was inactive in the nanomolar range (IC
50
 > 5 µM). This observation 
can be explained by the fact that the two aromatic rings linked with a flexible OCH
2
 linker in 
inhibitor 1 are positioned in an angle of roughly 90° in the ATX structure (see Figure 1B) which 
cannot be achieved by the (E)-CH=CH linker due to its rigid planar conformation.
Next, we explored the activity of compounds with a modified core (Table 2) in 
combination with the OCH
2
 linker, which had the highest activity of the linker modified 
molecules in Table 1. Reducing the carbon double bond in 1 resulted in little loss of activity 
in 21 with an IC
50
 value of 25 nM. Thus, although rigidity is preferred, the Michael acceptor 
can easily be removed without significant loss in activity. Reducing both the carbon double 
bond and the neighboring carbonyl in inhibitor 1 to hemiaminal 22, led to a significant 
loss in potency (IC
50
 = 1.6 μM). Inhibitor 23, where the hydroxyl moiety in compound 22 is 
N S
O
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N
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Entry Structure IC50 (nM) 
a 
1 
 
5.7 ± 0.4 
17 
 
147 ± 47 b 
18 
 
71 ± 17 
19 
 
10 ± 1 
36 
 
8.3 ± 0.9 
20 
 
> 5,000 
R1 = R2 = 
Table 1. IC
50
 values of the inhibitors resulting from 
the linker modification.
a IC
50
 values have been determined in the choline release 
assay using 40 μM LPC and 10 nM ATX. b The dose-
response curve of inhibitor 17 shows biphasic curve (see 
Supporting Figure S2).
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removed is not very potent either (IC
50
 
= 683 nM), indicates that the carbonyl 
moiety is important for binding. It 
appears from the crystal structure 
of inhibitor 1 bound to ATX that 
π-stacking between the phenyl ring of 
phenylalanine residue 274 (F274) and 
the carbonyl moiety in 1 is very likely 
seen their distance (4.1 Å, Supporting 
Figure S4).17 By removing the carbonyl 
moiety in 1 or by changing it into a 
hydroxyl moiety, π-stacking will be 
lost resulting in lower potencies as 
observed for inhibitor 22 and 23.
The sulfur heteroatom in the 
thiazolidine-2,4-dione core was 
replaced with other atoms and 
moieties. We started by replacing the 
sulfur atom in 1 with a methylene 
moiety gives compound 32 with an 
IC
50
 value of 7.3 nM, comparable to 
inhibitor 1. Replacement of the sulfur 
atom for an amino group (26, IC
50
 = 
26 nM) resulted in little loss in activity 
compared to inhibitor 1. When the 
amine in compound 26 is methylated, 
potency for the resulting inhibitor Z-28 
(IC
50
 = 6.7 nM) is slightly increased. 
Interestingly, the E-isomer of 28 (IC
50
 
= 5.3 nM) is marginally more potent 
than Z-28 or inhibitor 1, a finding that 
we did not anticipate. 
Intrigued by the characteristics 
of inhibitors Z-28 and E-28, we decided 
to calculate likely binding poses using 
molecular docking. In molecular 
docking the binding of the inhibitor to 
the protein is predicted by optimizing 
the inhibitor’s conformation such that the free energy of the overall system is minimized. 
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Entry Structure IC50 (nM) 
a 
1 
 
5.7 ± 0.4 
21 
 
25 ± 2 
22 
 
1594 ± 140 
23 
 
683 ± 88 
26 
 
26 ± 4 
E-28 
 
5.3 ± 0.5 b 
Z-28 
 
6.7 ± 0.4 
32 
 
7.3 ± 0.5 
S-35 
 
55 ± 9 
R-35 
 
59 ± 7 
B
OH
OH
F
R1 = R2 = 
Table 2. IC
50
 values of the inhibitors resulting from the 
core modification.
a IC
50
 values have been determined in the choline release 
assay using 40 μM LPC and 10 nM ATX. b E-28 contains 20% 
of the Z-isomer.
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A          ATX-inhibitor 1 crystal structure B             Inhibitor 1 docked into ATX
D   Docking poses for E-isomer of inhibitor 28C   Docking poses for Z-isomer of inhibitor 28
3rd pose
2nd pose
1st pose
3rd pose
2nd pose
1st pose
Figure 2: (A) Focus from inside the protein on the thiazolidine-2,4-dione core of inhibitor 1 
bound to ATX. (B) Inhibitor 1 docked into the active site of ATX to validate our docking approach. 
(C) The three best docking poses for the Z-isomer of 28. (D) The three best docking poses for the 
E-isomer of 28. Docking poses were generated using the docking program Glide.
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For this purpose, we used the Glide docking software because it can dock boron-containing 
inhibitors.18-20 Many docking programs, like AutoDock, can not dock boron-containing 
inhibitors because the boron atom is not defined in the software. To validate our docking 
approach where we constrain the boronic acid moiety, we first docked inhibitor 1 back into 
the ATX active site, resulting in a pose (Figure 2B) very similar to the original crystal structure 
(Figure 2A) with a root-mean-square deviation (RMSD) of 1.1 Å (for superimposed image 
see Supporting Figure S5). Next, we docked the Z- and E-isomers of inhibitor 28 (the three 
best docking poses are depicted in Figure 2C and D). The docking poses of Z-28 are similar to 
the original pose of inhibitor 1 in the ATX structure. However, two of the best three docking 
poses for E-28 suggest that the 4-fluorobenzyl moiety likely binds to a different area in the 
hydrophobic pocket (Figure 2D). The imidazolidine-2,4-dione core of E-28 is flipped around 
the double bond axis in the ATX binding site compared to its Z-isomer (compare Figure 2C 
with D). This observation is in agreement with the conformations of both isomers. In addition, 
the binding poses of Z-28 and E-28 resulting from our docking study suggest that the current 
4-fluorobenzyl moiety could be expanded from the methylene moiety in the 4-fluorobenzyl 
moiety with other substituents in future ATX inhibitors.
Finally, we evaluated inhibitors in which we introduced a rigidified three-ring system 
(Table 2) incorporating a tetrahydroisoquinoline motif that we deemed likely to bind. This 
modification avoids the presence of a Michael acceptor, while introducing rigidity and a 
new core structure. This modification resulted in the chiral inhibitor 35, which is still very 
potent although some activity is lost compared to 1. No significant difference is observed in 
potency between the S- and R-enantiomers of inhibitor 35, with IC
50
 values of 55 and 59 nM, 
respectively.
In summary, we explored structure-activity relations building on boronic acid-based ATX 
inhibitor 1, which resulted in a number of potent inhibitors. We used the crystal structure 
of ATX liganded with inhibitor 1 to explain the structure-activity relationships observed for a 
rational inhibitor modification approach. Our results suggest that this approach allows rapid 
structure guided modification. Finally, molecular docking efforts proved useful to explain 
unexpected high potency of E-isomer 28 and suggested that the lipophilic pocket near the 
ATX active site may be better exploited in the future for the design of new inhibitors. 
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4.3 Experimental section
General. The S- and R-enantiomers of building block 33 were purchased from CSPS Pharmaceuticals, 
San Diego, USA. All other chemicals were obtained from Sigma-Aldrich and used without further 
purification unless otherwise noted. Analytical thin layer chromatography was performed on 
aluminum sheets precoated with silica gel 60 F
254
. Column chromatography was carried out on silica 
gel (0.035-0.070, 90 Å, Acros).
For isolation by centrifugation a Heraeus Multifuge 3 
S-R 
centrifuge was used. Products were spun 
at 4400g at 298 K for 5 min. Nuclear magnetic resonance spectra (1H and 13C NMR) were determined 
in deuterated dimethyl sulfoxide (d
6
-DMSO) using a Bruker Avance 300 (1H: 300 MHz; 13C: 75 MHz) 
at 298 K, unless indicated otherwise. Peak shapes are indicated with the symbols ‘d’ (doublet), ‘dd’ 
(double doublet), ‘s’ (singlet), ‘bs’ (broad singlet) and ‘m’ (multiplet). Chemical shifts (δ) are given in 
ppm and coupling constants J in Hz. Dimethyl sulfoxide (δH = 2.50 ppm; δC = 39.51 ppm) was used as 
internal reference.
The purity of all tested compounds was determined by high-performance liquid chromatography 
coupled to mass spectrometry (HPLC-MS) and was greater than 95%. HPLC-MS measurements were 
performed on a system equipped with a Waters 2795 Seperation Module (Alliance HT), Waters 2996 
Photodiode Array Detector (190-750 nm), Atlantis® T3 C18 column (2.1 mm x 100 mm, 3 μm) and an 
LCTTM Orthogonal Acceleration Time of Flight Mass Spectrometer. Samples were run at a flowrate of 
0.40 mL min-1 at 313 K, using gradient elution (water/acetonitrile/formic acid) from 950/50/1 (v/v/v) 
to 50/950/1 (v/v/v).  
The preparative HPLC system was equipped with a Waters 1525 Binary HPLC Pump, a Waters 2487 
Dual λ Absorbance Detector and an Atlantis® C18 column (19 mm × 250 mm, 10 µm). Samples were 
run at a flowrate of 18 mL min-1 using gradient elution (water/acetonitrile) from 6/4 (v/v) to 1/9 (v/v).
General procedure for borylation of aldehydes and pinacol deprotection (12-16).
In a dry flask, bis(pinacolato)diboron (1.34 g, 5.28 mmol), the appropriate aldehyde (1.80 mmol) and 
potassium acetate (0.542 g, 5.52 mmol) were added to a solution of Pd(dppf)Cl
2
 (46.6 mg, 0.0637 
mmol) in dimethylformamide (15 mL). The reaction mixture was stirred under an atmosphere of 
argon for 18 h at 353 K. The reaction mixture was filtered over Hyflo Super Cel® medium and diluted 
with ethyl acetate (100 mL). The solution was washed with brine (50 mL and 25 mL), dried over 
magnesium sulfate and was concentrated. 
The crude product was dissolved in tetrahydrofuran (11 mL) and sodium periodate (2.22 g, 
10.4 mmol) and water (2.8 mL) were added. After stirring for 30 min, 1 M hydrochloric acid (1.1 
mL) was added, and after 2 h, additional sodium periodate (1.17 g, 5.47 mmol) was added and the 
solution was stirred for another 2 h. The reaction mixture was diluted with ethyl acetate (20 mL) and 
washed with water (10 mL). The water layer was extracted with ethyl acetate (15 mL). The combined 
organic layers were washed with brine (15 mL), dried over magnesium sulfate and the solution was 
concentrated under vacuum resulting in a light yellow solid. The resulting product was used without 
further purification. 
(4-((4-formylphenoxy)methyl)phenyl)boronic acid (12). Yield: 70%. 1H NMR: δ = 9.86 (s, 1H), 8.09 (s, 
1H), 7.87 (d, J = 8.8, 1H), 7.82 (d, J = 8.1, 1H), 7.42 (d, J = 8.1, 1H), 7.20 (d, J = 8.7, 1H), 5.24 (s, 1H). 
13C NMR: δ = 191.75, 163.73, 138.49, 134.74, 132.26, 130.22, 127.15, 115.76, 70.09, 39.95 (C-B(OH)
2
 
not visible). MS: m/z [M+H]+ calc. 257.10, obs. 257.10.
(4-(4-formylbenzamido)phenyl)boronic acid  (13). Yield: 81%. 1H NMR: δ = 10.47 (s, 1H), 10.12 (s, 
1H), 8.13 (d, J = 8.3, 2H), 8.06 (d, J = 8.5, 2H), 7.95 (s, 2H), 7.80 (d, J = 8.7, 2H), 7.75 (d, J = 8.7, 2H). 
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13C NMR: δ = 192.86, 164.74, 140.64, 139.93, 137.94, 134.70, 129.37, 128.38, 119.08 (C-B(OH)
2
 not 
visible). MS: m/z [M+H]+ calc. 270.09, obs. 270.11.
(4-((4-formylbenzamido)methyl)phenyl)boronic acid  (14). Yield: 72%. 1H NMR: δ = 10.09 (s, 1H), 
9.25 (t, J = 5.9, 1H), 8.08 (d, J = 8.3, 2H), 8.01 (d, J = 8.5, 2H), 7.75 (d, J = 8.1, 2H), 7.29 (d, J = 8.1, 2H), 
4.51 (d, J = 5.9, 2H). 13C NMR: δ = 192.85, 165.39, 141.10, 139.33, 137.74, 134.14, 129.39, 127.96, 
126.21, 42.78 (C-B(OH)
2
 not visible). MS: m/z [M+H]+ calc. 284.11, obs. 284.11.
(4-((4-formylphenyl)carbamoyl)phenyl)boronic acid (15). Yield: 72%. 1H NMR: δ = 10.62 (s, 1H), 9.92 
(s, 1H), 8.26 (bs, 2H), 8.05-7.90 (m, 8H). 13C NMR: δ = 191.61, 166.22, 144.79, 135.65, 134.00, 131.57, 
130.59, 126.66, 119.82 (C-B(OH)
2
 not visible). MS: m/z [M+H]+ calc. 270.09, obs. 270.11.
(E)-(4-(4-formylstyryl)phenyl)boronic acid (16). Yield: 75%. 1H NMR: δ = 9.99 (s, 1H), 8.06 (s, 2H), 7.97 
– 7.57 (m, 8H), 7.45 (dd, J = 16, 1H). 13C NMR: δ = 192.34, 143.05, 137.94, 135.08, 134.53, 131.97, 
129.98, 127.72, 127.02, 125.91 (C-B(OH)
2
 not visible). MS: m/z [M+H]+ calc. 253.10, obs. 253.13.
General method for Knoevenagel condensation (1, 17-20, 26 and E-28).
To a solution of 3-(4-fluorobenzyl)thiazolidine-2,4-dione (0.293 mmol) in ethanol (2.5 mL), piperidine 
(20 µL, 0.207 mmol) and the appropriate aldehyde (0.352 mmol) were added and the solution was 
refluxed for 22 h. 
(Z)-4-[(4-{[3-(4-fluorobenzyl)-2,4-dioxo-1,3-thiazolan-5-yliden]methyl}phenoxy) methyl]benzene boronic 
acid (1). Upon cooling the reaction mixture to room temperature the product precipitated out of 
solution. Dissolving the product in dimethyl sulfoxide and precipitating it with 0.5 M hydrochloric 
acid resulted in pure compound. Yield: 81%. 1H NMR: δ = 8.03 (s, 2H), 7.92 (s, 1H), 7.80 (d, J = 8.1, 
2H), 7.60 (d, J = 8.9, 2H), 7.41 (d, J = 8.0, 2H), 7.39 – 7.31 (m, J = 5.5, 8.8, 2H), 7.26 – 7.09 (m, J = 4.5, 
8.9, 4H), 5.21 (s, 2H), 4.82 (s, 2H). 13C NMR: δ = 167.38, 165.59, 161.66 (d, 1JCF = 244), 160.33, 138.19, 
134.28, 133.48, 132.33, 131.81 (d, 4JCF = 3), 129.95 (d, 
3JCF = 8), 126.67, 125.55, 117.89, 115.81, 
115.47 (d, 2JCF = 21), 69.52, 43.90 (C-B(OH)2 not visible). MS: m/z [M+H]
+ calc. 464.11, obs. 464.19.
(Z)-(4-(4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)benzamido) phenyl)boronic acid (17). 
Upon cooling the reaction mixture to room temperature the product precipitated out of solution. 
Crude compound was recrystallized from a dichloromethane/methanol mixture (4:1). Yield: 60%. 1H 
NMR: δ = 10.39 (s, 1H), 8.10-8.04 (m, 3H), 7.94 (s, 2H), 7.80-7.76 (m, 6H), 7.40-7.37 (m, 2H), 7.22-
7.16 (m, 2H), 4.84 (s, 2H). 13C NMR: δ = 167.12, 165.34, 164.66, 161.66 (d, 1JCF = 244), 140.57, 136.23, 
135.68, 134.69, 132.23, 131.60 (d, 4JCF = 3), 129.95 (d, 
3JCF = 8), 129.94, 128.53, 123.04, 119.01, 
115.42 (d, 2JCF = 21), 44.04 (C-B(OH)2 not visible). MS: m/z [M+H]
+ calc. 477.11, obs. 477.08.
(Z)-(4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)benzamido) methyl)phenyl) boronic 
acid (18). Title compound was purified using preparative HPLC. Yield: 5%. 1H NMR: δ = 9.17 (t, J 6.0, 
1H), 8.04-8.00 (m, 3H), 7.97 (s, 2H), 7.74-7.70 (m, 4H), 7.41-7.16 (m, 6H), 4.83 (s, 2H), 4.50 (d, J 5.8, 
2H). 13C NMR: δ = 167.15, 165.35, 165.32, 161.66 (d, 1JCF = 244), 141.21, 135.64, 135.41, 134.13, 
132.30, 131.58 (d, 4JCF = 3), 129.94 (d, 
3JCF = 8), 129.89, 128.11, 126.17, 122.82, 115.42 (d, 
2JCF = 21), 
44.02, 42.72 (C-B(OH)
2
 not visible). MS: m/z [M+H]+ calc. 491.12, obs. 491.17.
(Z)-(4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)phenyl)carbamoyl)phenyl) 
boronic acid (19). Title compound was purified using preparative HPLC. Yield: 21%. 1H NMR: δ =10.56 
(s, 1H), 8.25 (s, 2H), 8.00 (d, J 8.8, 2H), 7.93 (m, 5H), 7.66 (d, J = 8.8, 2H), 7.40-7.35 (m, 2H), 7.22-7.16 
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(m, 2H), 4.83 (s, 2H). 13C NMR: δ = 167.38, 166.05, 165.58, 161.64 (d, 1JCF = 244), 141.53, 135.73, 
134.00, 132.20, 131.76 (d, 4JCF = 3), 131.20, 129.92 (d, 
3JCF = 8), 127.84, 126.61, 120.39, 118.97), 
115.44 (d, 2JCF = 21), 43.89 (C-B(OH)2 not visible). MS: m/z [M+H]
+ calc. 477.11, obs. 477.18.
(4-((E)-4-((Z)-(3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)styryl)phenyl)boronic 
acid (20). Upon cooling the reaction mixture to room temperature the product precipitated out of 
solution. Dissolving the product in dimethyl sulfoxide and precipitating it with 0.5 M hydrochloric acid 
resulted in pure compound. Yield: 47%. 1H NMR: δ = δ 8.04 (s, 2H), 7.96 (s, 1H), 7.88 – 7.52 (m, 8H), 
7.49 – 7.12 (m, 6H), 4.83 (s, 2H). 13C NMR: δ = 167.20, 165.48, 161.64 (d, 1JCF = 244), 139.43, 138.09, 
134.52, 133.01, 131.94, 131.69 (d, 4JCF = 3), 130.93, 130.71, 129.91 (d, 
3JCF = 8), 127.78, 127.29, 125.77, 
120.38, 115.42 (d, 2JCF = 21), 43.94 (C-B(OH)2 not visible). MS: m/z [M+H]
+ calc. 460.10, obs. 460.06.
(Z)-(4-((4-((1-(4-fluorobenzyl)-2,5-dioxoimidazolidin-4-ylidene)methyl)phenoxy)methyl)phenyl) 
boronic acid (26). Final product was isolated by using preparative HPLC. Z-configuration confirmed 
by the chemical shift of the vinyl and amine proton reported in literature.21 Yield: 15%. 1H NMR: δ = 
10.68 (s, 1H), 8.06 (s, 2H), 7.80 (d, J = 8.1, 2H), 7.62 (d, J = 8.9, 2H), 7.41 (d, J = 8.1, 2H), 7.39 – 7.28 
(m, 2H), 7.24 – 7.10 (m, 2H), 7.04 (d, J = 8.9, 2H), 6.54 (s, 1H), 5.17 (s, 2H), 4.65 (s, 2H). 13C NMR: δ 
= 164.02, 161.49 (d, 1JCF = 244), 158.72, 154.89, 138.54, 134.22, 132.83 (d, 
4JCF = 3), 131.30, 129.63 
(d, 3JCF = 8), 126.55, 125.43, 115.35 (d, 
2JCF = 21), 110.30, 69.28, 40.60 (C-B(OH)2 not visible). MS: m/z 
[M+H]+ calc. 447.15, obs. 447.25.
(E)-(4-((4-((1-(4-fluorobenzyl)-3-methyl-2,5-dioxoimidazolidin-4-ylidene)methyl)phenoxy)methyl) 
phenyl)boronic acid (E-28). Title compound was purified using preparative HPLC. E-28 contains 20% 
of the Z-isomers which could not be separated. E-configuration confirmed by the chemical shift of 
the vinyl and methyl proton reported in literature.22 Yield: 28%. 1H NMR: δ = 8.04 (s, 2H), 8.01 (d, 
J = 9.0, 2H), 7.80 (d, J = 8.0, 2H), 7.41 (d, J = 7.9, 2H), 7.38 – 7.32 (m, 2H), 7.23 – 6.98 (m, 4H), 6.52 
(s, 1H), 5.16 (s, 2H), 4.65 (s, 2H), 3.15 (s, 3H), . 13C NMR: δ = 161.49 (d, 1JCF = 244), 161.18, 158.80, 
152.62, 138.54, 134.20, 132.74 (d, 4JCF = 3), 132.08, 129.83 (d, 
3JCF = 8), 127.23, 126.59, 125.57, 
117.51, 115.31 (d, 2JCF = 21), 114.41, 69.23, 40.78, 26.36 (C-B(OH)2 not visible). MS: m/z [M+H]
+ calc. 
461.17, obs. 461.19.
(4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-yl)methyl)phenoxy)methyl) phenyl)boronic acid (21). 
A mixture of compound 1 (50.1 mg, 0.108 mmol) and 10 wt% Pd/C (24.0 mg) in degassed methanol 
(3 mL) was stirred under a hydrogen atmosphere for 2 h. Extra 10 wt% Pd/C was added (12.0 mg) 
and the reaction was allowed to continue for one night. The mixture was filtrated and concentrated 
to dryness.  Preparative HPLC afforded the title compound. Yield: 18.3 mg, 77%. 1H NMR: δ = 8.03 
(s, 2H), 7.80 (d, J = 8.1, 2H), 7.39 (d, J = 8.1, 2H), 7.28 – 6.99 (m, 6H), 6.88 (d, J = 8.7, 2H), 5.06 (s, 
2H), 5.00 (dd, J = 4.4, 8.0, 1H), 4.60 (dd, J = 15.0, 21.5, 2H), 3.14 (dd, J = 8.0, 14.2, 1H). 13C NMR: δ 
= 173.71, 171.00, 161.50 (d, 1JCF = 244), 157.44, 138.74, 134.16, 131.58 (d, 
4JCF = 3), 130.56, 129.66 
(d, 3JCF = 8), 127.98, 126.52, 115.21 (d, 
2JCF = 21), 114.57, 69.12, 50.94, 43.56, 35.79 (C-B(OH)2 not 
visible). MS: m/z [M+H]+ calc. 466.13, obs. 466.25, [M-H
2
O+H]+ calc. 448.12, obs. 448.23.
(4-((4-((3-(4-fluorobenzyl)-4-hydroxy-2-oxothiazolidin-5-yl)methyl)phenoxy) methyl)phenyl)boronic 
acid (22). To a solution of compound 1 (50.0 mg, 0.108 mmol) in dimethyl sulfoxide (0.5 mL), sodium 
borohydride (16.3 mg, 0.430 mmol) was slowly added. After 9 h of stirring the reaction mixture was 
diluted with ethyl acetate (4 mL) and was washed with water (2x2 mL). The organic layer was dried 
over calcium chloride and concentrated in vacuo, resulting in the title compound. Yield: 30.2 mg, 
60%. 1H NMR: δ = 8.06 (s, 2H), 7.80 (d, J = 8.1, 2H), 7.39 (d, J = 8.0, 2H), 7.36 – 7.11 (m, 5H), 6.94 (d, 
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J = 8.7, 2H), 6.87 (d, J = 8.7, 2H), 6.71 (d, J = 6.2, 1H), 5.06 (s, 2H), 4.72 (dd, J = 7.7, 15.1, 1H), 4.10 
(d, J = 15.1, 1H), 3.67 (t, J = 7.9, 1H), 3.35 (s, 1H), 2.81 (dd, J = 7.3, 13.9, 1H), 2.70 (dd, J = 8.4, 13.9, 
1H). 13C NMR: δ = 169.70, 161.55 (d, 1JCF = 244), 157.13, 138.85, 134.15, 133.14 (d, 
4JCF = 3.0), 130.01, 
130.00 (d, 3JCF = 8), 129.73, 126.54, 115.38 (d, 
2JCF = 21), 114.64, 84.02, 69.11, 51.42, 44.02, 39.65. 
(C-B(OH)
2
 not visible). MS: m/z [M+H]+ calc. 468.15, obs. 468.23.
(4-((4-((3-(4-fluorobenzyl)-2-oxo-2,3-dihydrothiazol-5-yl)methyl)phenoxy) methyl)phenyl)boronic acid 
(23). To a solution of compound 1 (45.7 mg, 0.0989 mmol) in dimethyl sulfoxide (0.75 mL), sodium 
borohydride (29.1 mg, 0.769 mmol) was slowly added. After 7 h of stirring the reaction mixture, 
concentrated sulfuric acid (2x50 μl) was added over a 15 min interval. The reaction mixture was 
stirred for an additional 5 h. Ethyl acetate (25 mL) was added and the mixture was washed with water 
(4x10 mL). The organic layer was dried over calcium chloride and concentrated in vacuo, affording 
pure compound 23. Yield: 31.8 mg, 72%. 1H NMR: δ =8.05 (s, 2H), 7.79 (d, J = 8.1, 2H), 7.38 (d, J = 
8.1, 2H), 7.36 – 7.16 (m, 4H), 7.13 (d, J = 8.7, 2H), 6.95 (d, J = 8.7, 2H), 6.87 (s, 1H), 5.07 (s, 2H), 4.80 
(s, 2H), 3.73 (s, 2H). 13C NMR: δ = 170.43, 161.61 (d, 1JCF = 244), 157.13, 138.85, 134.17, 133.10 (d, 
4JCF 
= 3), 130.63, 130.63, 129.76 (d, 3JCF = 8), 129.42, 126.48, 121.56, 117.78, 115.50 (d, 
2JCF = 21), 114.86, 
69.16, 46.78, 32.91 (C-B(OH)
2
 not visible). MS: m/z [M+H]+ calc. 450.13, obs. 450.22.
3-(4-fluorobenzyl)imidazolidine-2,4-dione (25).  To a cooled solution (273 K) of hydantoin (8.01 
g, 80.1 mmol) in dimethylformamide (140 mL) sodium hydride (60% in oil, 1.80 g, 45.0 mmol) was 
added. A solution of 1-(bromomethyl)-4-fluorobenzene (5.0 mL, 41 mmol) in dimethylformamide (5 
mL) was added to the reaction mixture. The mixture was allowed to warm up to room temperature 
and was stirred for 6 h. Then the mixture was poured into water (200 mL) and hexane (200 mL) was 
added. After a night at 277 K the precipitate was filtered and dried to give a white solid. Yield: 4.7 g, 
56%. 1H NMR: δ = 8.14 (s, 1H), 7.45 – 7.21 (m, 1H), 7.26 – 7.09 (m, 1H), 4.51 (s, 2H), 3.97 (s, 2H). 13C 
NMR: δ = 171.91, 161.45 (d, 1JCF = 244), 157.29, 133.04 (d, 
4JCF = 3), 129.66 (d, 
3JCF = 8), 115.21 (d, 
2JCF 
= 21), 46.00, 40.29. MS: m/z [M+H]+ calc. 209.07, obs. 208.93.
3-(4-fluorobenzyl)-1-methylimidazolidine-2,4-dione (27).  To a cooled solution (273 K) of 3-(4-
fluorobenzyl)imidazolidine-2,4-dione (98.1 mg, 0.471 mmol) in dimethylformamide (0.5 mL), sodium 
hydride (60% in oil, 21.1 mg, 0.530 mmol) was added. Subsequently, iodomethane (33 µl, 0.53 mmol) 
was added to the reaction mixture. The mixture was allowed to warm up to room temperature and 
was stirred for 3 h. Then the mixture was poured into ice water (2.5 mL) and hexane (2.5 mL) was 
added. After a night at 277 K the precipitate was filtered and dried to give a white solid. Yield: 75 
mg, 72%. 1H NMR: δ = 7.34-7.12 (m, 4H), 4.52 (s, 2H), 4.01 (s, 2H), 2.86 (s, 3H). 13C NMR: δ = 170.20, 
161.46 (d, 1JCF = 244), 156.24, 132.92 (d, 
4JCF = 3), 129.68 (d, 
3JCF  = 8) , 115.21 (d, 
2JCF = 21), 51.36, 
40.74, 29.21. MS: m/z [M+H]+ calc. 223.09, obs. 223.06.
(Z)-(4-((4-((1-(4-fluorobenzyl)-3-methyl-2,5-dioxoimidazolidin-4-ylidene)methyl) phenoxy)methyl)phenyl)
boronic acid (Z-28). To a cooled solution (273 K) of hydantoin 26 (10.1 mg, 0.0224 mmol) and sodium 
hydride (60% in oil, 1.46 mg, 0.0365 mmol) in DMF (0.15 ml), iodomethane (2.25 µl, 0.0361 mmol) 
was added. The mixture was allowed to warm up to room temperature and was stirred for 4 h. Final 
product was isolated by using preparative HPLC. Z-configuration confirmed by the chemical shift of 
the vinyl and methyl proton reported in literature.22 Yield: 6.97 mg, 68%. 1H NMR: δ = 8.11 (s, 1H), 
7.80 (d, J = 8.1, 2H), 7.50 – 7.30 (m, 6H), 7.26 – 7.10 (m, 2H), 7.05 (d, J = 8.8, 2H), 6.76 (s, 1H), 5.14 
(s, 2H), 4.67 (s, 2H), 2.92 (s, 3H). 13C NMR: δ = 163.01, 159.92, 156.78 (d, 1JCF = 249), 138.52, 134.19, 
132.55 (d, 4JCF = 3), 131.28, 129.75 (d, 
3JCF = 8), 128.50, 126.58, 124.66, 115.31 (d, 
2JCF = 21), 114.55, 
111.56, 69.30, 41.12, 30.35 (C-B(OH)
2
 not visible). MS: m/z [M+H]+ calc. 461.17, obs. 461.12.
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(E)-(4-((4-((2,5-dioxopyrrolidin-3-ylidene)methyl)phenoxy)methyl)phenyl) boronic acid (31). To a 
heated (343 K) solution of compound 30 (159 mg, 0.442 mmol)14 in methanol (5 mL) aldehyde 12 
(106 mg, 0.414 mmol) was added. After 1 h of heating the reaction mixture was cooled using an ice 
bath resulting in precipitation of the title compound. The precipitate was filtered and washed with 
ice-cold methanol resulting in compound 31. Yield: 88 mg, 63%. 1H NMR: δ = 11.34 (s, 1H), 8.04 
(s, 2H), 7.80 (d, J = 8.0, 2H), 7.57 (d, J = 8.9, 2H), 7.41 (d, J = 8.0, 2H), 7.33 (t, 4J = 2.1, 1H), 7.10 (d, J 
= 8.8, 2H), 5.19 (s, 2H), 3.60 (d, 4J = 2.2, 2H). 13C NMR: δ = 175.80, 172.09, 159.47, 138.42, 134.22, 
132.00, 131.31, 126.96, 126.54, 124.16, 115.31, 69.31, 34.71 (C-B(OH)
2
 not visible). MS: m/z [M+H]+ 
calc. 338.12, obs. 338.11.
(E)-(4-((4-((1-(4-fluorobenzyl)-2,5-dioxopyrrolidin-3-ylidene)methyl)phenoxy) methyl)phenyl) boronic acid 
(32). To a solution of compound 31 (30 mg, 0.0890 mmol) in dimethylformamide (0.3 mL) sodium 
hydride (60% in oil, 3.65 mg, 0.0913 mmol) was added. After addition of 4-fluorobenzyl bromide 
(24 µl, 0.19 mmol), the reaction mixture was stirred for 4 h. In addition, potassium carbonate (2.04 
mg, 0.0148 mmol) was added and the reaction mixture was stirred overnight. Then the mixture was 
poured into ice water (0.9 mL) and hexane (0.3 mL) was added. After a night at 277 K the precipitate 
was filtered, dried and purified using preparative HPLC to give a white solid. E-configuration 
confirmed by the chemical shift of the vinyl proton reported in literature.14 Yield: 13 mg, 32%. 1H 
NMR: δ = 8.04 (s, 2H), 7.80 (d, J = 8.1, 2H), 7.61 (d, J = 8.9, 2H), 7.45 (t, 4J = 2.1, 1H ), 7.41 (d, J = 8.0, 
2H), 7.38 – 7.29 (m, 2H), 7.23 – 7.04 (m, 4H), 5.19 (s, 2H), 4.66 (s, 2H), 3.74 (d, 4J = 2.1, 2H). 13C NMR: 
δ = 174.19, 170.59, 161.44 (d, 1JCF  = 244), 159.65, 138.39, 134.22, 132.59 (d, 
4JCF = 3), 132.31, 132.17, 
129.73 (d, 3JCF = 8), 126.85, 126.54, 122.27, 115.36, 115.22 (d, 
2JCF = 21), 69.33, 40.71, 33.74 (C-B(OH)2 
not visible). MS: m/z [M+H]+ calc. 446.16, obs. 446.12.
(S)-2-(4-fluorobenzyl)-7-hydroxy-10,10a-dihydroimidazo[1,5-b]isoquinoline-1,3(2H,5H)-dione 
(S-34). Compound S-33 (100 mg, 0.518 mmol) was dissolved in a mixture of dioxane and water 
(3:1, 4 mL) and 30 wt% of sodium hydroxide solution was used to adjust the pH to 14. The reaction 
mixture was heated to 313 K and 4-fluorobenzyl isocyanate (100 μL, 0.785 mmol) was added. After 2 
h of stirring, the mixture was cooled to room temperature and the resulting solid was removed using 
centrifugation. From the resulting solution was dioxane evaporated and concentrated hydrochloric 
acid was used to adjust the pH to 1. After refluxing the reaction mixture for 2 h 30 it was cooled to 
278 K affording a white precipitate. Washing the precipitate with ice-cold water (3x1 mL) afforded 
pure compound S-34. Yield: 30 mg, 18%. 1H NMR: δ = 9.37 (s, 1H), 7.35 – 7.30 (m, 2H), 7.18 – 7.12 
(m, 2H), 7.06 – 7.03 (m, 1H), 6.65 – 6.63 (m, 2H), 4.77 (d, J = 16.8, 1H), 4.58 (s, 2H), 4.32 – 4.27 (m, 
2H), 3.05 (m, 1H), 2.82 – 2.64 (m, 1H). 13C NMR: δ = 172.76, 161.44 (d, 1JCF = 244), 156.07, 154.60, 
132.82 (d, 4JCF = 3), 132.35, 130.13, 129.51 (d, 
3JCF = 8), 121.45, 115.26 (d, 
2JCF = 21), 114.30, 112.67, 
54.54, 41.23, 40.56, 29.02. MS: m/z [M+H]+ calc.  327.11, obs. 327.09.
(R)-2-(4-fluorobenzyl)-7-hydroxy-10,10a-dihydroimidazo[1,5-b]isoquinoline-1,3(2H,5H)-dione 
(R-34). For reaction details see compound S-34. Yield: 29%.
(S)-(4-(((2-(4-fluorobenzyl)-1,3-dioxo-1,2,3,5,10,10a-hexahydroimidazo[1,5-b]isoquinolin-7-yl)oxy)
methyl)phenyl)boronic acid (S-35). To a heated solution (323 K) of compound S-34 (15.3 mg, 0.0469 
mmol) in acetone (0.3 mL), potassium carbonate (10.2 mg, 0.0738 mmol) and 4-(bromomethyl)
phenylboronic acid (12.4 mg, 0.0577 mmol) were added. After 4 h of stirring and heating, additional 
potassium carbonate (10.1 mg, 0.0730 mmol) was added and the suspension was stirred overnight. 
Finally, the reaction mixture was diluted with ethyl acetate and the organic layer was washed with 
1 M hydrochloric acid (2x0.5 mL) and brine (0.5 mL), dried over sodium sulfate and concentrated 
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in vacuo. The resulting solid was further purified using preparative HPLC affording pure compound 
S-35. Yield: 11 mg, 52%. 1H NMR: δ = 8.06 (s, 2H), 7.78 (d, J = 8.1, 2H), 7.50 – 7.27 (m, 4H), 7.27 – 
7.05 (m, 3H), 7.02 – 6.76 (m, 2H), 5.09 (s, 2H), 4.82 (d, J = 17.0, 1H), 4.58 (s, 2H), 4.42 – 4.20 (m, 2H), 
3.19 – 3.02 (m, 1H), 2.80 – 2.71 (m, 1H). 13C NMR: δ = 172.72, 161.46 (d, 1JCF = 244), 157.09, 154.60, 
138.74, 134.17, 132.81 (d, 4JCF = 3), 132.60, 130.23, 129.55 (d, 
3JCF = 8), 126.49, 123.60, 115.28 (d, 
2JCF 
= 21), 113.87, 112.47, 69.20, 54.40, 41.30, 40.60, 29.00 (C-B(OH)
2
 not visible). MS: m/z [M+H]+ calc. 
461.17, obs. 461.14.
(R)-(4-(((2-(4-fluorobenzyl)-1,3-dioxo-1,2,3,5,10,10a-hexahydroimidazo[1,5-b]isoquinolin-7-yl)oxy)
methyl)phenyl)boronic acid (R-35). For reaction details see compound S-35. Yield: 56%.
 
Spectral data on compounds. Spectral data (HPLC-MS, 1H and 13C NMR profiles) of all intermediates 
and target molecules is available free of charge via the Internet at http://pubs.acs.org.
Choline release assay.11 See Experimental section Chapter 3.
Docking Experiments, Protein and Ligand Preparation. The X-ray structure of ATX in complex with 
inhibitor 1 (PDB ID: 2XRG) was used for the docking studies. The protein structure was prepared 
using the Schrödinger Suite 2010 Protein Preparation Wizard (with Epik 2.1,23 Impact 5.6 and Prime 
2.2). The initial 3D structures of the ligands were generated using LigPrep 2.4 and the ligand partial 
charges were ascribed using the OPLS2005 force-field as performed by Glide 5.6.18-20 We defined the 
binding region by a 20 Å x 20 Å x 20 Å box centered on the central position of inhibitor 1 in the crystal 
ATX complex. We used positional constraints for the two oxygen atoms of the boronic acid and the 
arylic carbon direct next to the boron atom in inhibitor 1. The Glide Emodel score was used to rank 
the docking poses. Images were made using PyMOL 1.3.
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Supporting Figure S1.  Michael acceptor study of inhibitor 1. We incubated 100 μM of inhibitor 1 
((M+H+) = 464.11) with 10 mM of l-glutathione (reduced) in a Tris-HCl buffer (50 mM, pH 7.4) at 310 
K for 19 h.  L-glutathione is a natural occurring reducing agent which is abundantly present in blood 
(1 mM) and can act as a Michael donor. After 19 h of incubation no Michael addition was observed 
(compare LC spectrum and MS profile in A] and B] with C] and D]).
Supporting Figure S2.  Dose-response graph for 
inhibitor 17 (n=5).
Supporting Figure S3. Dose-response curves for 
inhibitors 19 and 36. 
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4.1 Å 
F274
Supporting Figure S4.   The distance between the oxygen of the carbonyl 
moiety in inhibitor 1 and the center of the aromatic ring of ATX residue 
F274 is 4.1 Å, suggesting π-stacking between these two moieties.
Supporting Figure S5.  Docked (transparent blue) and X-ray (magenta) 
pose of inhibitor 1.
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Syntheses supporting information
Syntheses aldehydes 2-6
4-((4-bromobenzyl)oxy)benzaldehyde (2). To a solution of 4-hydroxybenzaldehyde (1.02 g, 8.33 
mmol) and potassium hydroxide (0.533 g, 9.50 mmol) in dimethyl sulfoxide (13 mL), 4-(bromomethyl)
phenyl bromide (1.38 g, 5.51 mmol) was added. The reaction mixture was stirred at room 
temperature and after 1 h the precipitate was isolated by centrifugation, washed with water (3x15 
mL) and lyophilized resulting in the title compound. Yield: 1.5 g, 91% 1H NMR: δ = 9.87 (s, 1H), 7.87 
(d, J = 8.8, 2H), 7.60 (d, J = 8.5, 2H), 7.43 (d, J = 8.5, 2H), 7.20 (d, J = 8.7, 2H), 5.22 (s, 2H). 13C NMR: 
δ = 191.23, 163.02, 135.77 (C
Ar
-Br+C
Ar
COH), 131.74, 131.40, 129.89, 121.16, 115.27, 68.79. MS: m/z 
[M+H]+ calc. 291.00, 293.00, obs. 291.01, 293.02.
N-(4-bromophenyl)-4-formylbenzamide (3). Thionyl chloride (0.75 mL, 10.3 mmol) was added to 
a suspension of 4-carboxy benzaldehyde (0.517 g, 3.44 mmol) in dry toluene (15 mL). The reaction 
mixture became clear after 4 h of refluxing. Concentrating the solution resulted in a light brown 
solid. The crude product was dissolved in dichloromethane (12.5 mL) and 4-bromo aniline (0.607 g, 
3.53 mmol) and triethylamine (1.3 mL, 9.3 mmol) were added. After 1 h 30 of refluxing under an 
atmosphere of argon the reaction mixture was diluted with ethyl acetate (40 mL) and washed with 1 
M hydrochloric acid (40 mL) and saturated bicarbonate solution (40 mL). The organic layer was dried 
over magnesium sulfate and was concentrated resulting in a yellow solid. Yield: 707.1 mg, 68%. 1H 
NMR: δ = 10.58 (s, 1H), 10.12 (s, 1H), 8.13 (d, J = 8.5, 2H), 8.06 (d, J = 8.5, 2H), 7.77 (d, J = 8.9, 2H), 
7.56 (d, J = 8.9, 2H). 13C NMR: δ = 192.89, 164.81, 139.64, 138.26, 138.04, 131.49, 129.42, 128.43, 
122.28, 115.69. MS: m/z [M+H]+ calc. 304.00, 306.00, obs. 303.96, 305.96.
N-(4-bromobenzyl)-4-formylbenzamide (4). In a dry flask, thionyl chloride (3.3 mL, 45.2 mmol) was 
added to a suspension of 4-carboxy benzaldehyde (1.07 g, 7.13 mmol) in dry toluene (30 mL). The 
reaction mixture was refluxed for 5 h and concentrated in vacuo.  The crude product was dissolved in 
dichloromethane (25 mL) and 4-bromobenzyl amine (1.0 mL, 7.92 mmol) and triethylamine (1.3 mL, 
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7.17 mmol) were added. The reaction mixture was refluxed for 2 h. Finally, the mixture was diluted 
with ethyl acetate (60 mL) and washed with 1 M hydrochloric acid (40 mL) and bicarbonate solution 
(40 mL). The organic layer was dried over magnesium sulfate and concentrated in vacuo. Yield: 1.65 
g, 73%. 1H NMR: δ = 10.08 (s, 1H), 9.30 (t, J = 5.9, 1H), 8.08 (d, J = 8.3, 2H), 8.00 (d, J = 8.5, 2H), 7.52 
(d, J = 8.5, 2H), 7.30 (d, J = 8.5, 2H), 4.47 (d, J = 5.9, 2H). 13C NMR: δ = 192.85, 165.45, 139.15, 138.79, 
137.84, 131.15, 129.53, 128.81, 127.98, 119.82, 42.19. MS: m/z [M+H]+ calc. 318.01, 320.01, obs. 
317.95, 319.96.
2-(4-nitrophenyl)-1,3-dioxolane (37). To a solution of 4-nitrobenzaldehyde (3.95 g, 26.1 mmol) 
in dry toluene (10 mL), molecular sieves (4 Å, 2 g), dry ethylene glycol (10.0 mL, 179 mmol) and 
p-toluenesulfonic acid monohydrate (2.04 g, 10.7 mmol) were added was refluxed for 25 h using 
a Dean-Stark apparatus. Toluene (50 mL) and water (50 mL) were added and the water layer was 
extracted with toluene (2x50 mL). The organic layers were combined and washed with brine (3x100 
mL), dried over magnesium sulfate and finally concentrating in vacuo. Yield: 3.87 g, 76%. 1H NMR: 
δ = 8.25 (d, J = 8.8, 2H), 7.71 (d, J = 8.5, 2H), 5.89 (s, 1H), 4.05-3.97 (m, 4H). 13C NMR: δ = 147.91, 
145.20, 127.79, 123.45, 101.38, 65.02. MS: m/z [M+H]+ calc. 196.06, obs. 196.06.
4-bromo-N-(4-formylphenyl)benzamide (5). Compound 37 (3.87 g, 19.8 mmol) was dissolved in 
degassed tetrahydrofuran (250 mL) and 10 wt% Pd/C (480 mg) was added. After stirring the reaction 
mixture for 16 h under a hydrogen atmosphere it was filtered over Hyflo Super Cel® medium and 
was concentrated. The crude product was used without any further purification and was dissolved 
in dry dichloromethane (75 mL) and 4-bromobenzoyl chloride (3.57 g, 16.3 mmol) was added. The 
solution was stirred for 2 h and triethylamine (0.4 mL, 2.87 mmol) was added. Additional triethyl 
amine (2.8 ml, 20 mmol) was added over 2 h with time intervals of 30 min. After stirring for another 
1 h 30 the solution was diluted with ethyl acetate (200 mL) and washed with 1 M hydrochloric acid 
(100 mL) and brine (100 mL). The solution was dried over magnesium sulfate and concentrated in 
vacuo. Crude product (922 mg) was deprotected in dichloromethane (100 mL) using perchloric acid 
(50 mL). After stirring the mixture for 2 h it was diluted with ethyl acetate (100 mL) and neutralized 
with 30 wt% sodium hydroxide solution which initiated separation. The oranic layer was dried over 
magnesium sulfate and the solvent was concentrated in vacuo which resulted in an orange solid. 
Yield: 464.1 mg, 66%. 1H NMR: δ =  10.69 (s, 1H), 9.92 (s, 1H), 8.02 (d, J = 8.3, 2H), 7.93 (d, J = 8.5, 
2H), 7.90 (d, J = 8.5, 2H), 7.77 (d, J = 8.5, 2H). 13C NMR: δ = 191.62, 165.13, 144.61, 133.55, 131.68, 
131.46, 130.59, 129.94, 125.74, 119.92. MS: m/z [M+H]+ calc. 304.00, 306.00, obs. 304.03, 306.04.
(E)-4-(4-bromostyryl)benzaldehyde (6). To a solution of terephthalaldehyde (8.06 g, 60.1 mmol) 
in tetrahydrofuran (420 mL) were added diethyl(4-bromobenzyl)phosphonate (5.10 g, 16.6 mmol) 
and potassium tert-butoxide (2.92 g, 26.0 mmol). After 40 min stirring under an argon atmosphere 
additional potassium tert-butoxide (2.92 g, 26.0 mmol) was added and stirred for another 30 min. 
The reaction mixture was filtered and concentrated in vacuo and the resulting solid was purified 
using column chromatography (hexane-dichloromethane, 1:1) to provide the title compound. Yield: 
2.1 g, 43%. 1H NMR (CDCl
3
): δ = 9.98 (s, 1H), 7.86 (d, J = 8.4, 2H), 7.63 (d, J = 8.3, 2H), 7.50 (d, J = 8.6, 
2H), 7.39 (d, J = 8.5, 2H), 7.14 (dd, J = 16.4, 23.2, 2H). 13C NMR (CDCl
3
): δ = 191.75, 143.23, 135.78, 
135.74, 132.22, 131.10, 130.49, 128.55, 128.28, 127.20, 122.60. MS: m/z [M+H]+ calc. 287.01, 
289.01, obs. 286.97, 288.97. 
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Synthesis amine linker-based inhibitor 36
4,4,5,5-tetramethyl-2-(4-nitrophenyl)-1,3-dioxolane (38). 
A mixture of 4-nitrobenzaldehyde (6.07 g, 40.2 mmol), 
pinacol (6.31 g, 53.4 mmol) and p-toluenesulfonic acid 
monohydrate (0.225 g, 1.18 mmol) was refluxed in dry 
toluene (65 mL) for 4 h using a Dean-Stark apparatus. 
After cooling to room temperature, sodium hydroxide 
(0.216 g, 5.40 mmol) in ethanol (3 mL) was added to 
the mixture and stirred for 30 min. The suspension 
was filtered and the residue was washed with toluene 
(125 mL). The filtrate was washed with brine (3x100 mL), dried over sodium sulfate and finally 
concentrated in vacuo to provide the title compound. Yield: 9.3 g, 92%. 1H NMR: δ = 8.23 (d, J = 8.8, 
2H), 7.70 (d, J = 8.4, 2H), 6.00 (s, 0H), 1.27 (s, 6H), 1.17 (s, 6H). 13C NMR: δ = 147.54, 147.04, 127.37, 
123.40, 97.76, 82.75, 23.84, 21.89. MS: m/z [M+H]+ calc. 252.12, obs. 252.11.
4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)aniline (39).  A mixture of compound 38 (0.498 g, 1.98 
mmol) and 10 wt% Pd/C (50 mg) in degassed tetrahydrofuran (15 mL) under a hydrogen atmosphere 
was stirred for 7 h. The mixture was filtrated over Hyflo Super Cel® medium and the filtrate was 
concentrated in vacuo. Yield: 438 mg, 100%. 1H NMR: δ = 7.06 (d, J = 8.4, 2H), 6.51 (d, J = 8.5, 2H), 
5.71 (s, 1H), 5.10 (s, 2H), 1.21 (s, 6H), 1.19 (s, 6H). 13C NMR: δ =149.04, 127.44, 126.39, 113.12, 99.75, 
81.47, 24.34, 22.00. MS: m/z [M+H]+ calc. 222.15, obs. 222.14.
(4-(((4-formylphenyl)amino)methyl)phenyl)boronic acid (40). To a solution of amine 39 (1.06 
g, 4.79 mmol) in dry dimethylformamide (10 mL), potassium carbonate (0.612 g, 4.43 mmol) and 
4-bromomethylphenylboronic acid (0.880 g, 4.10 mmol) were added. After stirring overnight under 
an argon atmosphere the reaction mixture was diluted with ethyl acetate (100 mL). The mixture was 
washed with 0.1 M hydrochloric acid (3x50 mL), dried over magnesium sulfate and concentrated 
in vacuo. The resulting mixture of mono- and dialkylated products was purified using column 
chromatography (dichloromethane-methanol, 95:5) to isolate the monoalkylated intermediate 
(0.661 g, 45%).
The pinacol protecting group was removed as follows: To a solution of monoalkylated 
intermediate (0.140 g, 0.394 mmol) in tetrahydrofuran (3 mL), sodium periodate (0.107 g, 0.500 
mmol) and water (0.424 mL) were added. After 30 min of stirring under an atmosphere of argon, 1 M 
hydrochloric acid (0.284 mL) was added and stirred for one night. The reaction mixture was diluted 
with ethyl acetate (13 mL) and washed with brine (11 mL). The water layer was extracted with ethyl 
acetate and the combined organic layers were washed with brine (8 mL), dried over magnesium 
sulfate and concentrated in vacuo to afford the title compound in quantitative yield. Overall yield: 
100 mg, 45% (two steps). 1H NMR: δ = 9.58 (s, 1H), 7.97 (s, 2H), 7.74 (d, J = 8.1, 2H), 7.58 (d, J = 8.8, 
2H), 7.42 (t, J = 6.0, 1H), 7.30 (d, J = 8.0, 2H), 6.67 (d, J = 8.7, 2H), 4.39 (d, J = 6.0, 2H), . 13C NMR: δ 
= 189.55, 153.95, 140.88, 134.23, 131.77, 126.15, 125.05, 111.59, 45.79 (C-B(OH)
2
 not visible). MS: 
m/z [M+H]+ calc. 256.11, obs. 256.17.
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(Z)-(4-(((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)phenyl)amino) methyl)phenyl)
boronic acid (36). To a solution of 3-(4-fluorobenzyl)thiazolidine-2,4-dione (18.8 mg, 0.0835 mmol) 
in ethanol (0.2 mL), piperidine (8.2 µL, 0.0835 mmol) and aldehyde 40 (19.7 mg, 0.0772 mmol) 
were added and the solution was refluxed for 4 h. Upon cooling to room temperature the product 
precipitated out of solution. Pure compound was obtained after preparative HPLC purification. Yield: 
10 mg, 29%. 1H NMR: δ = 7.99 (s, 2H), 7.76 (s, 1H), 7.74 (d, J = 8.1, 2H), 7.47 – 7.23 (m, 7H), 7.20 
– 7.14 (m, 2H), 6.70 (d, J = 8.8, 2H), 4.79 (s, 2H), 4.37 (d, J = 5.8, 2H). 13C NMR: δ = 167.54, 165.66, 
161.59 (d, 1JCF = 244), 151.27, 141.03, 134.76, 134.24, 132.67, 132.01 (d, 
4JCF = 3), 129.84 (d, 
3JCF = 8), 
126.17, 119.94, 115.40 (d, 2JCF = 21), 112.57, 112.37, 45.84, 43.66 (C-B(OH)2 not visible). MS: m/z 
[M+H]+ calc. 463.13, obs. 463.20.
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phosphatases: 
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5.1 Introduction
The previous chapters describe the discovery, optimization and biological validation of 
autotaxin (ATX) inhibitors. Next to the phosphodiesterase ATX, protein phosphatases are 
another interesting class of enzymes in drug discovery.1 Like ATX, protein phosphatases 
have the ability to hydrolyze phosphate esters, however, their substrates are intracellular 
phosphorylated proteins rather than lipids. Therefore, ATX and protein phosphatases have 
different functions in biology. Here a short introduction on protein phosphatases is provided 
with the main focus on dual specificity phosphatases as an introduction to the next chapter.
After protein synthesis, approximately one-third of mammalian proteins are 
phosphorylated by protein kinases (Figure 1).2 Dynamic protein phosphorylation is one of the 
major mechanisms by which cells regulate transcription, signal transduction, proliferation, 
differentiation, motility and metabolism.3-8 The phosphorylation state of cellular proteins 
is tightly controlled by the concerted and reversible action of protein kinases and protein 
phosphatases. The importance of controlling the activity of protein kinases in biology has 
long been recognized and this has resulted in the development of several clinically approved 
protein kinase inhibitors (e.g. Imatinib). A growing body of evidence now demonstrates that 
the regulation of protein dephosphorylation by protein phosphatases is equally important, 
which stimulates the development of protein phosphatase inhibitors.4 
Protein phosphatases have historically have classified as serine/threonine (PSP),9 
tyrosine (PTP),10 and dual specificity (DUSP)11 phosphatases based on their preference 
for specific phosphorylated hydroxyl amino acids (Figure 1) over others. The unique 
feature that distinguishes DUSPs from PSPs and PTPs is their ability to dephosphorylate 
both phosphorylated tyrosine and serine/threonine residues within a protein substrate. 
Both classical PTPs and DUSPs share a similar mechanism of catalysis for the hydrolysis of 
phosphorylated substrates that involves the formation of a phosphoryl-enzyme intermediate 
(Figure 2).11-13 The highly conserved catalytic domain in DUSPs contains the consensus 
sequence HCXXGXXRS(T) (Table 1). The cysteine residue (C), which is essential for catalytic 
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Figure 1: The phosphorylation status of proteins is regulated by both protein phosphatases 
and protein kinases. Protein phosphorylation occurs predominately on the amino acids serine, 
threonine and tyrosine.
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activity, is positioned at the centre of the catalytic pocket.11 The arginine (R) of the consensus 
sequence coordinates to the phosphate group of the protein substrate to assist with catalysis. 
There is also a conserved aspartic acid present upstream of this conserved motif that acts 
as a general acid/base catalyst. The serine (S) of the 
consensus sequence, threonine (T) in some other 
protein phosphatases (i.e. DUSP23), most likely 
plays a role in stabilizing the cysteinyl anion through 
hydrogen bonding.14-16 The catalytic pocket of a 
DUSP is shallow, but broader than that of classical 
PTPs, which is thought to be the mechanism how 
DUSPs can simultaneously accommodate more than 
one phosphorylated residue.13
Although a number of potent and selective 
inhibitors of PSPs isolated from natural sources are 
known, like tautomycin and fostriecin,17 selective 
PTP or DUSP inhibitors are still rare.18 Genetic 
approaches using small interfering RNA (siRNA) can 
provide some insight into the biological function 
of these protein phosphatases in cells. However, 
some PTPs and DUSPs interact with other proteins 
and regulate their function in a manner that is 
independent of their phosphatase activity.19 In 
addition, wrong gene annotations in commercial 
siRNA libraries and the difficulty of reproducible 
transfections of siRNA ask for independent controls. 
Therefore, potent and selective small molecule 
inhibitors of protein phosphatases are valuable to 
Enzyme Substrate-enzyme complex Phosphoryl-enzyme intermediate
Protein substrate
Protein product
+ H2O
HN
O
OH P
O
OO
OH
HN
O
O
P
O
OO
HN
O
O
P
O
OO
HO O
Asp
S
Cys
NH2
H2N
HN
Arg
HO
Ser
HO O
Asp
S
Cys
NH2
H2N
HN
Arg
HO
Ser
O O
Asp
S
Cys
NH2
H2N
HN
Arg
HO
Ser
H
O
H
P
O
OO
DUSP3
DUSP13
DUSP2
DUSP4
DUSP5
DUSP26
DUSP1
DUSP27
DUSP22
DUSP14
DUSP12
DUSP16
DUSP10
DUSP5
PTPMT1
SSH3
DUSP15
DUSP6
DUSP7
DUSP13
V H C R E G Y S
V H C AMG V S
H C Q AG I S R
H C Q AG I S R
V H C E A G I S
V H C A V G V S
H C Q AG I S R
V H C V MG R S
H C L A G V S R
H C A A G V S R
H C H AG V S R
H C L A G I S R
H C Q AG V S R
H C Q AG V S R
H C K A G R S R
V H C K MG V S
V H C F A G I S
V H C L A G I S
V H C L A G I S
V H C V V G V S
R S
R S
S
S
R S
R S
S
R S
S
S
S
S
S
S
S
R S
R S
R S
R S
R S
Figure 2: Proposed catalytic mechanism for DUSPs and classical PTPs.
Table 1: Conserved Catalytic Domain 
for DUSPs and PTPs.
a Table displays the PTP signature 
sequence in DUSP3, a well studied DUSP, 
compared with the 20 closest human 
homologs. Conserved amino acids are 
depicted in blue. Serine (S) is partially 
conserved (purple).
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study the function of protein phosphatases, allowing immediate and reversible inhibition. 
The discovery of small molecule inhibitors of protein phosphatases has been challenging, 
especially the search for selective inhibitors. Selective inhibitors are difficult to obtain due to 
the highly conserved nature of the PTPs and DUSPs active site (Table 1).
In the next chapter we study the involvement of protein phosphatases in Salmonella 
typhimurium infection of human cells and we describe the discovery and development of 
inhibitors that target protein phosphatases that are essential for this infection process. 
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CHAPTER 6
Controlling bacterial infection by human dual specificity 
phosphatase inhibition 
Harald M.H.G. Albers, Coenraad Kuijl, Tiziana Scanu, Loes J.D. Hendrickx, Sharida Wekker, 
Nadha Farhou, Nora Liu, Patrick Celie, Huib Ovaa and Jacques J. Neefjes, Paper in preparation.
Abstract. Multidrug resistance (MDR) of bacteria is a serious social threat and a neglected 
area in the pharmaceutical industry. New intervention strategies besides conventional 
treatments are required to overcome MDR bacteria. Current treatments use antibiotics 
that target the pathogen but not the involved host protein pathway required for pathogen 
survival. Recently, it has been demonstrated by Kuijl et al. that H-89 inhibits intracellular 
growth of Salmonella (S.) typhimurium by inhibiting the host’s protein kinase PKB/Akt1. Here 
we describe an RNA interference screen of the human phosphatome that reveals several host 
dual specificity phosphatases (DUSP3, 11 and 27) that are essential for intracellular growth of 
S. typhimurium. In parallel, screening a tyrosine/dual specificity phosphatase targeted library 
of small molecules afforded inhibitors that reduced intracellular growth of S. typhimurium. 
One of these identified molecules inhibited the host proteins DUSP3, 11 and 27 confirming 
the target (DUSPs) lead (inhibitor) relationship for S. typhimurium infection. This inhibitor was 
further developed into a selective inhibitor for DUSP3 (IC
50
 = 0.33 μM) over DUSP27 (IC
50
 > 5 
μM) and molecular docking reveals a binding pose of this inhibitor for DUSP3 explaining this 
selectivity. In conclusion, targeting the host proteins required for pathogen survival appears to 
be a valid way to control bacterial infection and holds promise as a new therapeutic approach 
to treat bacterial infections in the clinic.
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6.1 Introduction
Bacterial infection is still a big social threat as proven by one of the world’s most severe outbreaks 
of Enterohaemorrhagic Escherichia coli (EHEC) in Europe last year.1 In addition, with multidrug 
resistance (MDR) of bacteria it becomes increasingly difficult to treat these bacterial infections.2 
New intervention strategies are required next to conventional treatments to overcome MDR in 
bacteria. Developing medicines that target host proteins essential for bacterial survival instead of 
killing bacteria directly with antibiotics could be an answer to this problem.
Many bacterial pathogens survive in intracellular compartments of host cells and use 
that location as a niche for growth while remaining undetected by the immune system.3 
These bacteria frequently remain in such compartments in a dormant state and are therefore 
difficult to reach by antibodies and antibiotics. For their survival, bacteria need to manipulate 
the host system to prevent transport from phagosomes to phagolysosomes where they can 
be degraded.4,5 
Using a combination of chemistry, small interfering RNA (siRNA) screening, 
biochemistry and cell biology, we have recently shown that the intracellular bacteria 
Salmonella (S.) typhimurium  activates a signaling network around the protein kinase PKB/
Akt1 to prevent delivery to lysosomal compartments where bacteria would otherwise have 
been degraded (Figure 1A).5 Bacteria activate the protein kinase PKB/Akt1 for their survival 
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Figure 1: (A) The PKB/Akt1 protein pathway involved in Salmonella (S.) typhimurium infection. By 
inhibiting PKB/Akt1 using small molecule inhibitor H-89, intracellular growth of S. typhimurium 
can be blocked. (B) Identified phosphatases by siRNA screening that reduce intracellular growth 
of S. typhimurium in human cells. (C) Novel identified S. typhimurium infection inhibitors by 
screening a tyrosine-based small molecule library (blue: tyrosine motif).
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and we inhibited this protein 
kinase with a commercial 
inhibitor (H-89, Figure 1A) 
which induced the bacterial 
elimination in human cells.5 
We now report the 
identification of protein 
phosphatases that control 
intracellular growth of S. 
typhimurium in the human 
host cell. The function of only 
few protein phosphatases 
is known and this class of 
enzymes is studied relatively 
poorly compared to protein 
kinases. Protein phosphatases 
are divided in three main 
classes based on their phosphorylated protein substrates; serine/threonine phosphatases, 
tyrosine phosphatases and dual specificity phosphatases (DUSP).6 The latter class is able to 
hydrolyze both phosphorylated serine, threonine and tyrosine residues and is member of the 
protein tyrosine phosphatase family. By silencing all protein phosphatases (Supporting Table 
S1) of the human host cell we have mainly identified protein tyrosine phosphatases, which 
control intracellular bacterial growth of S. typhimurium (Figure 1B). Among these identified 
protein tyrosine phosphatases several DUSPs were present (DUSP3, 11 and 27).
We tested a tyrosine-based small molecule library designed to target protein tyrosine 
phosphatases, including DUSPs. This library partly consisted of the previously described ATX 
inhibitors in Chapter 3. Compounds depicted in Figure 1C reduced the intracellular growth 
of S. typhimurium in host cells to a similar extent as obtained through phosphatase silencing. 
Important to note, these compounds were not toxic for S. typhimurium or the host cell alone 
(see Supporting Figures S1 and S2).
In this study we show that one of the identified inhibitors of intracellular growth of S. 
typhimurium act on the identified host DUSPs. Medicinal chemistry efforts then resulted in 
a selective DUSP3 inhibitor, which is a challenging task in the development of phosphatase 
inhibitors. The selectivity of this compound can be explained by molecular docking of this 
inhibitor into DUSP3 and 27 crystal structures.
6.2 Enzyme kinetics of DUSP3, 11 and 27
In order to test S. typhimurium inhibitors on DUSP activity we have developed an activity assay 
using 3-O-methylfluorescein phosphate (OMFP) as DUSP substrate (Figure 2A).7 The quenched 
+
OMFP OMF
485 nm 520 nm
DUSP
A
B
0 20 40 60 80 100
0
20
40
60
80
100 DUSP3
DUSP11
OMFP (M)
En
zy
m
e 
ve
lo
ci
ty
 (a
u)
0 20 40 60 80 100
0
10
20
30
DUSP27
OMFP (M)
En
zy
m
e 
ve
lo
ci
ty
 (a
u)
C
O
O
O
O OH
O
O
O
O O
P
O O
O
O
P
O
O
OH
Figure 2: (A) DUSP activity assay using OMFP as substrate. (B) 
Saturation curves for DUSP3 and 11. (C) Linear relationship of 
the phosphate hydrolysis velocity of DUSP27 and substrate 
concentration.
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OMFP substrate is hydrolyzed by the DUSPs into the fluorophore 3-O-methylfluorescein (OMF) 
and phosphate. First we studied the enzyme kinetics of DUSP3, 11 and 27 (Figure 2B and C) 
using this assay. DUSP3 and 11 show normal Michaelis–Menten kinetics giving saturation at 
high substrate concentration (Figure 2B) while DUSP27 shows a linear relationship between 
enzyme velocity and substrate concentration (Figure 2C). The Michaelis constants (K
m
 values) 
for DUSP3 and 11 are 50 μM and 59 μM, respectively. Due to the linear kinetics of DUSP27 its 
K
m 
is infinite under these conditions.
6.3 Effect of S. typhimurium inhibitors on DUSP activity
The compounds that reduced intracellular growth of S. typhimurium in human host cells 
have been tested on their effect on the the activity of the three DUSPs.  DUSP activity was 
measured at an OMFP concentration of 20 μM using an inhibitor concentration of 5 μM 
(Figure 3). The most active compound that inhibited all the three DUSPs is LH65.3 with high 
percentage inhibitions (PI) between 85% and 97%. This inhibitor did not show any preference 
for a specific DUSP (Figure 4A).
6.4 Structure-activity relationships of DUSP inhibitors
In order to increase the potency and selectivity of LH65.3 for the three DUSPs we synthesized 
analogs of this inhibitor. For this purpose we changed the benzyl (R1) and benzylidene 
(R2) moieties as depicted in Table 1. Activities of the compounds for DUSP3, 11 and 27 
were measured as percentage inhibition (PI) at an inhibitor concentration of 5 μM. First 
we replaced the 4-tert-butyl benzyl (R1) moiety in LH65.3 by 4-nitroacetophenone (1), 
4-trifluoromethyl benzyl (2), diphenyl methane (3), 2-(methyl)naphthalene (4), 4-bromo 
benzyl (5) and  4-fluoro benzyl (6). None of the modifications improved the activity of the 
inhibitors (Table 1). Next, we changed the position of the nitro and hydroxyl moiety in 
LH65.3 (compounds 7 and 14) which 
had a negative effect on DUSP inhibition. 
However, introduction of a methoxy group 
on the meta position (21) afforded full 
inhibition for all the three DUSPs. We then 
explored structure-activity relationships 
(SAR) of all the possible combinations of 
the previously described R1 and R2 groups 
(Table 1). In general, having a 4-hydroxy-3-
methoxy-5-nitrophenyl moiety for R1 (21-
26) has a positive effect on the potency 
of the inhibitors leading to almost full 
inhibition for the three DUSPs. The nature 
of the R1 group doesn’t seem to have a 
Co
ntr
ol
LH
10
1.2
LH
1.2
LH
1.4
LH
56
.1
LH
65
.3
HA
25
0
25
50
75
100
125
150 DUSP3
DUSP11
DUSP27
DU
SP
 a
cti
vi
ty
 (%
)
Figure 3: Effect of identified S. typhimurium 
infection inhibitors on the activity of DUSP3, 11 
and 27. DUSP activity (%) has been measured 
at an inhibitor concentration of 5 μM.
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large negative effect on the activity of the compounds when R2 is 4-hydroxy-3-methoxy-5-
nitrophenyl, with the only exception when R1 is 4-fluoro benzyl (27). Overall, poor activities 
were obtained for R1 as a 4-fluoro benzyl moiety (6, 13, 20 and 27), most of the activities (PI) 
for these compounds were below 15%.
6.5 Selectivity and mode of inhibition of inhibitor 8
For the most active compounds in Table 1 that evidenced full DUSP3 inhibition (dark 
green boxes) we have determined IC
50
 values for all the three DUSPs (Table 2) in order 
to find selective DUSP inhibitors. Obtained IC
50
 values for the inhibitors varied between 
0.33 and 2.4 μM. We were able to improve the activity of our reference inhibitor, 
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Table 1: Structure-activity relationships of DUSP inhibitors. Percentage inhibition (PI, %) at 5 μM 
of compound are given for DUSP3, 11 and 27, respectively.
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LH65.3, by a 5 fold for DUSP3 resulting in inhibitor 8. More importantly, inhibitor 8 is selective 
for DUSP3 (IC
50
 = 0.33 μM) compared to DUSP11 and 27 (IC
50
 = 0.73 μM and IC
50
 > 5 μM). In 
Figure 4A and 4B the dose-response curves for LH65.3 and 8 are depicted to visualize the gain 
in potency and selectivity of 8 for the three DUSPs compared to LH65.3.
Next, we studied the mode of inhibition of 8 using Lineweaver-Burk analysis. For DUSP3 
and 11, inhibitor 8 showed non-competitive inhibition (Figure 4C). Increasing the inhibitor 
concentration of inhibitor 8 did not change the V
max
 or K
m
 of DUSP27 (Figure 4C).
Entry R1 R2 DUSP3  DUSP1 1 DUSP27  
8 0.33 ± 0.06 0.73 ± 0.06 > 5.00 
23 0.59 ± 0.08 0.66 ± 0.03 0.94 ± 0.06 
25 0.93 ± 0.09 1.01 ± 0.09 0.70 ± 0.01 
24 1.21 ± 0.20 1.23 ± 0.02 1.45 ± 0.06 
4 1.27 ± 0.25 1.67 ± 0.09 2.53 ± 0.23 
21 1.36 ± 0.05 1.35 ± 0.08 1.79 ± 0.03 
26 1.40 ± 0.02 1.35 ± 0.07 1.65 ± 0.02 
1.53 ± 0.05 1.57 ± 0.06 1.86 ± 0.05 
5 1.62 ± 0.08 2.11 ± 0.10 1.81 ± 0.04 
22 1.74 ± 0.27 2.11 ± 0.17 2.43 ± 0.03 
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Table 2: IC
50
 values (μM) for the ten most potent DUSP inhibitors sorted by decreasing 
potency for DUSP3.
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6.6 Protein surface comparison between DUSP3 and 27
In order to explain the selectivity of inhibitor 8 for DUSP3 over DUSP27 we compared the 
protein surfaces of these two DUSPs. Several crystal structures of DUSP3 have been reported8-
10 but not for DUSP27 at the time of this study. Therefore we crystallized DUSP27 to make a 
structural comparison with DUSP3 (for details concerning the crystallization see Experimental 
section). In Figure 5 the electrostatic surfaces of DUSP3,10 inactive DUSP3 (C124S mutant) 
bound to a phosphorylated p38 peptide,8 and DUSP27 are displayed. In DUSP3 two pockets 
are clearly visible, the catalytic pocket (P1) and an arginine pocket (P2). The phosphorylated 
p38 peptide binds to these pockets with its phosphorylated tyrosine residue and 
phosphorylated serine residue to P1 and P2, respectively.8 The P1 and P2 pocket in DUSP3 are 
separated by a cleft were the p38 peptide still can bind. In DUSP27 this catalytic pocket P1 is 
clearly visible but the P2 pocket is not as abundantly present as in DUSP3. A clear difference 
between DUSP3 and 27 can be observed in the electrostatic surface potential. DUSP3 and 
inactive DUSP3 have identical electrostatic surfaces while DUSP27 is displaying a reversed 
electrostatic surface compared to DUSP3. This reversed electrostatic surface between DUSP3 
and 27 has been predicted using an DUSP27 homology model11 and confirmed by a recently 
resolved DUSP27 structure12 and our data.
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Figure 4: Selectivity and mode of inhibition. (A) Dose response curves for LH65.3. (B) Dose 
response curves for inhibitor 8. (C) Lineweaver-Burk analysis of inhibitor 8 for DUSP3, 11 and 27.
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6.7 Molecular docking of inhibitor 8 with DUSP3 and 27
Intrigued by the differences in the surfaces of DUSP3 and 27 we reasoned that molecular 
docking of inhibitor 8 with these two DUSPs could explain why this inhibitor is selective for 
DUSP3 over DUSP27. In our docking approach, using the program Autodock, we used a large 
docking site around 
catalytic pocket P1 
and arginine pocket 
P2 (docking space, 
30 Å x 30 Å x 30 Å) to 
see whether inhibi-
tor 8 has a preference 
for a different bind-
ing site than P1 and 
P2. However, the best 
binding site of inhibi-
tor 8 for DUSP3 and 
27 was catalytic pock-
et P1 (Figure 6). The 
best docking pose of 
inhibitor 8 for DUSP3 
+ 4V
- 4V
DUSP3 DUSP3 + p38 peptide
(C124S inactive mutant)
DUSP27
P2
P2
P1
P1
DUSP3 DUSP27
R
C
Y
R
C
R
HCREGYSR HCVMGRSR
- 8.0 kcal mol-1 - 6.4 kcal mol-1
Protein:
Catalytic sequence:
Docking energy:
2.3 Å 
Inhibitor 8
Figure 5: Surface representation displaying the electrostatic surface (blue is positive, red is 
negative) of the crystal structures of DUSP3 (PDB ID: 1VHR), inactive DUSP3 (C124S mutant) 
binding to a phosphorylated p38 peptide (PDB ID: 1J4X) and DUSP27. Catalytic site is indicated 
with P1 and an arginine pocket with P2.
Figure 6: Molecular docking suggests that inhibitor 8 (deep purple) 
binds in proximity of catalytic arginine residue (R) of DUSP3 and 27. A 
hydrogen bond is observed between a tyrosine residue (Y) in the DUSP3 
active site with the indicated carbonyl of inhibitor 8, this interaction is 
not possible in DUSP27.
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revealed an interaction with the catalytic arginine residue R130 of DUSP3 with the nitro group 
in 8. In addition, there is a hydrogen bond between the carbonyl of the 4-nitroacetophenone 
moiety in 8 with tyrosine residue Y128 (Figure 6). This hydrogen bond is not observed for the 
best docking pose of inhibitor 8 in DUSP27 because the tyrosine residue in not conserved 
in DUSP27 and is replaced by an arginine residue (Figure 6). This hydrogen bond of 8 with 
DUSP3 is a logical explanation why the affinity of 8 for DUSP3 (IC
50
 = 0.33 μM) is much higher 
than for DUSP27 (IC
50
 > 5 μM) and also for the higher predicted binding energy of inhibitor 8 
for DUSP3 (-8.0 kcal mol-1 versus -6.4 kcal mol-1).
6.8 Conclusions and Discussion
This study shows that the host proteins DUSP3, 11 and 27 of the host cell are essential 
for intracellular growth of the bacteria S. typhimurium. In our approach we used a small 
interfering RNA (siRNA) screen of the human phosphatome and a reversed chemical screen. 
In the latter methodology we screened tyrosine-based small molecules as a general tyrosine/
dual specificity phosphatase inhibitor library. One of the molecules (LH65.3) that resulted 
from the small molecule screen inhibited the identified DUSPs 3, 11 and 27 confirming the 
phosphatase target-inhibitor relationship.
Further development of LH65.3 resulted in a selective DUSP3 inhibitor (8) which has 
poor affinity for DUSP27. Molecular docking suggests that a hydrogen bond exists between 
inhibitor 8 and tyrosine residue Y130 in DUSP3 which is not present in DUSP27. This 
hydrogen bond probably explains the higher affinity of this inhibitor for DUSP3 over DUSP27. 
Binding site inhibitor 8
Inhibitor 8
NO2
S
N
O
O O
NO2
OHO
P
O O
O
SH
Substrate
O
P
O O
O
Binding site substrate
SH
Arg
Cys
Substrate
HN
NH2H2N +
HN
NH2H2N +
Figure 7: Model proposing the binding of inhibitors and tyrosine phosphorylated substrate with 
DUSP family phosphatases. Here DUSP inhibitor 8 (purple) is depicted as example. Tyrosine 
moieties of a substrate (green) and inhibitor 8 are located in the active site while the remaining 
part of these molecules binds to a different site in DUSP. Only the catalytic residues cysteine and 
arginine are depicted for clarity.
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Development of selective phosphatase inhibitors is a challenging task because of their close 
homology.
Somewhat controversial is the fact that the mode of inhibition for this selective 
inhibitor 8 is non-competitive. The tyrosine moiety in this inhibitor is introduced to target 
the phosphatase active site. In addition, unbiased molecular docking of inhibitor 8 shows 
a preference for the catalytic site of DUSP3 and 27. Our hypothesis explaining our results 
is depicted in Figure 7. In this model the binding site of tyrosine moieties of a tyrosine 
phosphorylated DUSP substrate and selective inhibitor 8 are in proximity of each other in 
the large DUSP active site while the remaining parts of the molecules bind to different sites 
outside the DUSP active site. A crystal structure of inhibitor 8 in complex with DUSP3 or 27 
should reveal its true binding. 
In conclusion, targeting host DUSP proteins essential for bacterial growth seems to be 
a valid way to fight bacterial infection and holds promise as a new therapeutic strategy to 
treat these infections. This new approach could be a useful addition to the current bacterial 
infection treatments that target solely the bacteria itself.
6.9 Experimental section
General. See Experimental section Chapter 4.
Synthesis inhibitor library. Inhibitors were synthesized as previously described with minor 
adjustments to the protocol.13-15 In short, to a cooled solution (277 K) of thiazolidine-2,4-dione (5.87 
g, 50 mmol) in DMF (100 ml) sodium hydride (60% in oil, 1.8 g, 45 mmol) was added. A solution of 
the appropriate benzyl bromide (36.8 mmol) in DMF (25 ml) was added to the reaction mixture. The 
mixture was allowed to warm up to room temperature and was stirred for 4 h. Then the mixture 
was poured into of ice water (250 ml) and hexane (100 ml) was added. After a night at 277 K the 
precipitated crystals were filtrated and dried to give N-alkylated thiazolidine-2,4-dione.
The resulting N-alkylated thiazolidine-2,4-dione (0.317 mmol) was dissolved in ethanol (2.5 mL) 
containing piperidine (70 µL, 0.709 mmol) and the appropriate aldehyde (0.348 mmol) was added 
and the solution was refluxed overnight. Upon cooling to room temperature the product precipitated 
out of solution. Centrifugation and washing with ethanol gave homogeneous compound.
(Z)-3-(4-(tert-butyl)benzyl)-5-(4-hydroxy-3-nitrobenzylidene)thiazolidine-2,4-dione (LH65.3). Yield: 
20%. 1H NMR: δ = 8.20 (d, J = 2.3, 1H), 7.95 (s, 1H), 7.77 (dd, J = 2.3, 8.8, 1H), 7.37 (d, J = 8.5, 2H), 
7.25 (dd, J = 8.6, 11.0, 3H), 4.79 (s, 2H), 1.25 (s, 9H). 13C NMR: δ = 166.93, 165.37, 153.69, 150.28, 
137.43, 135.51, 132.46, 131.63, 127.80, 127.49, 125.40, 123.93, 120.15, 119.96, 44.38, 34.21, 31.02. 
MS: m/z [M+H]+ calc.  413.12, obs. 412.92.
(Z)-5-(3-hydroxy-4-nitrobenzylidene)-3-(2-(4-nitrophenyl)-2-oxoethyl)thiazolidine-2,4-dione (8). 
Yield: 26%. 1H NMR: δ = 8.41 (d, J = 9.0, 2H), 8.33 (d, J = 9.1, 2H), 8.02 (d, J = 8.5, 1H), 7.99 (s, 1H), 
7.39 (d, J = 1.7, 1H), 7.27 (dd, J = 1.6, 8.6, 1H), 5.45 (s, 2H). 13C NMR: δ = 190.94, 166.52, 164.77, 
152.44, 150.61, 138.63, 138.23, 137.53, 131.84, 129.89, 126.13, 124.36, 124.00, 120.47, 119.81, 
48.28. MS: m/z [M+H]+ calc.  430.03, obs. 429.87.
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Phosphatase siRNA screen. Gene silencing was performed in 96 well plates with a human breast 
cancer (MCF-7) and glioblastoma (A-172) cell line. Cells were seeded at a density of 5000 cells per 
well and reverse transfected with DharmaFECT transfection reagent #4 and 50 nM siRNA (Human 
siGenome SMARTpool phosphatase library, Dharmacon). Two days after transfection, cells were 
infected with S. Typhimurium expressing DsRed16 was performed based on the infection protocol 
described by Steele-Mortimer et al. with minor changes.17 In short, two days before infection a 
bacterial culture was streaked from the frozen stock on LB agar plate. The next day, an overnight 
bacterial culture was prepared by inoculating 5 mL LB medium with one colony from the agar plate. 
The overnight culture was incubated at 310 K and 200 rpm for 16-20 h and then diluted 1:33 in fresh, 
pre-warmed (310 K) ampicillin (100 μg mL-1) containing LB medium for a further incubation of 3.5 
h. The bacterial culture (4 mL) was transferred to a 15 ml Falcon tube and pelleted in 4000 rpm for 
10 min at room temperature. The pellet was washed once with DMEM/FCS and resuspended in 
DMEM/FCS full medium (310 K). The cells were infected with an MOI of 50 for 20 min. After infection 
the cells were washed 4 times with DMEM/FCS containing 100 μg mL-1 gentamycin and remaining 
extracellular bacteria were killed by addition of DMEM/FCS medium with 100 μg mL-1 gentamicin for 
60 min. For the remaining infection period, the antibiotic concentration was lowered to 10 μg mL-1. 
After overnight infection cells were washed once with PBS and 30 μL of trypsin/EDTA was added for 
5 min followed by addition of 30 μL PBS/BSA 1%. The sample was fixed by addition of 60 μL PBS 
formalin 7%. 
Samples were analyzed by flow cytometry (BD FACSArray) for DsRed fluorescence as marker 
for Salmonella infection and proliferation. The data were normalized (cellHTS2, Bioconductor) and 
transformed into Z-scores.18
Small molecule screen. The infection of mammalian cells (MCF-7 or A172) with S. typhimurium 
expressing DsRed16 was performed based on the infection protocol described by Steele-Mortimer et 
al. with minor changes.17 In short, two days before infection a bacterial culture was streaked from the 
frozen stock on an ampicillin containing LB agar plate. The next day, an overnight bacterial culture 
was prepared by inoculating 5 mL of ampicillin containing LB medium with one colony from the agar 
plate. The overnight culture was incubated at 310 K and 200 rpm for 16-20 h and then diluted 1:33 
in 5 mL fresh, pre-warmed (310 K) ampicillin containing LB medium for a further incubation of 3.5 
h. 4 mL the culture was transferred to 15 mL Falcon tube and pelleted at 4000 rpm for 10 min at 
room temperature. The pellet was washed once with DMEM/FCS and resuspended in DMEM/FCS 
(310 K). In order to infect the cells with the MOI 20 for 30 min, the bacterial culture was diluted 
according to the following assumption: OD
595
 of 1 ≈ 1.3 x 109 CFU mL-1. To infect cells with bacteria, 
the cell culture medium was aspirated and 100 µL of bacteria in DMEM/FCS was added to the wells. 
Plates were centrifuged at 1000 rpm at room temperature for 5 min and incubated at 310 K with 5% 
CO
2
 in a humidified cell culture incubator to allow invasion for 1 h. The cells were washed 4 times 
with DMEM/FCS containing 100 µg mL-1 gentamycin and incubated for another 1 h in DMEM/FSC 
containing 100 µg mL-1 gentamycin. For the remaining infection period, the media was replaced with 
DMEM/FCS containing 10 µg mL-1 gentamicin and compound if indicated. Compounds were tested at 
10 µM in triplicate.
After overnight infection cells were washed once with PBS and incubated in 30 µl of trypsin/
EDTA for 5-10 min. Subsequently, 30 µL PBS/1% BSA was added used to resuspend the cells. 60 µL 
PBS/formalin (7%) was added to fix cells and bacteria. After at least 2 h samples were measured by 
FACS as previously described.
Effect of compounds on S. typhimurium growth in LB medium. An overnight bacterial culture was 
prepared by inoculating 5 mL of ampicillin (100 μg mL-1) containing LB medium with one colony 
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from an agar plate. The overnight culture was incubated at 310 K and 200 rpm for 16-20 h and then 
diluted 1:33 in fresh ampicillin (100 μg mL-1) containing LB medium. In a 96-wells plate, 100 µL of the 
bacteria containing medium was pipetted to an LB medium (100 µL) containing 20 µM of inhibitor. 
Bacterial growth was monitored by measuring the optical density at 595 nm (OD
595
).
Cell toxicity. See Experimental section Chapter 2.
DUSP activity assay.7 Measuring DUSP activity using 3-O-methylfluorescein phosphate (OMFP) 
as a substrate19 was determined as follows. In a black flat-bottom 96-wells plate was added 0.9 µL 
DMSO containing inhibitor, to 45 µL recombinant DUSP (~0.1 U) in a Tris-HCl buffer (9 mM Tris-HCl, 
11 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.01% triton X-100, pH 7.4). Finally, 45 µL of 40 μM OMFP 
in the previously described Tris-HCl buffer was added to each well using a multichannel pipet and 
instantaneously fluorescence was measured at room temperature (λ
ex
/λ
em
 = 485/520 nm). The above 
described mixture with DMSO alone was used as a positive control. OMFP without DUSP was taken 
as control for auto-hydrolysis of OMFP. For each inhibitor percentage inhibition (PI) was determined 
at a final inhibitor concentration of 5 µM. IC
50
 values of inhibitors have been determined in an 
inhibitor concentration range of 0.01 to 6 µM. Data were analyzed using Graphpad Prism software. 
In addition, the effect of the inhibitors on the fluorescence of the produced OMF was investigated 
using ~1 μM OMF at an inhibitor concentration of 5 μM (Supporting Figure S3).
Cloning, expression and purification of DUSPs. PCR fragments of phosphatase domains of DUSP3, 
11 and 27 (Supporting Table S2) containing a His-tag sequence have been cloned into a pETNKI-His-
3c-LIC-kan vector20 and were sequence verified. The resulting constructs have been transformed into 
BL21 (DE3) cells. Transformed cells were grown overnight in LB medium (2 mL) containing kanamycin 
(30 μg mL-1) and were subsequently inoculated in LB medium (1 L) with kanamycin (30 μg mL-1) until 
an OD
595
 of 0.6 was reached. Protein expression was induced by IPTG (0.5 mM) overnight at 293 K. 
Cells were spun down (3,000 x g, 15 min, 277 K) and the resulting cell pellet was resuspended in 
a Tris buffer (40 mM Tris, 200 mM NaCl, 5 mM β-mercaptoethanol, 5 mM imidazol, pH 8.0). After 
sonification the resuspension the cell debris and insoluble proteins were removed by centrifugation 
(14,000 x g, 30 min, 277 K) and the soluble fraction was incubated with Talon beads and washed with 
the above described Tris buffer. The Talon beads were eluted with a Tris buffer (40 mM Tris, 200 mM 
NaCl, 5 mM β-mercaptoethanol, 300 mM imidazol, pH 8.0) and collected fractions were analyzed on 
an SDS-PAGE gel. Fractions containing solely DUSP protein were pooled and purified by resource Q 
anion-exchange chromatography. For crystallization purpose, the His-tag purification label of DUSP27 
was removed by GST-tagged 3C protease cleavage overnight at 277 K. A final purification step of all 
DUSPs involved a S75 gel filtration using as eluent a Tris buffer (40 mM Tris, 100 mM NaCl, 5 mM 
β-mercaptoethanol, pH 8.0) resulting in a pure protein solution which was concentrated using a 
Centriprep column.
DUSP27 Crystallization. Screening of crystallization conditions for DUSP27 was performed 
at nanoliter scale in 96-well format. 200 nL sitting drops (100 nL DUSP27 (5 mg mL-1) and 100 nL 
reservoir solution) were prepared by the Mosquito dispensing robot (TTP Labtech) using the PACT 
and JCSG+ screens.21 Crystallization plates were stored and imaged at 277 K by the RockImager 
(Formulatrix) and at 293 K by the CrystalFarm (Bruker-AXS). Initial microcrystals and needle-like 
crystals were observed at 277 K in conditions from the PACT screen containing 0.1 M bis-Tris propane 
(pH 6.5 and pH 7.5), 20% PEG 3350 and either 0.2 M sodium nitrate, 0.2 M sodium fluoride or 0.2 M 
sodium-potasium phosphate. These crystals were used in microseeding experiments against the PACT 
and JCSG+ screen. Briefly, crystals were transferred to 75 µL of reservoir solution in an eppendorf 
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tube and vortexed for 30 s. Sitting drops were prepared from 100 nL of DUSP27 (5 mg mL-1), 100 nL 
reservoir solution and 10 nL seed solution. Crystals were observed in multiple conditions and further 
optimization of these conditions was performed using the Formulator microfluidics liquid dispensing 
robot (Formulatrix) with microseeding. Suitable crystals for X-ray diffraction studies were obtained 
at 277 K in 0.1 M Tris pH 8.0, 21% PEG 3350, 0.2 M sodium sulphate; in 0.1 M Tris pH 7.2, 12% PEG 
8000; in 0.1 M Tris pH 7.5, 0.2 M magnesium chloride and 16% PEG 6000. Crystals appeared as 
needles and as plates, with typical dimensions of 0.05 x 0.1 x 0.3 mm and 0.1 mm x 0.2 mm x 0.25 
mm, respectively.
Data collection and structure refinement. DUSP27 X-ray diffraction data was collected at 100 K from 
a crystal grown in 0.1 M Tris pH 7.5, 0.2 M magnesium chloride and 16% PEG 6000 at our home 
source (Microstar Ultra II (Bruker-AXS) with Mar345 image plate detector (Marresearch)). The crystal 
was cryoprotected in 0.1 M Tris pH 7.5, 0.2 M magnesium chloride, 18% PEG 6000 and 20% glycerol 
before freezing in liquid nitrogen solution. 100 images were collected with 1 degree oscillation and 
120 s exposure per frame and a crystal to detector distance of 200 mm (2.21 Å resolution at the edge 
of the detector). The diffraction data set was indexed and integrated using Mosflm22 and scaled using 
SCALA.23 Molecular replacement using the structure of DUSP13 (PDB ID: 2PQ5) as search model, was 
performed in Phaser.24 An initial model was build and revealed 2 molecules in the asymmetric unit. 
The model was subjected to automated tracing in ARP/wARP25 and was further refined using the 
software programs Refmac in CCP426 interspersed with manual rebuilding in Coot.27 Data collection 
and refinement statistics can be found in Supporting Table S3.
Molecular docking, protein and ligand preparation. The X-ray structures of DUSP3 (PDB ID: 1VHR) 
and DUSP27 were used for docking studies. The protein and ligand structures were prepared using 
Autodock version 1.5.4. The initial 3D structures of the ligands were generated using CORINA. We 
defined a region for docking by a 30 Å x 30 Å x 30 Å box centered around the P1 and P2 pocket of 
DUSP3 and 27. Final docking experiments were done using Autodock Vina.28 Graphics were made 
using PyMOL 1.3.
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Supporting Figure S1: Effect of compounds on S. typhimurium growth 
in LB medium. Bacterial growth of S. typhimurium was measured in the 
presence or absence of 10 μM of compound at a wavelength of 595 
nm. Data points have not been fitted for clarity.
Supporting Figure S2: Effect of compounds 
on cell viability of MCF-7 cells. Cell viability 
of MCF-7 cells was tested using the 
conditions of the S. typhimurium FACS assay. 
Compounds were incubated for 42 h at a 
concentration of 10 μM. Phenylarsine oxide 
(PAO) was used as a control for cell death. 
Supporting Figure S3: Effect of DUSP 
inhibitors on DUSP activity assay readout. 
Fluorescence of OMF was measured at an 
inhibitor concentration of 5 μM.
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Name Catalog number Locus id Accession id 
ENPP2 M-004601-01 5168 NM_006209 
PTPN6 M-009778-00 5777 NM_002831 
C7ORF16 M-018324-01 10842 NM_006658 
CDKN3 M-003879-00 1033 NM_005192 
DUSP1 M-003484-02 1843 NM_004417 
DUSP10 M-003965-01 11221 NM_007207 
DUSP2 M-003565-01 1844 NM_004418 
DUSP22 M-004517-00 56940 NM_020185 
DUSP4 M-003963-02 1846 NM_001394 
DUSP5 M-003566-01 1847 NM_004419 
DUSP6 M-003964-01 1848 NM_001946 
DUSP7 M-003567-00 1849 XM_037430 
DUSP8 M-003568-00 1850 NM_004420 
ILKAP M-010260-00 80895 NM_030768 
PFKFB1 M-006761-00 5207 NM_002625 
PFKFB2 M-006762-01 5208 NM_006212 
PFKFB3 M-006763-00 5209 NM_004566 
PFKFB4 M-006764-00 5210 NM_004567 
PPP1R1B M-012745-00 84152 NM_032192 
PPP2CA M-003598-00 5515 NM_002715 
PPP4C M-008486-01 5531 NM_002720 
PTPN5 M-003600-01 84867 NM_032781 
PTPRG M-008069-00 5793 NM_002841 
PTPRJ M-008476-01 5795 NM_002843 
PTPRR M-004017-01 5801 NM_002849 
PTPRT M-008072-01 11122 NM_007050 
TRIO M-005047-00 7204 NM_007118 
ACYP2 M-008864-00 98 NM_138448 
PPP1R16B M-004065-00 26051 NM_015568 
PPP2R3A M-017376-00 5523 NM_002718 
SAG M-011105-00 6295 NM_000541 
ZFHX1B M-006914-00 9839 NM_014795 
ACP5 M-009615-01 54 NM_001611 
PPP3CA M-008300-01 5530 NM_000944 
PSPH M-011888-01 5723 NM_004577 
ACP1 M-019058-00 52 NM_004300 
ACPP M-009262-00 55 NM_001099 
CDC14A M-003469-00 8556 NM_003672 
CDC14B M-003470-02 8555 NM_003671 
CDC25A M-003226-02 993 NM_001789 
CDC25B M-003227-02 994 NM_004358 
CDC25C M-003228-01 995 NM_001790 
DUSP11 M-007885-00 8446 NM_003584 
EPM2A M-006896-01 7957 NM_005670 
PPAP2B M-017312-01 8613 NM_003713 
PPAP2C M-011500-00 8612 NM_003712 
PPM1D M-004554-00 8493 NM_003620 
PPP1R3C M-017077-00 5507 NM_005398 
PTEN M-003023-01 5728 NM_000314 
PTPN14 M-008509-00 5784 NM_005401 
PTPRU M-009328-01 10076 NM_005704 
TPTE2 M-008107-00 93492 NM_130785 
CTDP1 M-009326-01 9150 NM_004715 
DUSP12 M-007886-01 11266 NM_007240 
Name Catalog number Locus id Accession id 
DUSP13 M-007887-00 51207 NM_016364 
DUSP14 M-007888-00 11072 NM_007026 
DUSP15 M-008484-01 128853 NM_080611 
DUSP18 M-007891-00 150290 NM_152511 
DUSP19 M-007892-01 142679 NM_080876 
DUSP21 M-007893-01 63904 NM_022076 
DUSP23 M-007909-00 54935 NM_017823 
MGC1136 M-008027-01 78986 NM_024025 
MGC26484 M-008030-00 168448 XM_171149 
MK-STYX M-008031-01 51657 NM_016086 
MTMR1 M-008037-01 8776 NM_003828 
MTMR2 M-008038-00 8898 NM_016156 
MTMR4 M-008040-01 9110 NM_004687 
MTMR7 M-008041-00 9108 XM_044727 
PDP2 M-022572-00 57546 NM_020786 
PPEF1 M-009479-00 5475 NM_006240 
PPEF2 M-012250-01 5470 NM_006239 
PPM1B M-008281-01 5495 NM_002706 
PPM1E M-008964-00 22843 NM_014906 
PPM1F M-009544-00 9647 NM_014634 
PPM1G M-005264-01 5496 NM_002707 
PPM1L M-008679-00 151742 NM_139245 
PPM2C M-008718-00 54704 NM_018444 
PPP1CA M-008927-00 5499 NM_002708 
PPP1CB M-008685-00 5500 NM_002709 
PPP2R1A M-010259-01 5518 NM_014225 
PPP2R5A M-009352-01 5525 NM_006243 
PPP2R5B M-009366-00 5526 NM_006244 
PPP2R5C M-009433-00 5527 NM_002719 
PPP2R5D M-009799-01 5528 NM_006245 
PPP2R5E M-008531-01 5529 NM_006246 
PPP3CC M-010005-00 5533 NM_005605 
PPP5C M-009259-00 5536 NM_006247 
PPP6C M-009935-01 5537 NM_002721 
PTP4A1 M-006333-01 7803 NM_003463 
PTP4A2 M-009078-00 8073 NM_003479 
PTP4A3 M-006859-01 11156 NM_007079 
PTPDC1 M-008584-00 138639 NM_152422 
PTPLA M-008742-00 9200 NM_014241 
PTPN1 M-003529-04 5770 NM_002827 
PTPN11 M-003947-01 5781 NM_002834 
PTPN12 M-008064-01 5782 NM_002835 
PTPN13 M-008065-00 5783 NM_006264 
PTPN21 M-009379-01 11099 NM_007039 
PTPN22 M-008066-00 26191 NM_012411 
PTPN23 M-009417-00 25930 NM_015466 
PTPN3 M-009372-01 5774 NM_002829 
PTPN4 M-009489-01 5775 NM_002830 
PTPN7 M-008394-00 5778 NM_002832 
PTPN9 M-008832-00 5780 NM_002833 
PTPRA M-004519-00 5786 NM_002836 
PTPRB M-004994-02 5787 NM_002837 
PTPRC M-008067-00 5788 NM_002838 
PTPRD M-008527-00 5789 NM_002839 
Supporting Table S1: List of screened phosphatase and phosphatase-like siRNAs
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Name Catalog number Locus id Accession id 
PTPRE M-008068-02 5791 NM_006504 
PTPRF M-008375-01 5792 NM_002840 
PTPRH M-009448-00 5794 NM_002842 
PTPRK M-004204-01 5796 NM_002844 
PTPRM M-006326-00 5797 NM_002845 
PTPRN M-009315-01 5798 NM_002846 
PTPRN2 M-008070-00 5799 NM_002847 
ACP2 M-008205-00 53 NM_001610 
INPP5B M-021811-01 3633 NM_005540 
ALPPL2 M-003455-01 251 NM_031313 
PPP3R1 M-009869-01 5534 NM_000945 
IGBP1 M-011298-01 3476 NM_001551 
ANP32E M-015844-00 81611 NM_030920 
LPPR4 M-009911-00 9890 NM_014839 
PPP2CB M-003599-02 5516 NM_004156 
ENPP1 M-003809-01 5167 NM_006208 
MAP3K7IP1 M-004770-00 10454 NM_006116 
ACP6 M-008665-00 51205 NM_016361 
INPP5D M-003013-01 3635 NM_005541 
DUT M-010258-00 1854 NM_001948 
SYNJ1 M-019486-01 8867 NM_003895 
PPP1R11 M-011917-01 6992 NM_021959 
DKFZP761G058 M-018772-00 152926 NM_152542 
FLJ40125 M-009006-00 147699 NM_178494 
AKAP11 M-009277-01 11215 NM_016248 
BPNT1 M-008664-01 10380 NM_006085 
PPM1A M-009574-01 5494 NM_021003 
ACPT M-008366-01 93650 NM_033068 
PHPT1 M-016904-00 29085 NM_014172 
ENPP3 M-004540-00 5169 NM_005021 
PTPN2 M-008969-00 5771 NM_002828 
PPP1R7 M-019589-00 5510 NM_002712 
LOC151242 M-023104-00 151242 XM_087137 
HSPC129 M-008272-00 51496 NM_016396 
MTM1 M-008036-01 4534 NM_000252 
ALPP M-003454-01 250 NM_001632 
MTMR3 M-008039-01 8897 NM_021090 
ENPP4 M-009214-01 22875 NM_014936 
PON1 M-009229-00 5444 NM_000446 
IMPA1 M-010172-01 3612 NM_005536 
PPP1R8 M-010903-00 5511 NM_002713 
PPP2R4 M-005214-00 5524 NM_021131 
Name Catalog number Locus id Accession id 
C21ORF6 M-013856-00 10069 NM_016940 
DUSP3 M-007894-00 1845 NM_004090 
ALPI M-008673-00 248 NM_001631 
TPTE M-008745-01 7179 NM_013315 
ENPP5 M-009805-01 59084 NM_021572 
PON2 M-009676-00 5445 NM_000305 
IMPA2 M-008348-00 3613 NM_014214 
PPP2R2A M-004824-01 5520 NM_002717 
OCRL M-010026-01 4952 NM_000276 
ENPP7 M-009059-00 339221 NM_178543 
PTPRS M-009662-01 5802 NM_002850 
SSH3 M-008937-00 54961 NM_017857 
FBP2 M-010139-01 8789 NM_003837 
PPAP2A M-019098-00 8611 NM_003711 
INPP1 M-008505-01 3628 NM_002194 
PR48 M-019459-00 28227 NM_013239 
PIB5PA M-009108-00 27124 NM_014422 
TENS1 M-009997-00 64759 NM_022748 
C14ORF24 M-018433-00 283635 NM_173607 
STYX M-009571-01 6815 NM_145251 
PTPN18 M-009385-00 26469 NM_014369 
RNGTT M-009782-00 8732 NM_003800 
FHIT M-004952-01 2272 NM_002012 
SYNJ2 M-012624-00 8871 NM_003898 
PPP1CC M-006827-00 5501 NM_002710 
PME-1 M-005211-00 51400 NM_016147 
CILP M-008295-00 8483 NM_003613 
FLJ23751 M-008557-00 92370 NM_152282 
FRMPD2 M-008854-00 143162 NM_152428 
MINPP1 M-009705-00 9562 NM_004897 
PTPRZ1 M-009685-00 5803 NM_002851 
INPP4B M-011539-00 8821 NM_003866 
ALPL M-008658-00 249 NM_000478 
PPP1R2 M-015361-00 5504 NM_006241 
I-4 M-012962-00 80316 NM_025210 
RWDD2 M-015117-00 112611 NM_033411 
DNAJC6 M-009885-00 9829 NM_014787 
ENPP6 M-008704-00 133121 NM_153343 
FBP1 M-008725-00 2203 NM_000507 
PPP2R2B M-003022-01 5521 NM_004576 
PTPRO M-008500-01 5800 NM_002848 
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DUSP  Amino acid sequence
MAHHHHHHSAALEVLFQGPGMSGSFELSVQDLNDLLSDGSGCYSLPSQPCNEVTPRIYVGN 
ASVAQDIPKLQKLGITHVLNAAEGRSFMHVNTNANFYKDSGITYLGIKANDTQEFNLSAYF 
ERAADFIDQALAQKNGRVLVHCREGYSRSPTLVIAYLMMRQKMDVKSALSIVRQNREIGPN 
DGFLAQLCQLNDRLAKEGKLKP 
 
 
 
MAHHHHHHSAALEVLFQGPGRFIAFKVPLQKSFEKKLAPEECFSPLDLFNKIREQNEELGL 
IIDLTYTQRYYKPEDLPETVPYLKIFTVGHQVPDDETIFKFKHAVNGFLKENKDNDKLIGV 
HCTHGLNRTGYLICIYLIDVEGVRPDDAIELFNRCRGHCLERQNYIEDLQNGPIRKNWNSS 
VPRSSDFEDSAHLMQPVHNKPVKQGPRYNLHQIQGHSAPRHFHTQTQSLQQSVRKFSENPH 
VY 
 
 
MAHHHHHHSAALEVLFQGPGYTHVNEVWPKLYIGDEATALDRYRLQKAGFTHVLNAAHGRW 
NVDTGPDYYRDMDIQYHGVEADDLPTFDLSVFFYPAAAFIDRALSDDHSKILVHCVMGRSR 
SATLVLAYLMIHKDMTLVDAIQQVAKNRCVLPNRGFLKQLRELDKQLVQQRRRSQRQDGEE 
EDGREL 
3
11
27 a
 
Data collection  
Space group P21212 
Cell dimensions    
    a, b, c (Å) 56.11, 60.62, 54.55 
    a, b, g  ()  90, 90, 90 
Resolution (Å) 2.2 (2.33-2.2) 
Rsym or Rmerge 0.094 (0.54) 
I / sI 4.0 (3.4) 
Completeness (%) 97.6 (97.6) 
Redundancy 3.8 (3.6) 
Reﬁnement  
Resolution (Å) 20-2.2 
No. reﬂections 8598 
Rwork / Rfree 0.28/0.32 
R.m.s. deviations  
    Bond lengths (Å) 0.012 
    Bond angles () 1.508 
DUSP27
Supporting Table S2: Amino acid sequences of DUSP3, 11 and 27. The catalytic domain 
containing the HCXXGXXR motif is underlined.
a In bold the amino acid sequence removed by GST-tagged 3C protease for crystallization purposes. 
Supporting Table S3:  Data 
collection and refinement statistics 
for DUSP27.
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Summary and future prospects
Autotaxin inhibitors
The first part of this thesis describes the development of inhibitors of autotaxin (ATX 
or ENPP2), a phosphodiesterase that is responsible for the production of the lipid 
lysophosphatidic acid (LPA) in the circulation. ATX is implicated in several diseases including 
inflammation, fibrotic disease and cancer, making it an interesting potential drug target to 
study. ATX inhibitors are required in the validation process of ATX as a drug target. However, 
at the start of this study, small molecule ATX inhibitors did not exist. In order to discover ATX 
inhibitors, ~40,000 small molecules were screened and several structural classes of inhibitors 
were identified (Chapters 2 and 3). After validation experiments a class of small molecules 
called thiazolidine-2,4-diones proved to be the most promising. This class was amenable to 
chemical optimization, allowing the synthesis and isolation of ~100 analogs of the confirmed 
thiazolidine-2,4-dione screening hit (Figure 1). In the handed optimization approach variations 
were introduced in a benzyl moiety (green) and a benzylidene moiety (blue), which are linked 
via a thiazolidine-2,4-dione core (Figure 1). The key step in the optimization approach was 
the replacement of a carboxylic acid in one of the screening hit analogs by a boronic acid. 
The boronic acid was introduced to target the oxygen nucleophile in threonine 210 (T210), 
an amino acid in the ATX active site which is essential for the activity of this enzyme. This 
modification resulted in a boronic acid-based inhibitor (HA130; IC
50
 = 30 nM, Figure 1) with 
almost a 100-fold increase in potency compared to our original screening hit (IC
50
 = 2.5 µM).
Next, the biological properties of HA130 as ATX inhibitor were explored (Chapter 2). 
It was shown that HA130 is a selective inhibitor of ATX and that it does not inhibit ENPP1, 
the closest family member of ATX. Finally, it was demonstrated that HA130 instantaneously 
lowers plasma levels of LPA in mice after intravenous administration. This implies that the 
production of LPA by 
ATX and LPA degradation 
by other enzymes is 
tightly and dynamically 
regulated. Thus, ATX 
can be targeted in vivo 
using boronic acid-based 
inhibitors.
The development 
of ATX inhibitors 
described in Chapters 
2 and 3 was conducted 
before the ATX crystal 
structure was resolved. 
Screening hit HA130 HA155
IC50 (nM): 2500 30 6 5
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Figure 1: Selection of ATX inhibitors described in this thesis. Benzyl 
and benzylidene moiety in the screening hit are highlighted in green 
and blue, respectively.
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In 2011, we obtained a crystal structure of ATX in complex with boronic acid-based inhibitor 
HA155 (IC
50
 = 6 nM, Figure 1). HA155 is a positional boronic acid isomer of HA130 with a 
higher affinity for ATX compared to HA130 (Chapter 3). The structure of HA155 bound to ATX 
proved that the boronic acid in HA155 indeed targets the threonine oxygen nucleophile in the 
ATX active site. Next, this structure was used to design new boronic acid-based inhibitors and 
replaced the thiazolidine-2,4-dione core in HA155 with other cores (Chapter 4) and variations 
of the ether linker in HA155 were investigated. This study finally led to the discovery of 
a highly active imidazolidine-2,4-dione analog of HA155 (E-28, IC
50
 = 5 nM) which had an 
E-configured double bond instead of a Z-configuration as in HA155 and all other evaluated 
analogs (Figure 1). To explain how E-28 could bind to ATX molecular docking studies were 
performed. These studies suggested that E-28 binds differently to the hydrophobic pocket 
in ATX compared to HA155 and other Z-configured analogs, opening possibilities for new 
inhibitor designs.
New inhibitor designs that could fully exploit the hydrophobic pocket in ATX are designs 
based on E-28. Extension from the methylene moiety in the 4-fluorobenzyl group of E-28 
with other aromatic moieties could target both regions in the hydrophobic pocket that are 
separately targeted by E-28 and HA155 alone.  
Since the current series of ATX inhibitors contain a fluorine atom, the introduction of 
the positron-emitting radionuclide fluorine-18 (F18) is an option. This will allow tracing of 
inhibitors in vivo (e.g. mice) using Positron Emission Tomography (PET) imaging to gather 
information about the pharmacokinetics of these inhibitors.
To validate ATX as a drug target, besides to ATX inhibitors, proper animal model systems 
that mimic ATX-driven diseases are needed. Few of these models exist today, especially 
proper models regarding cancer are lacking. Generation of such models and using them in 
combination with ATX inhibitors is the next step in the validation of ATX as a drug target.
DUSP inhibitors
After a short introduction on dual specificity phosphatases (DUSP, Chapter 5) the involvement 
of host phosphatases in bacterial infection of human host cells was studied. In this study 
a small interfering RNA (siRNA) phosphatase library was screened to learn which host 
phosphatases are required for the bacterial growth of Salmonella (S.) typhimurium in human 
host cells (Chapter 6). Among the phosphatases identified many DUSPs (DUSP3, 11 and 
27) were present. In parallel, a tyrosine phosphatase-targeted small molecule library was 
tested in order to discover molecules that inhibit S. typhimurium growth in human cells. 
Several compounds inhibited S. typhimurium growth in human host cells and one of these 
compounds inhibited the DUSPs that were identified from the siRNA screen. The most 
promising compound was then further optimized to result in a potent and selective DUSP3 
inhibitor (IC
50
 = 0.33 μM), with a 15-fold increased potency compared to DUSP27 (IC
50
 > 5 
μM). Molecular docking of this compound in both DUSP3 and 27 suggests a hydrogen bond 
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between this inhibitor and a tyrosine residue in DUSP3, which cannot be formed in DUSP27, 
explaining the selectivity of this inhibitor. This tyrosine residue is present in the active site 
of DUSP3 but is not conserved in the DUSP active site consensus sequence (HCXXGXXR). 
Therefore, targeting non-conserved active site residues in DUSPs could be a valid strategy for 
the development of selective DUSP inhibitors. Developing selective phosphatase inhibitors is 
a challenging task due to the highly conserved active site residues in phosphatases.
For the optimization of DUSP inhibitors a similar approach was taken as for the first 
optimization method used for the ATX inhibitors. In this method only the outer parts (benzyl 
and benzylidene moieties) of the inhibitor were modified and the thiazolidine-2,4-dione 
core part was left untouched. For increasing affinity and/or selectivity of the DUSP inhibitors 
it would be useful to introduce variations in the thiazolidine-2,4-dione core of the DUSP 
inhibitors using, for example, modifications that are described in Chapter 4.
The approach taken in Chapter 6 to inhibit host DUSP proteins that are essential for 
bacterial growth, seems to be a valid way to control bacterial infection. This new approach 
could be a useful addition to the current treatment of bacterial infections that target solely 
the bacteria itself, and hold promise as a new therapeutic strategy to treat bacterial infections 
with less chance for the development of drug resistance.
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Ontwikkeling van ATX- en DUSP-remmers
ATX-remmers
Autotaxine (ATX) is een enzym met lysofosfolipase D activiteit en is verantwoordelijk voor de 
productie van het bioactieve lipide lysofosfatidezuur (LPA) in de bloedcirculatie. LPA activeert 
verschillende processen in de cel zoals proliferatie, migratie en overleving van de cel. ATX 
en LPA lijken betrokken te zijn bij diverse ziekten zoals kanker, (chronische) ontstekingen en 
fibrose. Het is tot op heden echter nog niet duidelijk wat de exacte functies van ATX en LPA zijn 
in de ontwikkeling van deze ziektes. ATX-remmers kunnen hierin duidelijkheid verschaffen door 
bijvoorbeeld ATX te remmen in diermodellen waarin ATX-gerelateerde ziektes zijn opgewekt. 
Indien deze ATX-remmers een positief effect vertonen in de genoemde diermodellen 
dan kunnen ze direct verder ontwikkeld worden tot nieuwe medicijnen voor de mens.
In het begin van dit onderzoek waren er nog geen actieve en selectieve remmers voor 
ATX bekend. Er is daarom eerst een bibliotheek van ~40.000 commercieel verkrijgbare kleine 
moleculen getest op hun mogelijkheid om ATX te remmen. Dat heeft geresulteerd in de 
identificatie van een chemische klasse van verbindingen van gesubstitueerde thiazolidine-
2,4-dionen, die ATX selectief bleken te remmen. De beste verbinding van deze klasse is 
geselecteerd en chemisch gemodificeerd om het vermogen als ATX-remmer te optimaliseren. 
Deze optimalisatie heeft uiteindelijk een ATX-remmer opgeleverd, genaamd HA130, met een 
100 maal sterkere activiteit voor ATX. De belangrijkste modificatie was de introductie van een 
boorzuurgroep, ontworpen om te binden aan het katalytische threonine-residu in het actieve 
centrum van ATX om zo de activiteit van ATX te blokkeren.
Vervolgens is het effect van HA130 op de productie van LPA in het bloed van muizen 
onderzocht. Toediening van deze remmer aan muizen resulteerde in een zeer snelle verlaging 
van het LPA-niveau in het bloed. Hieruit bleek dat de productie en degradatie van LPA in de 
bloedcirculatie veel dynamischer is dan eerder was aangenomen. ATX-remmers kunnen dus 
het LPA-niveau in de bloedcirculatie verlagen en hiermee een belangrijke bijdrage leveren om 
de rol van ATX en LPA in ziekten verder op te helderen.
Tijdens de voorgaande studies was de  ruimtelijke structuur van ATX nog niet bekend. 
Deze structuur is belangrijk om de functie en het mechanisme van ATX op atomair niveau 
te bestuderen. Recentelijk is er een kristalstructuur van ATX gebonden aan de ATX-remmer 
HA155 opgehelderd, welke laat zien hoe HA155 bindt aan ATX. HA155 is de naam van een 
actiever boorzuuranaloog van de hierboven beschreven HA130. Deze kristalstructuur 
bevestigt de hypothese dat het  boorzuur in HA155 het actieve centrum van ATX blokkeert 
door te binden aan het nucleofiele zuurstofatoom van het katalytische threonine-residu in 
ATX.  De 4-fluorobenzylgroep van HA155 bindt aan een hydrofobe (waterschuwe) uitsparing 
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waar normaal gesproken de hydrofobe staart van LPA aan bindt. De kennis van hoe het 
HA155 molecuul aan ATX bindt geeft een idee waar in de chemische structuur van HA155 
modificaties toegestaan zijn. Gebruikmakend van deze kennis zijn er verschillende nieuwe 
boorzuuranalogen van HA155 ontworpen en gemaakt. Dit heeft uiteindelijk geresulteerd 
in een zeer actief boorzuuranaloog van HA155, genaamd E-28, dat een E-geconfigureerde 
dubbele binding heeft in plaats van een Z-configuratie zoals in HA155 en alle andere 
geteste analogen van HA155. Dit betekent dat de 4-fluorobenzylgroep in E-28 een compleet 
andere ruimtelijke oriëntatie heeft dan in HA155. Men zou dan ook verwachten dat deze 
4-fluorobenzylgroep anders bindt aan de hydrofobe uitsparing in ATX, in vergelijking met 
HA155. Om te verklaren hoe E-28 zou kunnen binden aan ATX zijn er computersimulaties 
uitgevoerd. In deze studie hebben we de binding van E-28 aan het actieve centrum van ATX 
gesimuleerd. Dit suggereerde dat E-28 anders bindt aan de hydrofobe uitsparing in ATX in 
vergelijking met HA155 en andere Z-geconfigureerde analogen. Echter, een kristalstructuur 
van E-28 gebonden aan ATX zal dit moeten bevestigen. De vinding dat E-28 mogelijk 
anders bindt aan de hydrofobe uitsparing in ATX dan HA155, kan gebruikt worden voor het 
ontwerpen van nieuwe ATX-remmers.
DUSP-remmers
Een ander belangrijk onderwerp beschreven in dit proefschrift is de bestrijding van 
bacteriële infecties door middel van het remmen van duale specificiteit fosfatasen (DUSP). 
Bacteriële infecties zijn nog steeds een grote sociale bedreiging. Zo sterven jaarlijks ongeveer 
500.000 mensen aan buiktyfus veroorzaakt door de bacterie Salmonella Typhi. De meeste 
sterfgevallen van deze ziekten vinden plaats in de derde wereld. Ook de recente uitbraak van 
de Enterohemorragische Escherichia coli (EHEC) bacterie in Europa laat zien dat bacteriële 
infecties serieus genomen moeten worden. Door de resistentie van bacteriën voor meerdere 
typen antibiotica (multidrug resistance, MDR) wordt het steeds moeilijker om deze bacteriële 
infecties te behandelen. Nieuwe strategieën zijn daarom nodig om deze resistente bacteriën 
te overwinnen.
Dikwijls verschuilen pathogene (ziekmakende) bacteriën zich in de cellen van de 
gastheer om zo te kunnen ontsnappen aan het immuunsysteem. Daarnaast hebben 
deze bacteriën  bepaalde eiwitten van de gastheercel nodig om te kunnen overleven. 
Het ontwikkelen van geneesmiddelen die aangrijpen op deze gastheer eiwitten, kan een 
alternatieve strategie zijn om bacteriële infecties te behandelen. In deze studie is er gekeken 
naar welke fosfatasen, een klasse van eiwitten, van humane gastheercellen essentieel zijn 
voor de overleving van de bacterie Salmonella (S.) typhimurium. Dit bleken de fosfatasen 
DUSP3, 11 en 27 te zijn. 
Daarnaast zijn er moleculen, die ontworpen zijn om DUSP-fosfatasen te remmen, 
getest op de vermindering van de S. typhimurium-infectie van menselijke gastheercellen. Eén 
van deze verbindingen bleek de eerder geïdentificeerde DUSP-eiwitten van de gastheer die 
117
Nederlandse Samenvatting
essentieel zijn voor S. typhimurium-infectie te remmen. Deze verbinding werd vervolgens 
geoptimaliseerd, wat resulteerde in een actieve en selectieve remmer van DUSP3, met 
een minstens 15-voudig verhoogde activiteit in vergelijking met DUSP27. Tegenlijkertijd 
is de kristalstructuur van DUSP27 opgelost naast de al bekende structuur van DUSP3. Een 
computersimulatie van de binding van deze remmer met zowel DUSP3 als met DUSP27 
suggereert een waterstofbrug tussen deze remmer en een tyrosine residu in DUSP3, dat 
niet gevormd kan worden in DUSP27. Dit is een mogelijke verklaring voor de selectiviteit van 
deze remmer voor DUSP3. Het tyrosine residu van DUSP3 dat een waterstofbrug vormt met 
de selectieve DUSP3-remmer, is niet geconserveerd in de consensus sequentie (HCXXGXXR) 
die typerend is voor het actieve centrum van de DUSP-familie. Het gebruikmaken van niet-
geconserveerde actieve centrum residuen in de DUSP-familie kan mogelijk een goede 
strategie zijn voor de ontwikkeling van selectieve DUSP-remmers met antibacteriële werking. 
Het ontwikkelen van selectieve fosfataseremmers is een uitdagende taak door de sterk 
geconserveerde actieve centrum residuen in fosfatasen.
Concluderend, het remmen van de activiteit van DUSP-eiwitten in de gastheer die 
essentieel zijn voor bacteriële overleving, lijkt een goede strategie te zijn om bacteriële 
infecties te bestrijden. Deze nieuwe aanpak kan een nuttige aanvulling zijn op de huidige 
behandeling van bacteriële infecties die zich alleen richten op het direct doden van de 
bacterie. Deze nieuwe strategie is ook interessant omdat de ontwikkeling van bacteriële 
resistentie tegen deze remmers wellicht moeilijker is.
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waarderen. Ook heb ik erg genoten van je wereldse verhalen onder het genot van een kopje 
koffie.
Tijdens mijn promotieonderzoek heb ik ook de eer gehad om verschillende studenten te 
begeleiden. Sharida, bedankt voor de vele analogen die je voor mij hebt gemaakt. Rob, jij 
hebt een belangrijke bijdrage geleverd aan hoofdstuk 4. Bedankt voor de mooie ATX-remmers 
die je hebt gemaakt. Loes, mijn eerste studente, hoe jou te bedanken? Het was erg plezierig 
om je te begeleiden en ik heb er zelf ook veel van geleerd. Jouw (academische) aanwezigheid 
zal niet vergeten worden.
Veel mensen vergeten dat een succesvolle afdeling steunt op de schouders van de 
ondersteunende staf. Trudi, Suzanne, Patty, Lennert, Marieke en Hans bedankt voor al jullie 
hulp. Daarnaast wil ik alle huidige en voormalige collega’s, in het bijzonder Nalan en Silvia, 
bedanken voor hun hulp en gezelligheid.
Vrienden zijn erg belangrijk tijdens een promotieonderzoek en ze zorgen voor de nodige 
ontspanning. Appel en Tielke, Willy en Edith, Daan en Maura, ik wil jullie bedanken voor alle 
gezellige avondjes en activiteiten en ik hoop dat er nog vele mogen volgen. Appel, ik wil jou 
in het bijzonder bedanken voor al je hulp rondom dit proefschrift. Naast je nieuwe baan en je 
drukke gezinsleven was je nooit te beroerd om kritisch te kijken naar mijn proefschrift.
Alfa-onderzoekers kunnen als de beste het bèta-onderzoek in perspectief plaatsen. Hiervoor 
wil ik mijn zus Karianne en mijn schoonbroer Raymond bedanken.
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Nawoord
Pap en Mam, zonder jullie was dit proefschrift nooit mogelijk geweest. Jullie hebben me 
altijd gesteund tijdens mijn lange studietraject en jullie toewijding was dan ook groot. Alle 
congressen die ik bijwoonde en prijzen die ik won werden nauwkeurig gearchiveerd. Ook 
stonden jullie altijd klaar als ik weer eens een keer moest verhuizen. Het was vaak moeilijk 
uit te leggen waar ik qua onderzoek mee bezig was, maar dat werd gelukkig gecompenseerd 
door de vele verhalen binnen huize Albers. Ik ben dankbaar dat ik jullie beiden persoonlijk 
kan bedanken: Pap en Mam, bedankt woa!
Patricia, lieve schat, waar te beginnen. We kennen elkaar al zo lang dat woorden eigenlijk 
overbodig zijn. Toch wil ik je bedanken voor je steun en begrip, vooral omdat onze dagelijkse 
levens zo verschillend zijn. We hebben de afgelopen jaren veel moeten opgeven door mijn 
nomadenbestaan, maar het heeft ook mooie momenten opgeleverd zoals onze reis naar 
Amerika en onze motorritten. Hopelijk mogen we nog veel van deze mooie momenten samen 
delen.
Harald

